P F -0 6 7 0 0 8 4 1 
Pr o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1A  PH A S E  2 B ,  R A N DOM I Z E D ,  DO U B L E  B L I N D ,  V E H I C L E  CO N T RO L L E D ,  
P A R A L L E L  G RO U P ,  DO S E R A NG I NG  S T U D Y  TO  A S S E S S  TH E  E F F I C A C Y ,  
S A F E T Y ,  TO L E R A B I L I T Y  A N D  PH A RM A COK I N E T I C S O F  P F -0 6 7 0 0 8 4 1  C R E AM  
AP P L I E D  O N C E  O R  TW I C E  D A I L Y  FO R  6  W E EK S  I N  P A R T I C I P A N T S  W I TH  
M I L DO R  MO D E R A T E  A TO P I C  D E RM A T I T I S
I n v e s t i g a t i o n a l  P r o d u c t  N um b e r : P F -0 6 7 0 0 8 4 1 
I n v e s t i g a t i o n a l  P r o d u c t  N am e : N o t  a p p l i c a b l e  ( N / A ) 
U n i t e d  S t a t e s  ( U S )  I n v e s t i g a t i o n a l  N e w  
D r u g  ( I N D )  N um b e r : 
E u r o p e a n  C l i n i c a l  T r i a l s  D a t a b a s e  
( E u d r a C T )  N um b e r : 2 0 1 8 - 0 0 3 0 5 0 - 2 4 
P r o t o c o l  N um b e r : B 7 9 3 1 0 2 2 
P h a s e : 2 b 
S h o r t  T i t l e : A  Ph a s e  2 b ,  m u l t i c e n t e r ,  r a n d om i z e d ,  d o u b l e -b l i n d ,  v e h i c l e  c o n t r o l l e d ,  p a r a l l e l  g r o u p  d o s e  
r a n g i n g  s t u d y  t o  a s s e s s  e f f i c a c y ,  s a f e t y ,  t o l e r a b i l i t y a n d  p h a rm a c o k i n e t i c s  of  P F -0 6 7 0 0 8 4 1  c r e am  i n  
p a r t i c i p a n t s  w i t h  m i l d o r  m o d e r a t e  a t o p i c  d e rm a t i t i s C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 2Protocol Amendment Su mmary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Original protocol 31 October 2018 Not applicable (N/A)

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3T A B L E  O F  CO N T E N T S 
L I S T  O F  T A B L E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
L I S T  O F  F I G U R E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 
1 .  P R O T O C O L  S UMM A R Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
1 . 1 .  S y n o p s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
1 . 2 .  S c h em a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3 
1 . 3 .  S c h e d u l e  o f  A c t i v i t i e s  ( S o A ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4 
2 .  I N T R O D U C T I O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9 
2 . 1 .  S t u d y  R a t i o n a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9 
2 . 2 .  B a c k g r o u n d . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9 
2 . 3 .  B e n e f i t / R i s k  A s s e s sm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7 
3 .  O B J E C T I V E S ,  E S T IM A N D S ,  A N D  E N D P O I N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7 
4 .  S T U D Y  D E S I G N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2 
4 . 1 .  O v e r a l l  D e s i g n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2 
4 . 2 .  S c i e n t i f i c  R a t i o n a l e  f o r  S t u d y  D e s i g n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 
4 . 4 .  E n d  o f  S t u d y  D e f i n i t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8 
5 .  S T U D Y  P O P U L A T I O N. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8 
5 . 1 .  I n c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9 
5 . 2 .  E x c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0 
5 . 3 .  L i f e s t y l e  C o n s i d e r a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4 
5 . 3 . 1 .  C o n t r a c e p t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4 
5 . 3 . 2 .  M e d i c a t i o n s / T r e a tm e n t s  D i s c o n t i n u a t i o n ,  N o n -M e d i c a t e d  Em o l l i e n t s  
a n d  B a t h i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4 
5 . 3 . 3 .  D i e t a r y  S u p p l em e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 
5 . 3 . 4 .  V a c c i n e  a n d  E x p o s u r e  t o  I n f e c t i o n  G u i d e l i n e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 C C I 
C C I 
C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 45.3.4.1. Pa rticipant Specific Recommendations .....................................45
5.3.4.2. Guidance Regarding Household Contact Vaccine -Related 
Exposure ............................................................................................46
5.3.5. Other Req
uirements ....................................................................................46
5.4. Screen Failures ........................................................................................................47
6. STUDY INTERVENTIO N
..................................................................................................47
6.1. Study  Intervention Administered ................................ ................................ ............ 48
6.1.1. Administration ............................................................................................48
6.1.1.1. Treated Atopic Dermatitis Areas ...............................................48
6.1.1.2. General Instructions ..................................................................48
6.2. Preparation/Handling/Storage/Accountability ........................................................50
6.2.1. Preparation and Dispensing ........................................................................51
6.2.2. I nvestigational Product Accountabilit y
......................................................52
6.2.3. Destruction of Investigational Prod uct Supplies ........................................52
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................52
6.3.1. Allocation to I nvestigational Product .........................................................52
6.3.2. Breaking the Blind ......................................................................................53
6.4. Study  Intervention Compliance ...............................................................................53
6.5. Concomitant Therapy ..............................................................................................54
6.5.1. Rescue Medicine .........................................................................................55
6.6. Dose Modification ...................................................................................................55
6.7. I ntervention after the End of the Study ...................................................................55
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................55
7.1. Discontinuation of Study  Intervention ....................................................................55
7.1.1. ECG Changes ..............................................................................................56
7.1.2. L
ocal Tolerability .......................................................................................56
7.1.3. Adverse Events ...........................................................................................56
7.1.3.1. Serious I nfections ......................................................................57
7.1.3.2. Treate d Infections ......................................................................57
7.1.4. Potential Cases of Decreased eGFR ...........................................................57
7.1.5. L aboratory  Abnormalities ................................ ................................ ........... 58
7.1.6. Pregnancy ...................................................................................................58

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 57.1.7. Suicidal I deation and Behavior ...................................................................58
7.1.8. Temporary  Discontinuation ........................................................................59
7.1.9. Discontinuation/End of Treatment Monitoring for Adverse Events, 
Laboratory , and Vital Signs .............................................................................59
7.2. Participant Discontin uation/Withdrawal from the Study ........................................59
7.3. L ost to Follow -
up ....................................................................................................60
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................61
8.1. Efficacy  Assessments ..............................................................................................62
8.1.1. Rater Qualifications
....................................................................................62
8.1.2. I nvestigator’s Global As sessment (IGA) ....................................................62
8.1.3. Eczema Area and Severity  Index (EASI) ...................................................63
8.1.3.1. Lesion Severity  by Clinical Signs
.............................................63
8.1.3.2. Percent BSA with Atopic Dermatitis (for efficacy )
..................64
8.1.3.3. Calculation of EASI  Score ........................................................65
8.1.4. Bod y Surface Area ......................................................................................66
8.1.4.1. Bod y Surface Area for IP need .................................................66
8.1.5. Peak Pruritus Numerical Rating Scale (PP -NRS) ......................................67
8.2. Safet y Assessments .................................................................................................67
8.2.1. Assessments at Screening Onl y
..................................................................67
8.2.1.1. Medical History .........................................................................67
8.2.1.2. Tuberculosis Testing .................................................................68
8.2.1.3. Chest Radiograph ......................................................................69
8.2.1.4. Skin Ty pe Assessment ..............................................................69
8.2.2. Assessments during Study ..........................................................................69
8.2.2.1. Phy sical Examinations ..............................................................69
8.2.2.2. Vital Signs .................................................................................70
8.2.2.3. Electrocardiograms
....................................................................71
8.2.2.4. Herpetiform Rash ......................................................................72
8.2.2.5. Clinical Safety  Laboratory  Assessments ...................................72
8.2.2.6. Creatinine, Cy statin C, and estimates of Glomerular 
Filtration Rate
....................................................................................73
8.2.2.7. Samples for Lipid Analy sis.......................................................73
8.2.2.8. Suicidal I deation and Behavior Risk 
Monitoring ......................74

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  68 . 2 . 2 . 9 .  L o c a l  T o l e r a b i l i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
8 . 2 . 2 . 1 0 .  P r e g n a n c y  T e s t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
8 . 3 .  A d v e r s e  E v e n t s  a n d  S e r i o u s  A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5 
8 . 3 . 1 .  T im e  P e r i o d  a n d  F r e q u e n c y  f o r  C o l l e c t i n g  A E  a n d  S A E  I n f o rm a t i o n . . . . . . . 7 5 
8 . 3 . 1 . 1 .  R e p o r t i n g  S A E s  t o  P f i z e r  S a f e t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 
8 . 3 . 1 . 2 .  R e c o r d i n g  N o n s e r i o u s  A E s  a n d  S A E s  o n  t h e  C R F . . . . . . . . . . . . . . . . . . . 7 6 
8 . 3 . 2 .  M e t h o d  o f  D e t e c t i n g  A E s  a n d  S A E s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 
8 . 3 . 3 .  F o l l o w -u p  o f  A E s  a n d  S A E s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 
8 . 3 . 4 .  R e g u l a t o r y  R e p o r t i n g  R e q u i r em e n t s  f o r  S A E s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6 
8 . 3 . 5 .  E x p o s u r e  d u r i n g  P r e g n a n c y  o r  B r e a s t f e e d i n g ,  a n d  O c c u p a t i o n a l  
E x p o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7 
8 . 3 . 5 . 1 .  E x p o s u r e  D u r i n g  P r e g n a n c y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7 
8 . 3 . 5 . 2 .  E x p o s u r e  D u r i n g  B r e a s t f e e d i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7 
8 . 3 . 5 . 3 .  O c c u p a t i o n a l  E x p o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 7 
8 . 3 . 6 .  M e d i c a t i o n  E r r o r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8 
8 . 4 .  T r e a tm e n t  o f  O v e r d o s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8 
8 . 5 .  P h a rm a c o k i n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 9 
8 . 7 . G e n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2 
8 . 7 . 1 .  S p e c i f i e d  G e n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2 
8 . 8 .  B i om a r k e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2 
8 . 9 .  H e a l t h  E c o n om i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3 
8 . 1 0 .  P a t i e n t  R e p o r t e d  O u t c om e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 
8 . 1 0 . 1 .  P a t i e n t -O r i e n t e d  E c z em a  M e a s u r e  ( P O EM ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 C C I 
C C I 
C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  78 . 1 0 . 2 .  D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x  ( D L Q I )  a n d  C h i l d r e n ’ s  
D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x  ( C D L Q I ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 
8 . 1 0 . 5 .  P e a k  P r u r i t i s  N um e r i c a l  R a t i n g  S c a l e  ( P P -N R S ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 5 
 
 
9 .  S T A T I S T I C A L  C O N S I D E R A T I O N S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7 
9 . 1 .  E s t im a n d s  a n d  S t a t i s t i c a l  H y p o t h e s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7 
9 . 2 .  S am p l e  S i z e  D e t e rm i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 8 
9 . 3 .  P o p u l a t i o n s  f o r  A n a l y s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 8 
9 . 4 .  S t a t i s t i c a l  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 9 
9 . 4 . 1 .  E f f i c a c y  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 9 
9 . 4 . 2 .  S a f e t y  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
9 . 4 . 2 . 1 .  E l e c t r o c a r d i o g r am  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
9 . 5 .  I n t e r im  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 1 
9 . 5 . 1 .  D a t a  M o n i t o r i n g  C omm i t t e e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2 
1 0 .  S U P P O R T I N G  D O C UM E N T A T I O N  A N D  O P E R A T I O N A L  
C O N S I D E R A T I O N S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3 
1 0 . 1 .  A p p e n d i x  1 :  R e g u l a t o r y ,  E t h i c a l ,  a n d  S t u d y  O v e r s i g h t  C o n s i d e r a t i o n s . . . . . . . . . . . . . . . 9 3 
1 0 . 1 . 1 . R e g u l a t o r y a n d  E t h i c a l  C o n s i d e r a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3 
1 0 . 1 . 1 . 1 .  R e p o r t i n g  o f  S a f e t y  I s s u e s a n d  S e r i o u s  B r e a c h e s  o f  t h e  
P r o t o c o l  o r  I C H  G C P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3 
1 0 . 1 . 2 .  F i n a n c i a l  D i s c l o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4 C C I 
C C I C C I C C I 
C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  81 0 . 1 . 3 .  I n f o rm e d  C o n s e n t  P r o c e s s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4 
1 0 . 1 . 4 .  D a t a  P r o t e c t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 5 
1 0 . 1 . 5 .  D i s s em i n a t i o n  o f  C l i n i c a l  S t u d y  D a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 5 
1 0 . 1 . 6 .  D a t a  Q u a l i t y  A s s u r a n c e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 7 
1 0 . 1 . 7 .  S o u r c e  D o c um e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8 
1 0 . 1 . 8 .  S t u d y  a n d  S i t e  C l o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8 
1 0 . 1 . 9 .  P u b l i c a t i o n  P o l i c y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 9 
1 0 . 1 . 1 0 .  S p o n s o r ’ s  Q u a l i f i e d  M e d i c a l  P e r s o n n e l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 9 
1 0 . 2 . A p p e n d i x2 :  C l i n i c a l  L a b o r a t o r y  T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 0 
1 0 . 3 .  A p p e n d i x  3 :  A d v e r s e  E v e n t s :  D e f i n i t i o n s  a n d  P r o c e d u r e s  f o r  R e c o r d i n g ,  
E v a l u a t i n g ,  F o l l o w -u p ,  a n d  R e p o r t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 2 
1 0 . 3 . 1 .  D e f i n i t i o n  o f  A E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 2 
1 0 . 3 . 2 .  D e f i n i t i o n  o f  S A E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 3 
1 0 . 3 . 3 .  R e c o r d i n g / R e p o r t i n g  a n d  F o l l o w -u p  o f  A E s  a n d / o r  S A E s . . . . . . . . . . . . . . . . . . . . . 1 0 4 
1 0 . 3 . 4 .  R e p o r t i n g  o f  S A E s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 7 
1 0 . 4 .  A p p e n d i x  4 :  C o n t r a c e p t i v e  G u i d a n c e  a n d  C o l l e c t i o n  o f  P r e g n a n c y  
I n f o rm a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 9 
1 0 . 4 . 1 .  M a l e  P a r t i c i p a n t  R e p r o d u c t i v e  I n c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 9 
1 0 . 4 . 2 .  F em a l e  P a r t i c i p a n t  R e p r o d u c t i v e  I n c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 9 
1 0 . 4 . 3 .  W om a n  o f  C h i l d b e a r i n g  P o t e n t i a l  (W O C B P ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 0 
1 0 . 4 . 4 .  C o n t r a c e p t i o n  M e t h o d s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 
1 0 . 5 .  A p p e n d i x  5 :  G e n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 4 
1 0 . 6 .  A p p e n d i x  6 :  L i v e r  S a f e t y :  S u g g e s t e d  A c t i o n s  a n d  F o l l o w -u p  A s s e s sm e n t s  
a n d  S t u d y  I n t e r v e n t i o n  R e -c h a l l e n g e  G u i d e l i n e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 5 
1 0 . 7 .  A p p e n d i x  7 :  E C G  F i n d i n g s  o f  P o t e n t i a l  C l i n i c a l  C o n c e r n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 7 
1 0 . 8 .  A p p e n d i x  8 :  C o u n t r y -S p e c i f i c  R e q u i r em e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 9 
1 0 . 9 .  A p p e n d i x  9 :  D i a g n o s i s  C r i t e r i a  f o r  A t o p i c  D e rm a t i t i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 0 
1 0 . 1 0 .  A p p e n d i x  1 0 :  P r o h i b i t e d  C o n c om i t a n t  M e d i c a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 1 
1 0 . 1 1 .  A p p e n d i x  1 1 :  F i t z p a t r i c k  S k i n  T y p e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 4 
1 0 . 1 2 .  A p p e n d i x  1 2 :  P a t i e n t  R e p o r t e d  O u t c om e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 5 
1 0 . 1 2 . 1 .  P e a k  P r u r i t i s  N um e r i c a l  S e v e r i t y  S c a l e  ( P P -N R S ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 5 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  91 0 . 1 2 . 3 .  P a t i e n t - O r i e n t e d  E c z em a  M e a s u r e  ( P O EM ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3 0 
1 0 . 1 2 . 4 .  D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x  ( D L Q I ) / C h i l d r e n ’ s  D L Q I . . . . . . . . . . . . . . . . . 1 3 1 
1 0 . 1 3 .  A p p e n d i x  1 3 :  C -S S R S  –C o l um b i a  S u i c i d e  S e v e r i t y  R a t i n g  S c a l e . . . . . . . . . . . . . . . . . . 1 3 5 
1 0 . 1 4 .  A p p e n d i x  1 4 :  e G F R  C a l c u l a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3 9 
1 0 . 1 5 .  A p p e n d i x  1 5 :  A b b r e v i a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4 0 
1 1 .  R E F E R E N C E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4 5 
L I S T  O F  T A B L E S 
T a b l e 1 . S c h e d u l e  o f  A c t i v i t i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4 
 
T a b l e 3 . T r e a tm e n t  A rm s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 
T a b l e 5 . I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t  ( I G A )  S c o r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3 
T a b l e 6 . C l i n i c a l  S i g n  S e v e r i t y  S c o r i n g  C r i t e r i a  f o r t h e  E c z em a  A r e a  a n d  S e v e r i t y  
I n d e x  ( E A S I ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4 
T a b l e 7 . D e t e rm i n a t i o n  o f  B o d y  R e g i o n  S u r f a c e  A r e a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4 
T a b l e 8 . A r e a  S c o r e  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5 
T a b l e 9 . B o d y  R e g i o n  W e i g h t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5 
T a b l e 1 0 . S k i n  T o l e r a b i l i t y  G r a d i n g  S y s t em . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
T a b l e 1 1 . P r o t o c o l -R e q u i r e d  L a b o r a t o r y  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 0 
L I S T  O F  F IG U R E S 
F i g u r e  1 . S t u d y  D e s i g n  S c h em a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3 
F i g u r e  2 . S t u d y  D e s i g n  S c h em a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4 
F i g u r e  3 . P e a k  P r u r i t u s  N um e r i c a l  R a t i n g  S c a l e  ( P P - N R S ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7 C C I 
C C I C C I 
C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis
Short Title:
A Phase 2b, multicenter, randomized, double -blind, vehicle controlled, parallel group dose 
ranging stud y to assess efficacy, safet y,tolerability , and pharmacokinetics (PK) of 
PF-06700841 cream in participants with mild or moderate atopic derma titis.
Rationale :
This multicenter, randomized, double -blind, vehicle controlled, parallel group, dose ranging 
study  is being conducted to provide data on efficacy , safet y, tolerabilit y and PK of multiple 
topical formulation concentrations of PF-06700841 topical cream in the treatment of 
mild-to-moderate atopic dermatitis (AD).  Th is is the first study  where a PF-06700841 cream 
formulation is being applied topically  to participants with AD.  Additionally , the study  is 
intended to enable selection of the dose and dosing regimen (once dail y [QD ]vs twice daily  
[BID]application) for the future clinical development of topical PF -06700841. 
Objectives, E ndpoints and E stimands :a
Objectives Endpoints Estimandsb
Prim ary Objective Prim ary Endpoint(s) Prim ary E stimands
To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle applied QD or 
BID, on percent change from 
baseline in Eczema Area and 
Severity Index (EASI) in 
participants with mild or 
moderate atopic dermatitis (AD).Percent change from baseline in EASI 
total score at Week 6.Estimand E1: This estimand is 
intended to provide a 
population level estimate of 
the treatment effect of the
investigational product ( IP) on 
a continuous endpoint; without 
the benefit of additional 
prohibited medications during 
treatment and regardless of 
participant compliance with 
the IP dosing.
Secondary Objective(s): Secondary Endpoints Secondary Estimands
To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, using Investigator’s Global 
Assessment (IGA) score 
assessment as endpoint in 
participants with mild or 
moderate AD.Key Secondary Endpoint:
Proportion of participants achieving 
IGA score of clear (0) or almost clear 
(1) (on a 5 point scale) and a reduction 
from baseline of 2points at Week 6.Estimand E2: This estimand is 
intended to provide a 
population level estimate of 
the treatment effect of the IP 
on a binary responder 
endpoint; without the benefit 
of additional prohibited 
medications and regardless of 
a participant compliance with 
the IP dosing.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 11To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, on change from baseline in 
EASI in participants with mild 
or moderate AD.Change from baseline in EASI total 
score at Week 6.All continuous secondary 
endpoints will be analyzed 
descriptively and using 
estimand E1 described above, 
when appropriate .
All categorical secondary 
endpoints will be analyzed 
descriptively and using 
estimand E2 described above, 
when appropriate .To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, using measures of patient 
reported outcomes (PRO), in 
participants with mild or 
moderate AD.Proportion of participants having 
2grades of reduction in weekly 
averages of Peak Pruritus Numerical 
Rating Scale (PP -NRS) at all site visit 
time points specified in t he SoA.
To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, using measures of disease 
affected area, in participants 
with mild or moderate AD.Percent change from baseli ne in 
affected Body Surface Area (BSA) at 
Week 6 and at other time points 
specified in the SoA.
To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, using measures of dis ease 
severity and symptoms as 
endpoints in participants with 
mild or moderate AD.Proportion of participants achieving 
EASI -75 (75% improvement from 
baseline).
To characterize the safety and 
tolerablility of multiple doses of 
PF-06700841 cream versus 
vehicle applied QD or BID in
participants with mild or 
moderate atopic dermatitis .a.Incidence of treatment -emergent 
adverse events (AEs and SAEs), 
significant changes in vital signs, 
clinical laboratory abnormalities, 
and electrocardiogram ( ECG ).
b.Incidence o f severity grades in skin 
tolerability at times indicated in 
SoA.There is no defined estimand 
for these endpoints and they 
will be analyzed using Pfizer 
data standards as applicable.
a.See Section 3 for Tertiary/Exploratory Objectives and Endpoints .
b.See Section 3 for detailed Estimand description .
Overall Design :
This multicenter, Phase 2b, randomized, double -blind, vehicle-controlled, parallel- group, 
dose-ranging study  will assess efficacy , safety, tolerability , and PK of the topical cream 
formulation of PF- 06700841 in the treatment of mild-to-moderate atopic dermatitis.   
Participants will be screened wit hin 6 weeks prior to the Day 1 application of investigational 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 12product ( IP)to confirm they  meet the selection criteria for the study .  The treatment period 
will be 6 weeks, followed by  follow -up period of 4 weeks. 
Number of Participants: 
The study  will e xplore QD and BID dosing regimen and will enroll 
approximately  
280participants (approximately  35participants per treatment arm) to allow for 
224completers (28 participants/arm). 
Intervention Groups and Duration:
There will be 8 dosing arms: 
4arms wit h increasing doses of active IPin QD dosing regimen ie PF -06700841 
cream in 0.1% (1mg/g) , 0.3% (3mg/g) , 1% (10mg/g) , and 3% 
(30mg/g) strengths;
2arms with increasing doses of active IP in BID dosing regimen ie PF -06700841 
cream in 0.3% (3mg/g) and 1 % (10mg/g) strengths;
1vehicle cream armin QD dosing regimen ; 
1vehicle cream arm in BID dosing regimen.
Participants will be randomized into one of the doses in the QD dosing regimen or BID 
dosing regimen of PF -06700841 or its matching vehicle in equa l ratio. 
A study  design 
schematic is presented in Section 1.2 .
Data Monitoring Committee: Yes
Statistical Methods
The primary  estimand will be estimated population -based average treatment effect on percent 
change from baseline in Eczema and Severity  Index ( EASI )score relative to vehicle at 
6 weeks for all randomized participants in the absence of prohibited medication without 
regard to compliance . 
The secondary  estimand will be the estimated population -based average treatment effect on 
the rates of Investigator’s Global Assessment ( IGA) response (percentage of participants 
with a score of 0 or 1 and a 2 point or greater decrease from baseline) at Week 6 relative to 
vehicle (with the same dosing schedule, QD or BID) without rega rd to compliance with IP in 
the absence of prohibited medication. 
All other secondary  continuous clinical endpoints will be anal yzed using the primary  
estimand, while all other secondary  categorical clinical endpoints will be analy zed using the 
secondary  estimand described above. 

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 3 O t h e r  e s t im a n d s  m a y  b e  u s e d  f o r  s om e  o f  t h e  p r im a r y  a n d  s e c o n d a r y  e n d p o i n t s  a s  a  m e a n s  t o  
e x am i n e  t h e  r o b u s t n e s s  o f  t h e  r e s u l t s  a n d  t o  c om p a r e  t o  a v a i l a b l e  l i t e r a t u r e  a s  n e e d e d .   
D e t a i l s  o f  t h e s e  a n a l y s e s  w i l l  b e  p r e s e n t e d  i n  t h e s t a t i s t i c a l  a n a l y s i s  p l a n  ( S A P ) . 
1 . 2 .S c h em a 
F i g u r e  1 . S t u d y  D e s i g n  S c h em a 
C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 141.3.Schedule of Activities (SoA)
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant.
Table 1. Schedule of Activities
Visit Identifiera Screening 
& WashoutDay 1
(Baseline)Day 8
Week 1Day 15
Week 2Day 22
Week 3Day 29
Week 4Day 43
Week 6
(EOT)Follow -up
(EOS)Early 
Termination 
(ET)
Visit Window -42 to -1 N/A 81 152 222 292 43228–35 Days 
post-last 
Dose
Visit Number 1 2 3 4 5 6 7
Enrollment Procedures
Informed Consent X
Eligibility Assessment X X
Demography X
Medical and Atopic Dermatitis HistorybX
Medication History X
Randomizati on X
Clinical Assessments
Complete Physical ExamcX X X
Targeted Physical ExamcX X X X X
Vital SignsdX X X X
Weight X X
Height X
ECGeX X X X
Chest RadiographfX
C-SSRSgX X X X X
Fitzpatrick Skin Type Assessment X
Laboratory Assessments
Hem atology ,Blood Chemistry, and Urinalysis X XhX X X X X X
Lipid Panel (Fasting)iX X
Tuberculosis TestjX

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 5 V i s i t  I d e n t i f i e r a S c r e e n i n g  
&  W a s h o u t D a y  1 
( B a s e l i n e ) D a y  8 
W e e k  1 D a y  1 5 
W e e k  2 D a y  2 2 
W e e k  3 D a y  2 9 
W e e k  4 D a y  4 3 
W e e k  6 
( EO T ) F o l l o w -u p 
( EO S ) E a r l y  
T e rm i n a t i o n  
( E T ) 
V i s i t  W i n d o w -4 2  t o  - 1 N / A 81 1 5 22 2 22 9 24 3 22 8 –3 5  D a y s  
p o s t -l a s t  
Do s e 
V i s i t  N um b e r 1 2 3 4 5 6 7
F o l l i c l e S t im u l a t i n g  H o rm o n e  ( F S H )  T e s t kX
B l o o d P r e g n a n c y  t e s t lX  X X
U r i n e  P r e g n a n c y  t e s t lX  X  X  X  X  X  X  X 
He p a t i t i s  T e s t i n g m,nX X
H I V  T e s t i n g X
V Z V  I g G  A b  ( a d o l e s c e n t s  o n l y ,  i f  a p p l i c a b l e ) oX
P h a rm a c o k i n e t i c s  ( P K ) 
P K  s am p l i n g  ( p r e -d o s e ) X  X  X  X  X  X 
 
 
I n v e s t i g a t i o n a l  P r o d u c t  R e l a t e d  P r o c e s s e s 
D i s p e n s e  d o s i n g  d i a r y / P R O sa n d  i n s t r u c t  o n  u s a g e X
A s s e s s  B S A  &  c a l c u l a t e  I P  n e e d X  X  X  X X
B o d y  S i t e  C h e c k l i s t X  X  X  X  X  X 
W e i g h  a n d  d i s p e n s e  I P X  X  X X
I P  a p p l i c a t i o n  a n d  o b s e r v a t i o n ( a t  s i t e ) X  X X  X  X
R e c o r d  d o s e  a n d  t im e  o f  I P  a p p l i c a t i o n  i n  e D i a r y  X        X
C o l l e c t  a n d  w e i g h  r e t u r n e d  I P  t u b e s  f o r  c om p l i a n c e  c h e c k X X  X  X X
R e v i e w  o f  d o s i n g  D i a r y / P R O s X  X X  X  X  X  X 
C o l l e c t  d o s i n g  D i a r y / P R O s XqX  X C C I 
C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 6 V i s i t  I d e n t i f i e r a S c r e e n i n g  
&  W a s h o u t D a y  1 
( B a s e l i n e ) D a y  8 
W e e k  1 D a y  1 5 
W e e k  2 D a y  2 2 
W e e k  3 D a y  2 9 
W e e k  4 D a y  4 3 
W e e k  6 
( EO T ) F o l l o w -u p 
( EO S ) E a r l y  
T e rm i n a t i o n  
( E T ) 
V i s i t  W i n d o w -4 2  t o  - 1 N / A 81 1 5 22 2 22 9 24 3 22 8 –3 5  D a y s  
p o s t -l a s t  
Do s e 
V i s i t  N um b e r 1 2 3 4 5 6 7
A D -R e l a t e d  C l i n i c a l  A s s e s sm e n t s 
E A S I X  X  X X  X  X  X  X  X 
I G A X  X  X X  X  X  X  X  X 
B S A X  X  X  X  X  X  X  X  X 
S a f e t y  M o n i t o r i n g 
C o n t r a c e p t i o n  c h e c k rX  X  X X   X   X  X  X 
R e v i e w  C o n c om i t a n t  T r e a tm e n t X  X  X X   X   X  X  X  X 
L o c a l  T o l e r a b i l i t y  A s s e s sm e n t s sX        X  X  X 
S e r i o u s  a n d  n o n -s e r i o u s  a d v e r s e  e v e n t  m o n i t o r i n g X            X  X 
P a t i e n t  R e p o r t e d  O u t c om e s  ( P R O )  A s s e s sm e n t s t
i n -c l i n i c  c om p l e t i o n 
P O EM X  X  X X  X  X 
D L Q I / C D L Q I X  X  X X  X  X 
a t -h om e  c om p l e t i o n 
P P -N R S  A t  l e a s t  7  
d a y s  p r i o r  
t o  D a y  1 X        X  X  X 
 
A b b r e v i a t i o n s :  =  o n g o i n g / c o n t i n u o u s  e v e n t ;  B S A  =  B o d y  S u r f a c e  A r e a ;  ;  C -S S R S  =  C o l um b i a  S u i c i d e  S e v e r i t y  R a t i n g  S c a l e ;  
D L Q I / C D L Q I  =  D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x / C h i l d r e n ’ s  D L Q I ; E A S I  =  E c z em a  A s s e s sm e n t  S e v e r i t y  I n d e x ;  E C G = e l e c t r o c a r d i o g r am ;  E O S  =  E n d  o f  S t u d y ;  E O T  =  E n d  o f  
T r e a tm e n t ;  E T  =  E a r l y  t e rm i n a t i o n ;  h C G  =  -H um a n  C h o r i o n i c  G o n a d o t r o p i n ;  H D L  =  H i g h  D e n s i t y  L i p o p r o t e i n ;  ;  
I G A =I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t ;  I P  =  I n v e s t i g a t i o n a l  P r o d u c t ; ;L D L  =  L o w  D e n s i t y  L i p o p r o t e i n ;  
 P C P  =  P r im a r y  C a r e  P h y s i c i a n ;  P E :  P h y s i c a l  E x am i n a t i o n ; ;  ;  P O EM  =  P a t i e n t  
o r i e n t e d  e c z em a  m e a s u r e ;  P P -N R S  =  P e a k  P r u r i t i s  N um e r i c a l  r a t i n g  S c a l e ; ;   
;T B  =  T u b e r c u l o s i s ; V Z V  =  V a r c i l l a  Z o s t e r  V i r u s .C C I 
C C I C C I 
C C I C C I 
C C I C C I 
C C I C C I 
C C I 
C C I C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 7 a . D a y  r e l a t i v e  t o  s t a r t  o f  s t u d y  t r e a tm e n t  ( D a y 1 ) .
b . A t o p i c  D e rm a t i t i s  D i s e a s e  H i s t o r y  i n c l u d e s  c o l l e c t i o n  o f  d e t a i l s  o f  A D :  A D  d i a g n o s i s ,  t h e  u s e  o f  t o p i c a l  t r e a tm e n t s ,  s y s t em i c  t r e a tm e n t s  a n d  o t h e r  t r e a tm e n t s  f o r  A D  t a k e n  
d u r i n g  t h e  3 m o n t h s / 9 0 d a y s  p r i o r  t o  S c r e e n i n g /W a s h o u t  w i t h  d o s e ,  d u r a t i o n  o f  t r e a tm e n t ,  a n d  r e a s o n  f o r  d i s c o n t i n u a t i o n .   A l l  o t h e r  d r u g s  ( i n c l u d i n g s u n s c r e e n ,  o v e r  t h e  
c o u n t e r  m e d i c a t i o n ,  v i t am i n s ,  a n d  d i e t a r y  s u p p l em e n t s )  t a k e n  w i t h i n  2 8 d a y s  p r i o r  t o  t h e  S c r e e n i n g /W a s h o u t  v i s i t  s h o u l d  b e  r e c o r d e d .  
c . F u l l  P h y s i c a l  E x am i n a t i o n ( P E ) :  i n c l u d e s ,  b u t  i s  n o t  l im i t e d  t o  t h e  f o l l o w i n g  o r g a n  o r  b o d y  s y s t em s - h e a d ,  e a r s ,  e y e s ,  n o s e ,  m o u t h ,  s k i n ,  h e a r t  a n d  l u n g ,  l ym p h  n o d e s ,  
g a s t r o i n t e s t i n a l ,  m u s c u l o s k e l e t a l ,  a b d om e n ,  c a r d i o v a s c u l a r ,  a n d  n e u r o l o g i c a l  s y s t em s .   I n  a d d i t i o n ,  a n  a s s e s sm e n t  w i l l  b e  m a d e  o f  t h e  c o n d i t i o n  o f  a l l  A D  i n v o l v e d  s k i n ;  
D i s e a s e  f o c u s e d P h y s i c a l  E x am i n a t i o n :  i n c l u d e s  a l l  s k i n  ( t r e a t a b l e  a n d  n o n -t r e a t a b l e  a r e a s )  a n d  e v a l u a t i o n  o f  a n y  c u r r e n t  o r  r e p o r t e d  s ym p t om s  f o r  c l i n i c a l l y  s i g n i f i c a n t  
c h a n g e s . S k i n  s w a b s  m a y  b e  o b t a i n e d  i f  h e r p e t i f o rm  r a s h  i s  n o t i c e d  d u r i n g  t h e  P E  t o  r u l e  o u t  V Z V  i n f e c t i o n . 
d . V i t a l  S i g n s :  T em p e r a t u r e  ( O r a l o r t ym p a n i c  t em p e r a t u r e ) ,  p u l s e  r a t e ,  a n d  b l o o d  p r e s s u r e  w i l l  b e  t a k e n  i n  s u p i n e  p o s i t i o n ,  a f t e r  t h e  p a r t i c i p a n t  h a s  b e e n  l y i n g  c a lm l y  f o r  a  
m i n im um  o f  5m i n u t e s .   A s s e s sm e n t  o f  v i t a l  s i g n s  s h o u l d  p r e c e d e  b l o o d  d r a w  f o r  c l i n i c a l  l a b o r a t o r y  t e s t s . 
e . L o c a l  r e a d ,  s i n g l e  E C G  ( i n  s u p i n e p o s i t i o n )  a t  a l l  t im e  p o i n t s  i n d i c a t e d .   T r i p l i c a t e  E C G  w i l l  b e  c o n d u c t e d  a s  a p p r o p r i a t e  p e r  S e c t i o n  8 . 2 . 2 . 3.
f . C h e s t  X -r a y  o r  o t h e r  a p p r o p r i a t e  d i a g n o s t i c  im a g e  ( i e ,  C A T  o r  M R I )  m a y  b e  p e r f o rm e d  u p  t o  1 2w e e k s  p r i o r  t o  S c r e e n i n g .  O f f i c i a l  r e a d i n g  m u s t  b e  l o c a t e d  a n d  a v a i l a b l e  i n  
t h e  s o u r c e  d o c um e n t a t i o n .   S e e  S e c t i o n  8 . 2 . 1 . 3f o r  m o r e  d e t a i l s .  
g . S i t e  s t a f f  i s  t o  a dm i n i s t e r  t h e  C o l um b i a  S u i c i d e  S e v e r i t y  S c a l e  ( C -S S R S )  t o  a l l  p a r t i c i p a n t s  a t  s c r e e n i n g  a n d  s c o r e  imm e d i a t e l y .   P a r t i c i p a n t s  w h o  h a v e  r e c e n t  o r  a c t i v e  
s u i c i d a l  i d e a t i o n  o r  b e h a v i o r  o r  c l i n i c a l l y  s i g n i f i c a n t  d e p r e s s i o n  w i l l  b e  e x c l u d e d  f r om  t h e  s t u d y  o r  d i s c o n t i n u e d  f r om  t h e  s t u d y  p e r  S e c t i o n  5 . 2 .  F o r  p a r t i c i p a n t s  m e e t i n g  
e x c l u s i o n a r y  r e s u l t s  o n  t h e  C -S S R S ,  i t  i s  r e c omm e n d e d  t h e  p a r t i c i p a n t ’ s  p r im a r y  c a r e  p h y s i c i a n  ( P C P )  s h o u l d  b e  i n f o rm e d ,  a n d  t h e  p a r t i c i p a n t  r e f e r r e d  t o  a  m e n t a l  h e a l t h  
p r o f e s s i o n a l ,  e i t h e r  b y  t h e  P C P  o r  t h e  i n v e s t i g a t o r a c c o r d i n g  t o  t h e i r  u s u a l  p r a c t i c e .   S e e  S e c t i o n  8 . 2 . 2 . 8f o r  m o r e  d e t a i l s . 
h . B l o o d  d r a w  f o r  h em a t o l o g y  a n d  s e r um  c h em i s t r y  o n  D a y 1  w i l l  b e  p e r f o rm e d  b e f o r e  t h e  i n -c l i n i c  I P  a p p l i c a t i o n .   I f  t h e  s c r e e n i n g  h em a t o l o g y a n d  s e r um  c h em i s t r y  a r e  
p e r f o rm e d  w i t h i n  7 d a y s  p r i o r  t o  D a y 1 ,  t h e n  D a y 1  h em a t o l o g y  a n d  s e r um  c h em i s t r y  t e s t s  w i l l  b e  p e r f o rm e d  a t  t h e  d i s c r e t i o n  o f  t h e  i n v e s t i g a t o r  o r  h i s / h e r  d e s i g n e e .   
L a b o r a t o r y  t e s t s  w i t h  a b n o rm a l  r e s u l t s  ( p e r  S e c t i o n  7 . 1 . 5 ) m a y  b e  r e p e a t e d  o n c e  d u r i n g  t h e  s c r e e n i n g  p e r i o d ;  t h e  l a s t  v a l u e  w i l l  b e  u s e d  t o  d e t e rm i n e  e l i g i b i l i t y .  
i . P a r t i c i p a n t s  m u s t  b e  f a s t i n g  ( w a t e r  o n l y )  f o r  8 h o u r s  p r i o r  t o  v i s i t s  w h e n  l i p i d  p a n e l  i s  b e i n g  t a k e n .   I n c l u d e s  t o t a l  c h o l e s t e r o l ,  L D L ,  H D L  a n d  t r i g l y c e r i d e s . 
j . A  d o c um e n t e d  T B  t e s t  p e r f o rm e d  w i t h i n  1 2w e e k s  p r i o r  t o  S c r e e n i n g i s  a c c e p t a b l e .   P a r t i c i p a n t s  w i t h  a  h i s t o r y  o f  t u b e r c u l o s i s  m a y  n o t  r e q u i r e  T B  t e s t i n g  a s  p e r  t h e  p r o t o c o l  
e x c l u s i o n  c r i t e r i a  i n  S e c t i o n  5 . 2 .   I n  a d d i t i o n  t o  p r o t o c o l  r e q u i r e d  T B  t e s t i n g ,  s i t e s  s h o u l d  f o l l o w  t h e i r  l o c a l  s t a n d a r d s  f o r  T B  s t a t u s  d e t e rm i n a t i o n ,  w h i c h  m a y  i n c l u d e  c h e s t  
X - r a y ,  C AT  o r  M R I  ( a s  p e r  l o c a l  r e g u l a t i o n ) .   S e e  S e c t i o n  8 . 2 . 1 . 2 f o r  a d d i t i o n a l  d e t a i l s .   O f f i c i a l  r e a d i n g  m u s t  b e  l o c a t e d  i n  t h e  s o u r c e  d o c um e n t . 
k . A  h i g h  f o l l i c l e  s t im u l a t i n g  h o rm o n e  ( F S H )  l e v e l  i n  t h e  p o s tm e n o p a u s a l  r a n g e  m a y  b e  u s e d  t o  c o n f i rm  a  p o s tm e n o p a u s a l  s t a t e  i n  w om e n  n o t  u s i n g  h o rm o n a l  c o n t r a c e p t i o n  o r  
h o rm o n e  r e p l a c em e n t  t h e r a p y  ( H R T ) . 
l . S e r um  p r e g n a n c y  t e s t i n g  a t  s c r e e n i n g  i s  r e q u i r e d  f o r  w om e n  o f  c h i l d b e a r i n g  p o t e n t i a l  (W O C B P ) .   Pr e g n a n c y  t e s t s  m a y  a l s o  b e  r e p e a t e d  m o r e  f r e q u e n t l y  a s  p e r  r e q u e s t  o f  
I R B s / E C s  o r  i f  r e q u i r e d  b y  l o c a l  r e g u l a t i o n s .   P r e g n a n c y  t e s t s  w i l l  a l s o  b e  d o n e  w h e n e v e r  1 m e n s t r u a l  c y c l e  i s  m i s s e d  d u r i n g  t h e  a c t i v e  t r e a tm e n t  p e r i o d  ( o r  w h e n  p o t e n t i a l  
p r e g n a n c y  i s  o t h e r w i s e  s u s p e c t e d ) .   T w o  n e g a t i v e  p r e g n a n c y  t e s t s  a r e  r e q u i r e d  b e f o r e  r a n d o m i z a t i o n  ( o n e  n e g a t i v e  s e r um  p r e g n a n c y  t e s t  a t  s c r e e n i n g  a n d  o n e  n e g a t i v e  u r i n e  
p r e g n a n c y  t e s t  a t  D a y 1  v i s i t ) .  S e r um  w i l l  a l s o  b e  c o l l e c t e d  a t  D a y  1  t o  t e s t  p r e g n a n c y ,  t h e  r e s u l t s  o f  w h i c h  m a y  b e  r e c e i v e d  a f t e r  D a y 1.   I f  u r i n e  p r e g n a n c y  t e s t  i s  p o s i t i v e 
a f t e r  I P  a p p l i c a t i o n ,  s e r um  p r e g n a n c y  t e s t  w i l l  b e  c o n d u c t e d ,  I P  a p p l i c a t i o n  p a u s e d  a n d  s p o n s o r  c l i n i c i a n  a n d  s p o n s o r  m e d i c a l  m o n i t o r  n o t i f i e d  imm e d i a t e l y .  
m . I n c l u d e s  t e s t i n g  f o r  H e p a t i t i s B  S u r f a c e  A n t i g e n  ( H B s A g )  a n d  H e p a t i t i s B  C o r e  A n t i b o d y  ( H B c A b ) ;  H e p a t i t i s B  S u r f a c e  A n t i b o d y  ( H B s A b )  w i l l  b e  r e f l e x  t e s t e d  i f  
p a r t i c i p a n t s  a r e  p o s i t i v e  f o r  H B s A b .   H B s A bw i l l  b e  t e s t e d  f o r  a l l  p a r t i c i p a n t s  i f  r e q u i r e d  b y  c o u n t r y -s p e c i f i c  r e g u l a t i o n s ,  S e e  c o u n t r y -s p e c i f i c  d e t a i l s  i n  A p p e n d i x 8.  
H e p a t i t i s  C  V i r a l  R N A  ( H C V  R N A )  w i l l  b e  r e f l e x  t e s t e d  i f  p a r t i c i p a n t s  a r e  p o s i t i v e  f o r  H C V A b . 
n . [ i f  r e q u i r e d  b y  c o u n t r y -s p e c i f i c  r e g u l a t i o n s ]  H e p a t i t i s  B  v i r u s  ( H B V )d e o x y r i b o n u c l e i c  a c i d  ( D N A ) a s s e s sm e n t s  w i l l  b e  r e f l e x  t e s t e d  o n l y  i f  H B s A g  a n d  H B c A b  a r e  n e g a t i v e  
a n d  H B s A b  i s  p o s i t i v e  w i t h o u t  d o c um e n t a t i o n  o f  p r i o r  H B V  v a c c i n a t i o n  a t  s c r e e n i n g  a n d  f o r  p a r t i c i p a n t s  w h o  h a d  n e g a t i v e  H B s A g ,  p o s i t i v e  H B c A b  a n d  p o s i t i v e  H B s A b  
w i t h  d o c um e n t a t i o n  o f  H B V  v a c c i n a t i o n  a t  s c r e e n i n g .
o . V Z V  I g G  a n t i b o d y  t e s t i n g  i s  r e q u i r e d  t o  c o n f i rm  e l i g i b i l i t y  i n  a d o l e s c e n t  p a r t i c i p a n t s  w h o  h a v e  n o t  r e c e i v e d  a t  l e a s t  o n e  d o s e  o f  a  v a r i c e l l a  v a c c i n e . 
C
C
I
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 8 q . O n l y  f o r  p a r t i c i p a n t s  w h o  d o  n o t  m e e t  r a n d om i z a t i o n  c r i t e r i a .
r . T h e  c o n t r a c e p t i o n  c h e c k  i s  a n  o p p o r t u n i t y  t o  c o n f i rm  t h a t  c o n t r a c e p t i o n ,  i f  a s s i g n e d ,  i s  u s e d  c o n s i s t e n t l y  a n d  c o r r e c t l y .   A l s o ,  i t  i s  t h e  o p p o r t u n i t y  t o  a s s e s s  c h a n g i n g  p o t e n t i a l  
t o  f a t h e r / b e a r  c h i l d r e n  a n d  a l l o w s  f o r  a l t e r i n g  c o n t r a c e p t i o n  i f  n e w  d i s e a s e  c o n t r a i n d i c a t e s  a  s e l e c t e d  m e t h o d  o f  c o n t r a c e p t i o n  o r  i f  n o n -c h i l d b e a r i n g  s t a t u s  i s  a c h i e v e d .  
s . L o c a l  t o l e r a b i l i t y  a t  t h e  s i t e  o f  I P  a p p l i c a t i o n  w i l l  b e  a s s e s s e d  p r e - d o s e  a n d  imm e d i a t e l y  a f t e r  p o s t - d o s e .
t . P P -N R S w i l l  b e  a s s e s s e d  d a i l y  d u r i n g  t h e  s c r e e n i n g  p e r i o d  ( a t  l e a s t  7d a y s  imm e d i a t e l y  p r i o r  t o  D a y 1 )  a n d  f r om  D a y 1  t o  E O T  v i s i t  (W e e k 6 )  a n d  t h e n ,  a t  f o l l o w -u p ;   
 
 
 
 
  
 C
C
IC C I 
C
C
I
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 192.INTRODUCTION
PF-06700841 is a TYK2 /JAK1 inhibitor that is currently being investigated for m ultiple 
therapeutic indications.
2.1.Study Rationale 
The purpose of th is study is to assess PF-06700841 efficacy , safety, tolerab ility andPK of 
multiple topical formulation concentrations of PF -06700841, in mild to moderate A D
population .  In addition, the study  is intended to enable selection of a dose and dosing 
regimen ( QD vs. BID) for the future clinical development of PF -
06700841.  Oral formulation 
of PF -06700841 has been studied in 
multiple indications , but this is the first study  in topical 
formulation to be applied to participants with mild or moderate AD. 
2.2.Background 
Atopic dermatitis (AD), also known as atopic eczema, is a common, chronic, inflammatory  
skin disorder characterized by  flaky  skin lesions, intense pruritus, and a general deterioration 
in quality  of life.  Atopic dermatitis can affect any  age gr oup.1  Prevalence esti mates suggest 
approximately  10% of adults and 
10%- 20% of children suffer from AD.   AD usually  begins 
in earl y childhood and continues to intermittently  and unpredictabl y flare in adolescence and 
in adulthood.  Up to 18% of those affected with AD suffer wit
h severe disease.  The burden 
of disease is substantial for children, adolescents, and adults, as well as their family  members 
and caregivers.
Progress in the development of topical therapies for AD has not advanced as rapidly  as other 
areas in dermatology .  Patients with persistent AD often require long -term intermittent 
treatment, in addition to 
topical treatments, which can be self-administered at home, remain 
timely and are easily  accessible option. 
There are a limited number of treatments available fo r AD.  Current treatments for AD 
include emollients, topical corticosteroids (eg, betamethasone, clobetasol, fluocinonide), 
topical calcineurin inhibitors (eg, pimecrolimus, tacrolimus), and coal tar preparations.  
Crisaborole was approved as a topical tre atment in December 2016 b y the USFederal Drug 
Administration ( FDA )for use in patients with mild to moderate AD.  Additional treatments 
generall y reserved for severe AD include phototherap y (eg, ultraviolet A light [ UVA] with or 
without psoralen, ultravio letB light [ UVB ] narrowband or broadband) and sy stemic agents 
(eg, corticosteroids, cy closporine, recombinant IFN-, mycophenolate mofetil, methotrexate 
[MTX], azathioprine [AZA ], intravenous immunoglobulin) .2None of the currentl y available 
therapies offer a cure; therefore, the main aims of existing treatments are to reduce the 
occurrence of acute flares, increase the time between relapses, reduce pruritus and reduce the 
resulting sleep disturbance s.3,4

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 20For AD patients not responding to topical therapies and phototherap y, off -label use of 
systemic agents, which include sboth oral corticosteroids and oral immunosuppressan ts 
remain the last viable treatment option.  Sy stemic therapy  options are associated with 
potentially  severe adverse effects and require careful monitoring.  The risk of toxicity  and 
side effects remain a concern when s ystemic agents are used.  For these r easons the use of 
these agents is limited to short courses or intermittent therap y.
Other s ystemic agents used to treat AD are under clinical development or recentl y approved.  
Dupilumab, an injectable human monoclonal antibody targeting interleukin (IL)-4and -13,
was approved b y the FDA in March 2017 and received marketing authori sation in Europe in 
September 2017 .  This offers a novel mechanism of action for the treatment of moderate to 
severe AD. However, the approved dosing for dupilumab as an initial dose of 2 x 300 mg 
subcutaneous injections followed by  300 mg every other week injections may  limit the 
desirability  of this treatment.
Therefore, the prominent unmet medical need in the topical treatment of AD is for an 
effective , safe topical agent with out restrictions on long
-term or continuous use, and without 
local or s ystemic side effects, and to be approved for use on all body regions, and will be 
approved for use in adolescents .
Mechanism of Action
The pathoph ysiology  of AD is the product of a complex interaction between various 
susceptibility  genes, host environmental factors, infectious agents, defects in skin barrier 
function, and immunologic responses.  The predominant sy mptom of AD (ie pruritus and the 
resulting scratching) t ypically  sets off an amplification cy cle of atopic skin inflammation.  
Activation of T lymphocy tes, dendritic cells, macrophages, keratinocy tes, mast cells, and 
eosinophils results in a release of numerous pro- inflammatory  cytokines and chemokines.  
This amplification cy cle sustains the inflammatory  responses characteristic of atopic 
dermatitis lesions.  Acute atopic dermatitis lesions have been associated with a 
Th2phenoty pe, showing dominance of interleukin ( IL) -4, IL -5, IL -13, and IL -31 secretion.  
While IL -
4producing Th2cells may  drive the development of atopic skin lesions, chronic 
lesions show either the coexistence of both IL -4producing T h2and IFN -producing 
T
h1cells or T h1 dominance.  This coexistence of Th2 and Th1responses or Th1dominance 
is more likely  tobe the underly ing immunopathology  in adult participants who have had 
atopic dermatitis chronically  or intermittently  since childhood.  Recent evidence5supports 
IL-31 having an important role in pruritus and in flammation in AD.6,7
In the skin ,cytokines induced by  Janus Kinase ( JAK) signaling impact several cellular 
inflammatory  functions such as apoptosis of inflammatory  T cell infiltrates and promoting 
Thelper (Th) cell 
differentiation.   C-X- C motif chemokine ligand 10 (CXCL10 ) , C-C motif 
chemokine ligand 26 ( CCL 26)andmatrix metalloprotease 12 (MMP12 )have been reported 
to be induced b y cytokines acting via the JAK cla ss of kinases8-11and are implicated in 
inflammatory  and autoimmune conditions of the skin .12-17Inaddition, impairment of the 
skin barrier protein filaggrin has also been implicated in inflammatory  and autoimmune 
diseases of the skin ,18and its expression has been reported to increas e upon inhibition of JAK

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 1 e n z y m e s .9F o l l o w i n g  t o p i c a l  a p p l i c a t i o n o f  t h e  c l i n i c a l  f o rm u l a t i o n  t o  f r e s h l y  e x c i s e d  h um a n  
s k i n ,  P F -0 6 7 0 0 8 4 1  c a u s e d  a  d o s e -d e p e n d e n t  i n h i b i t i o n  o f  g e n e  e x p r e s s i o n  o f  
p r o -i n f l amm a t o r y  m o l e c u l e s  C X C L 1 0 ,  C C L 2 6  a n d  MM P 1 2  (m e a s u r e d  b y  c h a n g e s  i n  
m e s s e n g e r  r i b o n u c l e i c  a c i d  [ m R N A ]  i n  t h e  p r e s e n c e  a n d  a b s e n c e  o f  P F -0 6 7 0 0 8 4 1 )  a n d  a  
d o s e -d e p e n d e n t  s t im u l a t i o n  o f  t h e  s k i n  b a r r i e r  p r o t e i n ,  f i l a g g r i n .   T h u s  P F -0 6 7 0 0 8 4 1  s h o w e d  
p h a rm a c o l o g y  i n  h um a n  s k i n  b y  t h e  t o p i c a l  a p p l i c a t i o n ,  c o n s i s t e n t  w i t h  t h e  k n o w n  a c t i v i t y  o f  
P F -0 6 7 0 0 8 4 1  o n  J A K c l a s s  o f  k i n a s e s .
T h e  T y r o s i n g  K i n a s e 2  ( T Y K 2 )a c t i v i t y  o f  P F -0 6 7 0 0 8 4 1  w i l l  b l o c k  I L -2 3  s i g n a l i n g  w h i c h  i s  
im p o r t a n t  f o r  T h 1 7  a n d  T h 2 2  c e l l  d i f f e r e n t i a t i o n ,  b r i n g i n g  a b o u t  t h e  p o t e n t i a l  f o r  a c t i v i t y  i n  
c e r t a i n  s u b t y p e s  o f  A D  t h a t  a p p e a r  t o  h a v e  g r e a t e r  d e p e n d e n c e  o n  T h1 7  a n d  T h2 2  p a t h w a y s ,  
i n c l u d i n g  e a r l y - o n s e t  p e d i a t r i c  A D ,  i n t r i n s i c  ( n o n -a l l e r g i c  A D ) ,  a n d  A D  i n  A s i a n  a n d  
A f r i c a n -Am e r i c a n  p a r t i c i p a n t s .1 9 -2 2 
P F -0 6 7 0 0 8 4 1  i s  a  d u a l  T Y K 2 / J A K 1  i n h i b i t o r  w i t h  g o o d  s e l e c t i v i t y  p r o f i l e  o v e r  o t h e r  h um a n  
k i n a s e s .   B a s e d  o n  i t s  c y t o k i n e  i n h i b i t i o n  p r o f i l e ,  P F -0 6 7 0 0 8 4 1  i s  e x p e c t e d  t o p r o v i d e 
t h e r a p e u t i c  b e n e f i t  i n  t h e t r e a tm e n t  o f  A t o p i c  D e rm a t i t i s  b y  t a r g e t i n g  t h e  s i g n a l i n g  o f  
c y t o k i n e s  i n  T h 1,  T h 2a n d  T h 1 7  l y m p h o c y t e s . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 2   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 3  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
   
 
 
 
 
  
  
 
  
  
 
 
  
 
  
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 4  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  2 7  
 
 
 
 
 
 
 
 
 
 
 
 
 
2 . 3 . B e n e f i t / R i s k  A s s e s sm e n t 
T h i s  i s  t h e  f i r s t  s t u d y  w h e r e  a  P F -0 6 7 0 0 8 4 1  c r e am  f o rm u l a t i o n  i s  b e i n g  a p p l i e d  t o p i c a l l y  t o  
p a r t i c i p a n t s w i t h  a t o p i c  d e rm a t i t i s .   T h i s  i s  a l s o  t h e  f i r s t  s t u d y  w h e r e  P F -0 6 7 0 0 8 4 1  c r e am  
f o rm u l a t i o n  w i l l  b e  a p p l i e d  t o  p a r t i c i p a n t s  f r om  1 2 - 1 8 y e a r s  o f  a g e  w i t h  A D .  
JA K k i n a s e  i n h i b i t o r s  h a v e  s h o w n  e f f i c a c i o u s  i n  A D  s t u d i e s .   I n  a d d i t i o n ,  s y s t em i c  e x p o s u r e s
f o l l o w i n g  t o p i c a l a p p l i c a t i o n  o f  P F -0 6 7 0 0 8 4 1  i s  e x p e c t e d  t o  b e  l o w e r  t h a n  t h a t  o b s e r v e d  
f o l l o w i n g  o r a l  a dm i n i s t r a t i o n  i n  a l o p e c i a  a r e a t a  ( B 7 9 3 1 0 0 5 )  a n d  p s o r i a s i s  ( B 7 9 3 1 0 0 4 )  
s t u d i e s  t h e r e f o r e ,  n o  c h a n g e  i sa n t i c i p a t e d  i n  b e n e f i t / r i s k  p r o f i l e .  
M o r e  d e t a i l e d  i n f o rm a t i o n  a b o u t  t h e  k n o w n  a n d  e x p e c t e d  b e n e f i t s  a n d  r i s k s  a n d  r e a s o n a b l y  
e x p e c t e d  a d v e r s e  e v e n t s  ( A E s )  o f  P F -0 6 7 0 0 8 4 1  m a y  b e  f o u n d  i n  t h e  I B ,  w h i c h  i s  t h e  s i n g l e  
r e f e r e n c e  s a f e t y  d o c um e n t  ( S R S D )  f o r  t h i s  s t u d y .  
3 . O B J E C T I V E S ,  E S T IM A N D S ,  A N D  E N D PO I N T S
O b j e c t i v e s E n d p o i n t s E s t im a n d s 
P r im a r y  O b j e c t i v e :  P r im a r y  E n d p o i n t ( s ) : P r im a r y  E s t im a n d s :  
T o  c om p a r e  t h e  e f f i c a c y o f  
m u l t i p l e  d o s e  l e v e l s  o f  
P F -0 6 7 0 0 8 4 1  t o p i c a l  c r e am  
v e r s u s  v e h i c l e ,  a p p l i e d  Q D  o r  
B I D ,  o n  p e r c e n t  c h a n g e  f r om  
b a s e l i n e  i n  E c z em a  A r e a  a n d  P e r c e n t  c h a n g e  f r om  b a s e l i n e  i n  
E A S I  t o t a l  s c o r e  a t  W e e k 6 . E s t im a n d  E 1 :  T h i s  e s t im a n d  i s  
i n t e n d e d  t o  p r o v i d e  a  p o p u l a t i o n  
l e v e l  e s t im a t e  o f  t h e  t r e a tm e n t  
e f f e c t  o f  t h e I P  o n  a  c o n t i n u o u s  
e n d p o i n t ;  w i t h o u t  t h e  b e n e f i t  o f  
a d d i t i o n a l  p r o h i b i t e d  m e d i c a t i o n s  C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 28Severity Index (EASI) in 
participants with mild or 
moderate atopic dermatitis (AD). during treatment and regardless of 
participant compliance with the 
IP dosing.
Population:
Participants with mild or 
moderate AD as defined by the 
inclusion and exclusion criteria; 
without the benefit of receiving 
prohibited medications during 
treatment and regardless of 
compliance.
Inter -current Events: 
a.Prohibited medication –all 
scores in participants who 
receive prohibited medication 
post randomization will be 
omitted from the analysis and 
treated as missing scores. 
Missing scores will be 
imputed based on the 
assumption that participants 
do not benefit from the IP 
treatment.
b.Withdraw al and all other 
events leading to missing 
data w ill be treated similarly 
assuming par ticipants have 
efficacy values similar to 
control participants. 
c.Inadequate compliance –
participants data will be used 
as recorded.
Population level summary: 
The percent change from baseline 
mean difference between treated 
and vehicle in EASI score.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 29Secondary Objective(s): Secondary Endpoints: Secondary Estimands:
To compare the efficacy of 
multiple dose levels of 
PF-06700841 topical cream 
versus vehicle, applied QD or 
BID, using Investigator’s Global 
Assessment (IGA) score 
assessment as endpoint in 
participants with mild or 
moderate AD. Key Secondary Endpoint:
Proportion of participants achieving 
IGA score of clear (0) or almost 
clear (1) (on a 5 point scale) and a 
reduction from baseline of 2points 
at Week 6.Estimand E2: This estimand is 
intended to provide a population 
level estimate of the treatment 
effect of the IP on a binary 
responder endpoint; w ithout the 
benefit of additional prohibited 
medications and regardless of a 
participant compliance with the 
IP dosing.
Population:
Participants with mild or 
moderate AD as defined by the 
inclusion and exclusion criteria; 
without the benefit of receiving 
prohibited medications during 
treatment and regardless of 
compliance.
Inter -current Events: 
a.Prohibited medication –
response will be considered 
negati ve for participants who 
receive prohibited medication 
post-randomization.
b.Withdraw al and all other 
events leading to missing 
data w ill be treated similarly 
assuming that participants no 
longer receive benefit from 
the IP and hence will be 
treated as failur e for endpoint 
above.
c.Inadequate compliance –
participants data will be used 
as recorded.
Population level summary: 
The difference in proportions 
betw een IP treated and vehicle 
response rates.
To compare the efficacy of 
multiple dose levels of 
PF-0670084 1 topical cream 
versus vehicle, applied QD or 
BID, on change from baseline in 
EASI in participants with mild or 
moderate AD.Change from baseline in EASI total 
score at Week 6.All continuous secondary 
endpoints will be analyzed 
descriptively and using est imand 
E1 described above, when 
appropriate .
All categorical secondary 
endpoints will be analyzed 
descriptively and using estimand 

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 0 T o  c om p a r e  t h e  e f f i c a c y  o f  
m u l t i p l e  d o s e  l e v e l s  o f  
P F -0 6 7 0 0 8 4 1  t o p i c a l  c r e am  
v e r s u s  v e h i c l e ,  a p p l i e d  Q D  o r  
B I D ,  u s i n g  m e a s u r e s  o f  p a t i e n t  
r e p o r t e d  o u t c om e s  ( P R O ) ,  i n  
p a r t i c i p a n t s  w i t h  m i l d  o r  
m o d e r a t e  A D . P r o p o r t i o n  o f  p a r t i c i p a n t s  h a v i n g  
2g r a d e s  o f  r e d u c t i o n  i n  w e e k l y  
a v e r a g e s  o f P e a k  P r u r i t u s  N um e r i c a l  
R a t i n g  S c a l e  ( P P -N R S )  a t  a l l  s i t e  
vi s i t  t im e  p o i n t s  s p e c i f i e d  i n  t h e  
S o A .E 2  d e s c r i b e d  a b o v e ,  w h e n  
a p p r o p r i a t e .
T o  c om p a r e  t h e  e f f i c a c y  o f  
m u l t i p l e  d o s e  l e v e l s  o f  
P F -0 6 7 0 0 8 4 1  t o p i c a l  c r e am  
v e r s u s  v e h i c l e ,  a p p l i e d  Q D  o r  
B I D ,  u s i n g  m e a s u r e s  o f  d i s e a s e  
a f f e c t e d  a r e a ,  i n  p a r t i c i p a n t s  w i t h  
m i l d  o r  m o d e r a t e A D . P e r c e n t  c h a n g e  f r om  b a s e l i n e  i n  
a f f e c t e d  B o d y S u r f a c e  A r e a  ( B S A )  
a t  W e e k 6  a n d  a t  o t h e r  t im e  p o i n t s  
s p e c i f i e d  i n  t h e  S o A .
T o  c om p a r e  t h e  e f f i c a c y  o f  
m u l t i p l e  d o s e  l e v e l s  o f  
P F -0 6 7 0 0 8 4 1  t o p i c a l  c r e am  
v e r s u s  v e h i c l e  c r e am ,  a p p l i e d  Q D  
o r  B I D ,  u s i n g  m e a s u r e s  o f  d i s e a s e  
s e v e r i t y  a n d  s ym p t om s  a s  
e n d p o i n t s  i n  p a r t i c i p a n t s  w i t h  
m i l d  o r  m o d e r a t e  A D . P r o p o r t i o n  o f  p a r t i c i p a n t s  a c h i e v i n g  
E A S I -7 5  ( 7 5%  im p r o v em e n t  f r om  
b a s e l i n e ) . 
T o  c om p a r e  s a f e t y  a n d  
t o l e r a b i l i t y  o f  m u l t i p l e  d o s e s  o f  
P F - 0 6 7 0 0 8 4 1  c r e am  v e r s u s  
v e h i c l e ,  a p p l i e d  Q D  o r  B I D ,  i n  
p a r t i c i p a n t s  w i t h  m i l d  o r  
m o d e r a t e  A D . a . I n c i d e n c e  o f  t r e a tm e n t -em e r g e n t  
a d v e r s e  e v e n t s  ( A E s  a n d  S A E s ) ,  
s i g n i f i c a n t  c h a n g e s  i n  v i t a l  s i g n s ,  
c l i n i c a l  l a b o r a t o r y  a b n o rm a l i t i e s  
a n d  E C G . 
b . C h a n g e  f r om  b a s e l i n e i n  c l i n i c a l  
l a b o r a t o r y  v a l u e s  ( c h em i s t r y  a n d  
h em a t o l o g y ,  l i p i d s ) . 
c . C h a n g e  f r om  b a s e l i n e  i n  E C G  
p a r am e t e r s  ( h e a r t  r a t e ,  Q T ,  Q T c ,  
P R  a n d  Q R S  i n t e r v a l s ) . 
d . C h a n g e  f r om  b a s e l i n e  i n  v i t a l  
s i g n s  ( b l o o d  p r e s s u r e ,  p u l s e  r a t e  
a n d  t em p e r a t u r e  m e a s u r em e n t s ) . 
e . I n c i d e n c e  o f  s e v e r i t y  g r a d e s  i n  
s k i n  t o l e r a b i l i t y  a t  t im e s  
i n d i c a t e d  i n  S o A .T h e r e  i s  n o  d e f i n e d  e s t im a n d  f o r  
t h e s e  e n d p o i n t s  a n d  t h e y  w i l l  b e  
a n a l y z e d  u s i n g  P f i z e r  d a t a  
s t a n d a r d s  a s  a p p l i c a b l e .
  
 
  
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 1  
 
 
E A S I -9 0 ,  
  
,  E A S I -9 0 
9 0%  
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 .C C I 
C C I C C I 
C C I 
C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 2  
 
 
 
  
 
 
  
 
 
 
  
4 . S T U D Y  D E S IG N 
4 . 1 . O v e r a l l  D e s i g n 
T h i s  P h a s e 2 b ,  m u l t i -c e n t e r ,  r a n d om i z e d ,  d o u b l e -b l i n d ,  v e h i c l e -c o n t r o l l e d ,  p a r a l l e l  g r o u p ,  
d o s e -r a n g i n g s t u d y  w i l l  a s s e s s  e f f i c a c y ,  s a f e t y ,  t o l e r a b i l i t y  a n d  P K  o f  a  t o p i c a l  f o rm u l a t i o n  o f  
P F - 0 6 7 0 0 8 4 1 ,  w h e n a p p l i e d  o n c e  o r  t w i c e  d a i l y ,  i n  p a r t i c i p a n t s  w i t h  m i l d o r  m o d e r a t e  a t o p i c  
d e rm a t i t i s .   T h i s  i s  t h e  f i r s t  s t u d y  w h e r e  a  P F -0 6 7 0 0 8 4 1  c r e am  f o rm u l a t i o n  i s  b e i n g  a p p l i e d  
t o  p a r t i c i p a n t s  w i t h  a t o p i c  d e rm a t i t i s .  
P a r t i c i p a n t s  w i l l  b e s c r e e n e d w i t h i n  6 w e e k s  p r i o r  t o  t h e  D a y 1  d o s e  o f  I P  t o  c o n f i rm  t h e y  
m e e t  t h e  s e l e c t i o n  c r i t e r i a  f o r  t h e  s t u d y .   T h e  t r e a tm e n t  w i l l  b e  6 w e e k s ,  f o l l o w e d  b y  a  
4w e e k f o l l o w -u p .   T h e  t o t a l  s t u d y  d u r a t i o n  i s  a p p r o x im a t e l y  1 6 w e e k s . 
A t  t h e  s t a r t  o f  t h e  s t u d y,  a d u l t  p a r t i c i p a n t s  1 8 - 7 5 y e a r s o f  a g e  (o r  m i n im um  a g e  b a s e d  o n  
c o u n t r y -s p e c i f i c  c r i t e r i a )  w i t h  m i l d  o r  m o d e r a t e  a t o p i c  d e rm a t i t i s w i l l  b e  e n r o l l e d .   O n c e  
a p p r o x im a t e l y  2 0%  o f  p a r t i c i p a n t s  h a v e  c om p l e t e d  a t  l e a s t  2 w e e k s  (W e e k 2  v i s i t )  o f  
t r e a tm e n t ,  a s s e s sm e n t  o f  s a f e t y  a n d  t o l e r a b i l i t y  d a t a  w i l l  b e  c o n d u c t e d  b y  a n  i n d e p e n d e n t  
I n t e r n a l  R e v i e w  C omm i t t e e ( I R C ) .  Af t e r  c o n f i rm i n g  a c c e p t a b l e  s a f e t y  a n d  t o l e r a b i l i t y ,  t h e  
m i n im um  a g e  o f  m a l e  p a r t i c i p a n t s  t o  b e  e n r o l l e d  i n  t h i s  s t u d y  w i t h  m i l d  o r  m o d e r a t e  a t o p i c 
d e rm a t i t i s  w i l l  b e  l o w e r e d  t o  1 2 y e a r s .  
A s s um i n g  2 0%  d r o p o u t  r a t e ,  a  t o t a l  o f  a p p r o x im a t e l y  2 8 0 p a r t i c i p a n t s  ( a p p r o x im a t e l y  
3 5 p a r t i c i p a n t s  p e r  t r e a tm e n t  a rm )  w i l l  b e  r a n d om i z e d  t o  e n s u r e  c om p l e t i o n  o f  a p p r o x im a t e l y  
2 2 4 p a r t i c i p a n t s  ( 2 8 p a r t i c i p a n t s / a rm ) .  
M u l t i p l e  s a f e t y ,  e f f i c a c y ,  P K  a n d  p h a rm a c o d y n am i c s  ( P D )  r e l a t e d  a s s e s sm e n t s  w i l l  b e  
p e r f o rm e d  d u r i n g  t h e  t r e a tm e n t a n d  f o l l o w -u p  p e r i o d .  C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 3  
 
 
 
P a r t i c i p a n t s  w i l l  b e  r a n d om i z e d t o  1 o f  8 t r e a tm e n t  a rm s  i n  t h e  r a t i o  o f  1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 .   
I n v e s t i g a t o r s ,  p a r t i c i p a n t s ,  a n d  t h e  s p o n s o r  s t u d y  t e am  w i l l  b e  b l i n d e d  a s  t o  i n v e s t i g a t i o n a l  
p r o d u c t  ( P F -0 6 7 0 0 8 4 1  c r e am  v s  v e h i c l e  c r e am ) .  
T a b l e 3 . T r e a tm e n t  A rm s 
T r e a tm e n t  
A rm T a r g e t  N um b e r  o f  
P a r t i c i p a n t s  R a n d om i z e d A p p r o x im a t e  N um b e r  o f  
C om p l e t e r s I n v e s t i g a t i o n a l  P r o d u c t 
A 3 5 2 8 V e h i c l e  c r e am  Q D 
B 3 5 2 8 P F -0 6 7 0 0 8 4 1  0 . 1%  c r e am  Q D 
C 3 5 2 8 P F -0 6 7 0 0 8 4 1  0 . 3%  c r e am  Q D 
D 3 5 2 8 P F -0 6 7 0 0 8 4 1  1 . 0%  c r e am  Q D 
E 3 5 2 8 P F -0 6 7 0 0 8 4 1  3 . 0%  c r e am  Q D 
F 3 5 2 8 V e h i c l e  c r e am  B I D * 
G 3 5 2 8 P F -0 6 7 0 0 8 4 1  0 . 3%  c r e am  B I D * 
H 3 5 2 8 P F -0 6 7 0 0 8 4 1  1 . 0%  c r e am  B I D * 
A  s t u d y  d e s i g n  s c h em a t i c  i s  i n  F i g u r e  2b e l o w .C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 4 F i g u r e  2 . S t u d y  D e s i g n  S c h em a 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 5 4 . 2 . S c i e n t i f i c  R a t i o n a l e  f o r  S t u d y  D e s i g n 
T h i s  6 -w e e k  s t u d y  i s  f i r s t  t im e  a  t o p i c a l  P F -0 6 7 0 0 8 4 1 c r e am  f o rm u l a t i o n  i s  b e i n g  e v a l u a t e d  
i n  a  m i l d -t o -m o d e r a t e  A D p o p u l a t i o n w i t h  a n  a f f e c t e d  b o d y  s u r f a c e  a r e a  ( B S A )  o f  2 -2 0% .  
Mu l t i p l e  f o rm u l a t i o n  c o n c e n t r a t i o n s  a r e  b e i n g  t e s t e d  i n  t w o  d o s i n g  r e g im e n s( Q D  v s  B I D ) t o  
a s s e s s  e f f i c a c y ,  s a f e t y ,  t o l e r a b i l i t y a n d  P K .   T h e  d u r a t i o n  o f  t h e  s t u d y  i s  a p p r o p r i a t e  t o  a s s e s s  
t h e e f f i c a c y ,  s a f e t y  a n d  t o l e r a b i l i t y p r o f i l e  o f  t o p i c a l  P F -0 6 7 0 0 8 4 1 .   T h e  c u r r e n t  n o n c l i n i c a l  
t o x i c o l o g y  p a c k a g e  s u p p o r t s  t h e  s t u d y  d u r a t i o n s  o f  u p  t o  1 2 w e e k s . 
P r im a r y  a n d  k e y  s e c o n d a r y  r e g i s t r a t i o n  e n d p o i n t s  o f  t h i s  s t u d y  a r e :  p e r c e n t  c h a n g e  f r om  
b a s e l i n e  i n  E c z em a  A r e a a n d  S e v e r i t y  I n d e x  ( E A S I ) ,  a c o n t i n u o u s e n d p o i n t  a n d  
I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t  ( I G A ),  a  b i n a r y  e n d p o i n t  r e s p e c t i v e l y .  
M a l e  A d o l e s c e n t s 
P r e v a l e n c e  e s t im a t e s  s u g g e s t  a p p r o x im a t e l y  1 0% - 2 0%  c h i l d r e n  s u f f e r  f r om  A D .   A D  u s u a l l y  
b e g i n s  i n  e a r l y  c h i l d h o o d  a n d  c o n t i n u e s  t o  i n t e rm i t t e n t l y  a n d  u n p r e d i c t a b l y  f l a r e  i n  
a d o l e s c e n c e  a n d  i n  a d u l t h o o d .   T h e r e f o r e ,  i n c l u s i o n  o f  a d o l e s c e n t  p o p u l a t i o n  w i l l  p r o v i d e  a n  
es t im a t e  o f  t h e  e f f i c a c y  o f  P F -0 6 7 0 0 8 4 1  i n  t h i s  p o p u l a t i o n  a n d  w i l l  a s s i s t  i n  f u t u r e  
r e g i s t r a t i o n  a n d  P h a s e 3  p l a n n i n g .   P F -0 6 7 0 0 8 4 1  h a s  b e e n  a s s o c i a t e d  w i t h  f e t o t o x i c i t y  i n  
a n im a l s .   S i n c e  t h e  s y s t em i c  P F - 0 6 7 0 0 8 4 1  e x p o s u r e  f o l l o w i n g  t o p i c a l  t r e a tm e n t  i s  u n k n o w n ,  
o n l y  m a l e  a d o l e s c e n t  p a r t i c i p a n t s  w i l l  b e  e n r o l l e d  a t  t h i s  t im e  t o  a v o i d  a n y  r i s k  o f  p r e g n a n c y  
i n  a d o l e s c e n t  f em a l e s  i n  a n  u n l i k e l y  e v e n t  o f  f a i l u r e  t o  s t r i c t l y  f o l l o w  c o n t r a c e p t i o n  
r e q u i r em e n t s . 
P K  A s s e s sm ent s 
S i n c e  t h i s  i s  a  f i r s t  t o p i c a l  a p p l i c a t i o n  s t u d y  o f  P F -0 6 7 0 0 8 4 1 ,  P K  s am p l e s  w i l l  b e  c o l l e c t e d  a t  
e a c h  v i s i t  t o  c h a r a c t e r i z e s y s t em i c  P K .   U n d e r s t a n d i n g  o f  s y s t em i c  e x p o s u r e s  w i l l  i n f o rm  t h e  
p o t e n t i a l  c o n t r i b u t i o n  o f  s y s t em i c  e x p o s u r e  t o  t h e  o v e r a l l  p h a rm a c o l o g y  i n  t h i s  s t u d y .
 
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 6 P a t i e n t - R e p o r t e d  O u t c om e  M e a s u r e s 
P a t i e n t  r e p o r t e d  o u t c om e s  w i l l  e v a l u a t e  c h a n g e s  i n  A D  s y m p t om s  a n d  h e a l t h  r e l a t e d  q u a l i t y  
o f  l i f e .   T h e   
P e a k -P r u r i t i s  N um e r i c a l  R a t i n g  S c a l e  ( P P -N R S )a r e  a s s e s sm e n t s  o f  t h e  s ym p t om s  a s s o c i a t e d  
w i t h  A D ,  p r e d om i n a n t l y  i t c h i n g ,  r e d n e s s ,  s c a l i n g ,  b u r n i n g ,  s t i n g i n g ,  c r a c k i n g ,  f l a k i n g  a n d  
p a i n .   
T h e  P a t i e n t O r i e n t e d  E c z em a  
M e a s u r e  ( P O EM )  i s  a n  a s s e s sm e n t  o f  t h e  f r e q u e n c y  o f  t h e  m o s t  c omm o n  s y m p t om s  o f  A D ,  
w h i c h  h a s  b e e n  a s s e s s e d  f o r  l a b e l i n g  i n  o t h e r  A D  t r e a tm e n t s . T h e  D e rm a t o l o g y  L i f e  Q u a l i t y  
I n d e x  ( D L Q I )  a s s e s s e s  d e rm a t o l o g y  s p e c i f i c  im p a c t  o n  q u a l i t y  o f  l i f e ,  w h i c h  h a s  a l s o  b e e n  
u s e d  f o r  l a b e l i n g  o f  A D  t r e a tm e n t s .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C C I 
C C I C C I C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  3 8  
 
   
 
 
  
  
  
 
 
 
 
 
 
 
 
 
4 . 4 . E n d  o f  S t u d y  D e f i n i t i o n 
A  p a r t i c i p a n t  i s  c o n s i d e r e d  t o  h a v e  c om p l e t e d  t h e  s t u d y  i f  t h e y  h a v e  c om p l e t e d  a l l  p h a s e s  o f  
t h e  s t u d y  i n c l u d i n g  t h e  f o l l o w -u p  v i s i t  ( V i s i t 7 ) ,  a p p r o x im a t e l y  2 8 - 3 5 d a y s  p o s t -l a s t  d o s e 
a p p l i c a t i o n .
T h e  e n d  o f  t h e  s t u d y  i s  d e f i n e d  a s  t h e  d a t e  o f  t h e  l a s t  v i s i t  ( V i s i t7 ) b y  l a s t  p a r t i c i p a n t ,  a c r o s s  
a l l  s i t e s .
5 . S T U D Y  PO P U L A T IO N 
T h i s  s t u d y  c a n  f u l f i l l  i t s  o b j e c t i v e s  o n l y  i f  a p p r o p r i a t e  p a r t i c i p a n t s  a r e  e n r o l l e d .   T h e  
f o l l o w i n g  e l i g i b i l i t y  c r i t e r i a  a r e  d e s i g n e d  t o  s e l e c t  p a r t i c i p a n t s  f o r  w h om  p a r t i c i p a t i o n  i n  t h e  
s t u d y  i s  c o n s i d e r e d  a p p r o p r i a t e .   A l l  r e l e v a n t  m e d i c a l  a n d  n o nm e d i c a l  c o n d i t i o n s  s h o u l d  b e  
t a k e n  i n t o  c o n s i d e r a t i o n  w h e n  d e c i d i n g  w h e t h e r  a  p a r t i c u l a r  p a r t i c i p a n t  i s  s u i t a b l e  f o r  t h i s  
p r o t o c o l .  
P r o s p e c t i v e  a p p r o v a l  o f  p r o t o c o l  d e v i a t i o n s  t o  r e c r u i tm e n t  a n d  e n r o l lm e n t  c r i t e r i a ,  a l s o  
k n o w n  a s  p r o t o c o l  w a i v e r s  o r  e x em p t i o n s ,  i s  n o t  p e rm i t t e d . C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 395.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Female participants between the ages of 18 and 75 years, i nclusive, at the time of 
informed consent at Screening or male participants between the ages of 12 and 
75years, inclusive, at the time of informed consent at Screening .
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Note: Female participants who are of child -bearing potential must not be intending to 
become pregnant, currently  pregnant, or lactating .
Note : Male participants between the ages of 12 and <18 years (or the minimum 
country -specific age of consent) are eligible to enroll only  after safety /tolerability is 
reviewed and deemed acceptable by an IRC review of the data from approxi mately  
20% of enrolled participants.
Type of Participant and Disease Characteristics:
2.The following atopic dermatitis criteria must be met:
a.Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at 
least 3 months (Appendix 9 ); the clinical diagnosis of atopic dermatitis will be 
confirmed according to the criteria of Hanifin and Rajka26at the Screening Visit .
b.Have an Investigator’s Global Assessment (IGA) score of 2 (mild), or 
3(moderate) at screening and at Day 1(prior to first dose of the I P).
c.Have atopic dermatitis on the head (including face, but excluding hair -bearing 
scalp), neck, trunk (excluding groin and genitals), or limbs, including palms and 
soles, covering at least 2% of total BSA and up to and including 20% of total 
BSA at Screening and at Day 1 (Visit 1).  At least 2% of the total BSA will need 
to be on the head (including face, but excluding hair bearing scalp), neck, trunk 
(excluding groin and genitals), or limbs (excluding palms and soles).
Note: Refer to Section 8.1.4 for methods of calculating %BSA.
d.Have an EASI total score of 3 to 21 at Screening and at Day 1.
Note : Refer to Section 8.1.3 for method of calculating EASI scores .
e.Have Peak Pruritis - Numerical Rating Scale (PP -NRS) of G rade  2, at Day 1.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 403.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, l ifesty le considerations, and other study  procedures.
Note : Refer to Section 5.3 for L ifestyle considerations.
Weight:
4.Body weight 40kg and Bod y Mass Index (BMI) 17.5 kg/m2up to 35 kg/m2
(inclusive) at Scre ening and at Day 1.
Informed Consent:
5.
Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the informed 
consent document (ICD) and in this protocol.
5.2.
Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1. A ctive forms of dermatitides/eczematous conditions (eg, contact dermatitis, 
seborrhhoeic, discoid, gravitational, aste atotic and dishy drotic eczema) or other 
inflammatory  skin diseases, ie, not AD or evidence of skin conditions (eg, psoriasis, 
viral infection, fungal infection, bacterial infection ) that would interfere with 
evaluation of atopic dermatitis or response to t reatment.
2.Any psychiatric condition including recent or active suicidal ideation or behavior that 
meets an y of the following criteria at Screening or Day 1: 
a.Suicidal ideation associated with actual intent and a method or plan in the past 
year: “Yes” answe rs on items 4 or 5 of the Columbia suicide severit y rating scale 
(
C-SSRS ) (Appendix 13);
b.Previous history  of suicidal behaviors in the past 5 years: “Yes” answer (for 
events that occurred in the past 5 years) to an y of the suicidal behavior items of 
the C -SSRS;
c.Any lifetime history  of serious or recurrent suicidal behavior;
d.The presence of an
y current major psychiatric disorder that is not explicitly 
permitted in the inclusion /exclusion criteria ;
e.In the opinion of the investigator or Pfizer (or designee) exclusion is required.
3.Fitzpatrick skin ty pe score >5.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 414. C urrent or recent history  (approximately , within 3 months) of severe, progressive, or 
uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, 
pulmonary , cardiovascular, or neurological disease.
5.
Ahistory  of any  lymphoproliferative disorder (such as Epstein Barr Virus [EBV] –
related l ymphoproliferative disorder ), history  of lymphoma, leukemia, malignancies 
or signs and s ymptoms suggestive of current l ymphatic disease.
Note : Adequatel y treated or excised non -metastatic basal cell or squamous cell cancer 
of the skin, or cervical carcinoma in situ are allowed.
6. A histor y (single episode) of disseminated herpes zoster or disseminated herpes 
simplex, or a recurrent (more than one episode of) localized, dermatomal herpes 
zoster.
7. A history  of systemic (within approximately  3months), chronic or acute skin 
infection (within a pproximately  2weeks) requiring hospitalization, parenteral 
antimicrobial, antivirals, antiparasitics, antiprotozoals, or antifungals therapy , or as 
otherwise judged clinically  significant b y the investigator.
8. A known immunodeficiency  disorder or a first -degree relative with a hereditary  
immunodeficiency .
9. U ndergone significant trauma or major surgery  within 1 month prior to screening.
10.A current or past medical history  of conditions associated with thrombocy topenia, 
coagulopathy or platelet dysfunction.
11. Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administ ration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make the participant inappropriate for entry  into 
this study .
Prior/Concomitant Therapy:
12. V accinated or exposed to a live or attenuated vaccine within the 6 weeks prior to the 
first dose of IP, or is expected to be vaccinated or to have household exposure to 
these vaccines during treatment or up until follow -up visit .
Note : Male participants 12 to <18 years old without documented evidence of havin g 
received at least onedose of the varicella vaccine in countries where the vaccine is 
approved and standard of care or those who do not have evidence of prior exposure to 
varicella zoster virus (VZV) based on serological testing (ie, varicella zoster vir us 
immunoglobulin G antibody  [VZV IgGAb]) at screening are excluded.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 42Prior/Concurrent Clinical Study Experience:
13.Previous administration with an investigational drug within 4weeks (or as 
determined b y the local requirement) or 5 half-lives pr ior to Scree ning (whichever is 
longer). 
Note: local regulations or other factors may  require more than 4 weeks.
Note: Any investigational or experimental therapy taken or procedure performed for 
AD, psoriasis, psoriatic arthritis or rheumatoid arthritis in the previo us 1 year should 
be discussed with the Pfizer Medical Monitor (or designee).  Participants cannot 
participate in studies of other investigational or experimental therapies or procedures 
at an y time during their participation in this study .
14.Participants who have received prior treatment with any  TYK2 and/or JAK inhibitors
within 3 months 
or 5half-lives preceding Screening (whichever is longer).
Diagnostic Assessments:
15.A Screening 12 -lead ECG that demonstrates clinically  significant abnormalities 
requiring t reatment (eg, acute my ocardial infarction, serious tachy -or 
brady-arrhy thmias) or that are indicative of serious underly ing heart disease 
(eg,cardiomy opathy , major congenital heart disease, low voltage in all leads, 
Wolff -Parkinson- White sy ndrome) or cri teria associated with Q wave interval 
(QT)/Fridericia -corrected Q wave interval (QTcF) abnormalities including .
16.A marked prolongation of QTcF interval (>450 milliseconds [ms ec
]) on the screening 
ECG :
a.A history  of additional risk factors for Torsade de Poin tes (TdP) (eg, heart failure, 
hypokalemia, famil y history of Long QT S yndrome);
b.Use of concomitant medications that prolong t he QT/QTcF interval ;
c.If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 
2more times and the average of the 3 QTc or QRS values should be used to 
determine the participant’s eligibility.  Computer -interpreted ECGs should be 
overread b y a ph ysician experienced in reading EC Gs before excluding 
participant .
17.Participants with ANY of the following abnormalities in clinical laboratory tests at 
Screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat, if deemed necessary : 
a.Hemoglobin <11 g/dL (<100 g/L)or hematocrit <30%; 
b.White blood cell count <3.0 x 109/L(<3000 mm3); 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 43c.Absolute neutrophil count <1.5 x 109/L(<1500 mm3); 
d.Absolute ly mphocy tecount of <1.0 x 109/L(<1000/mm3);
e.Platelet count <100 x
109/L(<100,000/mm3); 
f.Estimated glomerular filteration rate ( eGFR )<60mL/min/1.73 m2using 
creatinine or cy statin C based calculation s (Section 7.1.4);
g.Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values 
2times the UL N; 
h.Total bilirubin 1.5times the ULN; 
participant s with a history  of Gilbert's 
syndrome may  have a direct bi lirubin measured and would be eligible for this 
study  provided the direct bilirubin is  ULN;
i.Creatin inekinase (CK) >3times the UL N.
18. In the opinion of the investigator or sponsor, have any  uncontrolled clinically  
significant laboratory  abnormality  that would affect interpretation of stud y data or the 
participant’s participation in the study .
19.Infected with My cobacterium tuberculosis (TB) as defined by  the following: 
a.A positive Interferon Gamma Release Assay  (IGRA) test or positive
Mantoux/Purified Protei n Derivative 
(PPD ) tuberculin skin test ;
b.Any chest imaging (chest x -ray, computed tomography  (CA T Scan) or Magnetic 
Resonance Imaging ( MRI )) taken at screening (or performed and documented 
within 12weeks prior to Screening ) with changes suggestive of act
ive TB 
infection will be excluded ;
c.A participant who has been treated or is currently  being treated for active or latent 
TB infection ;
d. A history  of either untreated or inadequately  treated latent or active TB infection.
20.Infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C 
viruses.  ( Also s ee country -specific exclusion criteria in Appendix 8).
Note: For Hepatitis B, all participants will undergo testing for Hepatitis B Surface 
Antigen (HBsAg) and Hepati tisB Core Antibod y (HBcAb) during Screening.  
Participants who are HBsAg positive are not eligible for the study .  Participants who 
are HBsAg negative and HBcAb positive will be reflex tested for Hepatitis B Surface 
Antibody  (HBsAb
) and if HBsAb is positi ve, may be enrolled in the stud y; if HBsAb 
is negative, the participant i s not eligible for the study . 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 44Note: For Hepatitis C, all participants will undergo testing for Hepatitis C antibody  (HCV
Ab)during Screening .  Participant s who are hepatitis C antib ody (HCV Ab) positive require 
further testing with HCV RNA polymerase chain reaction ( PCR
) and are allowed to enroll if 
HCV RNA PCR negative.
Other Exclusions:
21.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator, or 
Pfizer employ ees, including their family  members, directly  involved in the conduct of 
the study . 
22. A history  of alcohol or substance abuse within 6 months prior to Screening that in the
opinion of the investigator will preclude participation in the study .
23.In the opinion of the investigator or Sponsor Clinician or Sponsor Medical Monitor , 
the participant is inappropriate for entry  into this study .
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contracep tion methods (see 
Appendix 4and Section 10.4.4) and will confirm that the participant has been instructed in 
its consistent and correct use.  At time points in dicated in the schedule of activities (SoA) , the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctl
y and document the conversation and the participant’s 
affirmation in the participant’s chart (participants need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception).  In addition, the investigator or 
designee will instruct the participant to call immediately if th e selected contraception method 
is discontinued or if pregnancy  is known or suspected in the participant or partner.
5.3.2. Medications/Treatments Discontinuation, Non -Medicated Emollients and Bathing
Participants are required to discontinue and avoid using certa in medications and treatments as 
described in participant selection criteria.  Participants should be instructed at each visit to 
contact the stud y site investigator promptly  if there are any  intended changes or additions to 
concomitant medications. 
All m edications and treatments that could affect atopic dermatitis must be discontinued for 
the duration of the stud y.  The only exception is that shampoo containing tar, salicy lic acid or 
low or least potent corticosteroid products (Class 6or 7corticosteroid s, namely  
hydrocortisone  1% and hy drocortisone acetate 1%) is allowed for atopic dermatitis on 
hair-bearing scalp throughout the study .  Due to the potential to affect atopic dermatitis with 
ultraviolet light exposure, participants must also avoid prolonged exposure to the sun and 
avoid the use of tanning booths, sun lamps or other ultraviolet light sources during the stud y. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 45The non- medicated emollient and sunscreen are the only  topical products permitted to be 
used on atopic dermatitis skin during the W ashout/Screening period (onl y exception is the 
use of permitted topical products for atopic dermatitis on hair -bearing scalp).  Participants 
will stop apply ing non -medicated emollient and sunscreen on atopic dermatitis skin on the 
day before Day 1 (Visit 1).  During the stud y period, use of non -medicated emollient and 
sunscreen are allowed only  on skin that was considered normal or non- lesional at Day 1 
(Visit 1) (ie, never treated with IP).  Any non -medicated emollient used by  the participant 
during the st udy should be documented in study  records and the Case Report Form (CRF).
Through and including Week 6 visit , participants are to continue to treat all treatment -eligible 
atopic dermatitis areas identified at Day 1
(Visit 1) once or twice dail y in accordan ce with the 
original dosing regimen assigned, regardless of clearing or improvement of atopic dermatitis.  
Any new atopic dermatitis areas occurring following Day 1 (Visit 1) should also be treated 
with the IP. 
The treatment areas should not be bathed or showered for at least 4 hours after appl ying the 
IP.  Bathing or showering is permitted pre-dose and the application areas must be dry  prior to 
cream application.
5.3.3. Dietary Supplements
For the purposes of this protocol, dietary  supplements are defined as vit amins, minerals, 
purified food substances , and herbals with pharmaceutical properties. Vitamins, minerals 
and purified food substances are allowed in amounts not known to be associated with adverse 
effects (such as h ypervitaminosis).
Herbals supplements a re only  allowed on a case by  case basis; please contact the Pfizer staff.
Herbals eg ,St. John’s Wort that are known to have an effect on drug metabolism must be 
discontinued at least 4 weeks or 5 half-lives (whichever is longer) before Day 1.
Participan ts should not consume grapefruit or grapefruit juice or citrus fruits eg, Seville 
oranges, pomelos within 7 days prior to Day 1 and until collection of the final PK blood 
sample.
5.3.4. Vaccine and Exposure to Infection Guidelines
5.3.4.1. Participant Specific Recommendat ions
It is recommended that all participant s should be up- to- date with respect to standard of care 
vaccinations (as defined by  their country  health ministry ) or AD guidelines.  Vaccination of 
participant s with live components is prohibited within the 6 weeks prior to first dose of 
investigational product.  Adolescent participants without documented evidence of having 
received at least one dose of the varicella vaccine or those who are without evidence of 
previous varicella zoster exposure as confirmed by VZV IgG Ab serological testing are 
excluded. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 465.3.4.2. Guidance Regarding Household Contact Vaccine -Related Exposure
Current routine household contact with children and others who have been vaccinated with 
live vaccine components may  pose a risk during treatment and for 6 weeks following 
completion of the study .  Some of these vaccines include varicella (“chickenpox”) vaccine, 
oral polio vaccine, and theinhaled flu vaccine.  Following vaccination with live component 
vaccines, the virus may  be shed in bodily  fluids, i ncluding stool, and there is a potential risk 
that the virus may  be transmitted.  Participants are suggest edthat exposure (through routine 
contact) should be avoided following vaccination (of others) with these vaccines for the 
stated time period:
1.Varicel la or attenuated typhoid fever vaccination for 4 weeks following vaccination.
2.Oral polio vaccination for 6 weeks following vaccination.
3.Attenuated rotavirus vaccine for 10 days following vaccination.
4. FluMist(inhaled flu vaccine) for 1 week following vacc ination.
Participants should avoid exposure to vaccinated or infected persons and contact the 
investigator promptl y should they  develop signs or sy mptoms of infections.
5.3.5. Other Requirements
1.Agree to avoid strenuous exercise during the study , especiall y withi n one week prior 
to the scheduled stud y visits and maintain adequate hydration, if possible.
2.On study visit days, do not smoke or ingest caffeine (eg, tea, coffee, some soft 
drinks/colas/energy  drinks and power bars) during the 30 minutes prior to blood
pressure and pulse (heart) rate measurements.
3.On study visit days, showering or bathing is permitted prior to attending the study  
visit, but do not moisturize.
4.On study visit days, take prescribed permitted concomitant medication, as needed, 
prior to the stu dyvisit, if it can be administered with water only.
5.Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or 
other ultraviolet light sources during the stud y.
6.Contact the study site investigator if there are any changes or addi tions to 
concomitant medications.
7.Avoid having major elective surgery .
8. The participant should continue all non- pharmacological therapies, such as phy sical 
therap y, as indicated.  However, the participant should avoid changing the type or 
intensity  of thera py or initiating new therapy  until after Week 6 visit. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 479.When apply ing the IP, the participant will not be required to wear gloves.  However, 
participants should be instructed to wash their hands with mild soap and water before 
and after each application. 
10.If study  participants needs someone else to assi st with apply ing investigational 
product on hard to reach areas (eg back), this person must wear gloves to avoid 
accidental exposure to the IP.  In order to limit the potential risk associated with 
accidental exposure, this individual should not be a pregnant or breastfeeding female.
5.4. S creen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to investigational product in the study .  A minimal 
set of screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from re gulatory authorities.  Minimal information 
includes demograph y, screen failure details, eligibility  criteria, and any  serious adverse event 
(SAE).
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
re-screened once if they  fail the screening evaluation for reasons related to incidental 
transitory  conditions, unless the reason for the screen failure is the disease severit y inclusion 
criteria. 
All screening assessments must be repeated during re-screening, with t he exception of chest 
radiograph, HIV, Hepatitis and TB testing.   These assessments do not have to be repeated if 
re-screening is done within 3 months of the initial screening visit and these assessments were 
performed during the initial screening visit.
6.
STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol , the term investigational product may  be used 
synony mously  with study  intervention.
Study  intervention cream will be packaged in tubes containing 54 or 57 grams of either 
vehicle or PF -06700841 for topical application.  Treatment assignment will be blinde d.  The 
tubes will be provided in cartons and both will be labelled in a blinded fashion according to 
local regulatory  requirements. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 486.1.Study Intervention Administered
For this study , investigational products are the following:
PF-06700841 cream, in 0.1%, 0. 3%, 1%, and 3% strengths; may  also be referred to as 
1mg/g, 3 mg/g, 10 mg/g , and 3 0mg/g, respectively .
Vehicle cream; may  also be referred to as vehicle and/or placebo.
PF-06700841 creams will be supplied in four different strengths: 0.1%, 0.3%, 1% and 
3%(w/w), light mineral oil, white petrolatum, oley l alcohol, emulsify ing wax, diethy lene 
glycol monoeth yl ether , poly ethylene gly col400, 2 -phenox yethanol, and purified water.
Vehicle cream (no active drug in the formulation) contains light mineral oil, wh ite 
petrolatum, oley l alcohol , emulsify ing wax, diethylene gly col monoethy l ether , poly ethylene 
glycol 400, 2- phenoxy ethanol, and purified water.
All active and vehicle creams will be packaged in laminate tubes contai ning 54grams or 
57grams of either veh icle cream or PF -
06700841 cream for topical a pplication .  All tubes 
will be provided in cartons and labelled in a blinded fashion according to local regulatory  
requirements.
6.1.1. Administration
6.1.1.1. Treated Atopic Dermatitis Areas
Atopic Dermatitis treatment areas will be all areas affected by AD, except hair -bearing 
scalp
Before the Day 1 initial IP application is performed, the designated areas for treatment will 
be identified at the Day 1 Visit and documented in the participant’s source document study  
records ( body -site check list ).  The participant and/or caregiver will be provided with 
documentation of the designated treatment areas.   Treated AD area identified on Day 1 
should be continued to be treated even if substantial improvement or clearing of AD occurs.
  
If new AD areas emerge during the stud y, IP should be applied to these new areas after 
consultation with the I nvestigator.
6.1.1.2. General Instructions
On study Day 1 until the final dose at Week 6 visit , the IP should be applied once or twice
daily (around same t ime of the day ), to all treatable AD involved areas (excluding the scalp) 
identified at Day 1.
All participants will be supplied with instructions on application and dose frequency 
commensurate to assigned treatment arm.   Those participants having difficu lty reaching 
treatment -
eligible atopic dermatitis areas (eg, back) may  be assisted by  another person who 
will need to apply  the IP to the participant according to the investigational product 
application instructions.  The person assisting with the applicat ion must wear gloves to avoid 
any exposure to the IP.If a participant misses apply ing a dose, the participant should apply  

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 49this dose provided this dose should have been applied within the last 6 hours.  For longer 
intervals, the dose should be skipped.  The missed dose should be recorded in the dosing 
diary .  The next dose should be applied according to the regular dosing regimen.
Day 1 (Baseline 
Visit )
Participants and/or caregivers will be encouraged to observe and participate in the initial IP 
applica tion on Day 1.  All subsequent doses, including the second dose on Day 1 (if 
applicable), will be applied at home.  The participant and/or caregiver will be instructed to 
complete the Dosing Diary  starting with the first dose applied in the clinic on Day 1through 
Week 6(each time IP is applied) for all IP doses applied.
A thin layer of IP 
cream will be applied at a target application rate of approximately  
2mg/cm2.
In order for participant or caregiver to keep track of the treatable BSA cleared, a paper 
version of the bod y check list may be provided on Day 1. 
Post Day 1 Visits
Post Day 1 (Baseline /Visit 1), any  new atopic dermatitis on treatment -eligible areas 
identified by  the participant or caregiver(s) should also be treated with the I P.  Decision to 
apply the IP to new eligible areas should be made following assessment by the I nvestigator 
or his/her designee.   Body  site check -list will be updated and IP need will be re -
assessed at 
every  site visit during the treatment period.  If the total, treatable BSA exceeds 
20% (inclusion criteria requirement) during the six- week treatment period, the participant 
will still remain eligible for the study , given, that the total, treatable BSA does not exceed 
22%.  If the total, treatable BSA reaches 22%, the Sponsor may decide to di scontinue the 
participant.
The reason for maintaining IP treatment areas the same as identified at Day 1
(Baseline/ Visit1) is to understand the efficacy , systemic safet y, and local tolerability of 
PF-06700841 cream when applied to BSA of 2-20% for 6 weeks in participants with mild or 
moderate atopic dermatitis. 
Participants and/or caregivers will be instructed not to wipe investigational product off the 
skin, avoid apply ing an occlusive dressing to the treated areas, and refrain from swi
mming or 
bathing/washing the treated areas within 4hours after application.
Use of an y topical product (eg, sunscreens, moisturizers or non- medicated emollients) is 
prohibited on ADskin from Day 1(Baseline/Visit 1) to the end of treatment period 
(Week6), except for permitted products on scalp. 
Under no circumstances will the investigational drug application regimen be modified 
(eg,frequency  of application increased or reduced, not stopped, or the application rate 
[target 
2mg/cm2]increased or reduced ) during the study .  Temporary  discontinuation of 
investigational drug may  be appropriate under some circumstances (eg, surgery , non- serious 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 50infections) and should be discussed with the Medical Monitor (or designee) preferabl y prior 
to temporary  discontinu ation of investigational drug.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are repor ted and resolved before use of the study  intervention, as 
applicable for temperature -monitored shipments.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.  All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records).  All study 
interventions will be accounted for using an investigational product accountability  
form/record.
4.Further guidance and information for the final disposition of unused study  
interventions are provided in the investigational product manual ( IP manual ).
5.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the product label. 
6.Study  interventions should be stored in their original containers and in accordance 
with the labels. 
7.Site staff will instruct participants on the proper storage requirements for take -home 
study  intervention. 
8.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken.  The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible.  Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervention.  I t will not be considered a protocol deviation if Pfizer 
approves the use of the study  intervention after the temperature excursion.   Use of the 
study  intervention prior to Pfizer approval will be considered a protocol deviation.   

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 51Specific details regarding the definition of an excursion and information the site 
should report for each excursion will be provided to the site in the I P manual.
9.The sponsor or designee will provide guidance on the destruction of unused study  
intervent ion(eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by  Pfizer, and all destruction must be adequately  
documented.
Additional details about accountability , storage, destruction, and excursion reporting can be 
found in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
theIPready for a pplication or dispensing to the participant/caregiver b y qualified staff.  
Dispensing is defined as the provision of IP, concomitant treatments, and accompany ing 
information by qualified staff member(s) to a healthcare provider, participant, or caregiver in 
accordance with thisprotocol.  L ocal health authority  regulations or investigator site 
guidelines may  use alternative terms for these activities.
The IPwill be dispensed ina blinded fashion using an interactive response technology  (IRT)
system at Day 1/Baseline ,Week 1 (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 5) visits.  A 
qualified staff member will dispense the IP via unique container numbers on the cartons 
provided
, in quantities appropriate for the study  visit schedule and the treatable % BSA.
For doses to be applied at home, the participant or caregiver should be instructed to maintain 
the product in its original package provided throughout the course of dosing an d return the 
product and its original package (including empt y, partial used and unused tubes) to the site 
at the next study  visit.  All previously dispensed IP tubes will be retained by the site.   For 
each participant, IP tubes with caps will be weighed i ndividually or collectively  by the study  
site before dispensing and after return and the weights will be recorded.   The sponsor will use 
the recorded weights to estimate usage (eg, mg/cm2/application) for each participant.  Note 
that the weight recorded on the IP label is a nominal weight and not an exact weight of the IP 
and tube. 
Investigational product will be assigned to participants at the Day 1(Baseline /Visit 1) visit 
once the participant is successfull y randomized through the IRT s ystem.  The inves
tigator , 
appropriate delegate or site personnel willaccess the I RT s ystem at screening and all 
subsequent IP dispensing visits to enter information including, but not limited to, the 
participants height, weight and % affected BSA to receive correct tube n umbers to be 
dispensed to the participant .  Alternatively , the tool to standardize th eIP need calculation 
across participants and study  sites may  be provided by  the sponsor. 
The calculation of % BSA is described in Secti on 8.1.4.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 52All tubes of investigational product dispensed or returned will be recorded and documented.
6.2.2. Investigational Product Accountability 
The investigator site must maintain adequate records documenting the receipt, use, l oss, or 
other disposition of the IP supplies.  All investigational products will be accounted for using 
a drug accountability  form/record.  All tubes of the IPmust be returned to the investigator by  
the participant at every  visit and at the end of the trial.
The participant will be asked to bring all dispensed IP (including empt y, partially used and 
unused tubes) 
at every  ‘compliance check’ visit; participants will be asked to bring dosing 
diary  to the clinic at every  clinic visit.  Detailed drug accountab ility records, including tube 
weights measured in the clinic, will be maintained by study  staff for each participant.
The original IP accountability  log, or equivalent document, must be accurately  completed, 
signed b y the Investigator , and retained at the study  site (with a copy  supplied to the 
Sponsor) when the stud y is complete.
6.2.3. Destruction of Investigational Product Supplies 
For all IP returned to the investigator b y the participant, the investigator will maintain the 
returned suppl y until destruction i s authorized. 
The sponsor or designee will provide guidance on the destruction of unused investigational 
product (eg, at the site).  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are d estroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer, and all destruction must be adequatel y documented.
Further guidance and information for the final disposition of unused study  interventions are 
provided in the I P manual.
6.3.Measures to Minimize Bias: Randomization and Blinding
Allocation to treatment will occur via an Interactive Response Technology (I RT) sy stem.  
The sy stem will be programmed with blind
-breaking instruction s.  Refer to Section 6.3.2 for 
further details. 
6.3.1. Allocation to Investigational Product
For this study , the IP is PF - 06700841 (or its matching vehicle) topical cream.  Participants
will be randomized into one of the doses in QD dosing regimen or BID dosing regimen of 
PF-06700841 cream or its matching vehicle cream . 
AttheDay 1 (Baseline/Visit 1 )visit, provided all inclusion/exclusion criteria have been met, 
the participant will be randomized to trial medication.  Th e investigative site will contact an 
interactive response technology  (IRT) sy stem ( or interactive Web -based response [I WR]).  
Allocation of participants to treatment arm s will proceed through IRT.  The site personnel 
(study  coordinator or specified designe e) will be required to enter or select information 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 53including but not limited to the user’s identification (ID) and password, the protocol number, 
the participant number .  The site personnel will then be provided with a treatment 
assignment, randomization n umber, and dispensable unit (DU) or container number.  The 
IRT s ystem will provide a confirmation report containing the participant number, 
randomization number, and DU or container number assigned.  The confirmation report must 
be stored in the site’s fil es. 
The study -specific IRT reference manual and IP manual will provide the contact information 
and further details on the use of the IRT s ystem.
Investigational product will be dispensed at the study  visits summarized in the SoA. 
Returned IP must not be re
-dispensed to the participants.
6.3.2. Breaking the Blind
At the initiation of the study , the study  site will be instructed on the method for blind 
breaking.  The method will be an electronic process and will use I RT s ystem.  The I RT wi ll 
be programmed with blind- breaking instructions.  Blinding codes should be broken onl y in 
exceptional circumstances when knowledge of the actual treatment code is absolutely  
essential for further management of the participant.  I n case of an emergency , the investigator 
has the sole responsibility for determining if un -blinding of a participant’s treatment 
assignment is warranted.  Participant safet y must always be the first consideration in making 
such a determination.  If the investigator decides that un-blinding is warranted, the 
investigator should make every effort to contact the sponsor prior to un -blinding a 
participant’s treatment assignment unless this could delay  further management of the 
participant.  If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within 24 hours after breaking the blind.  The date and reason that the blind was broken must 
be recorded in the source documentation and case report form (CRF). 
The study -specific I RT reference manual and IP manual w ill provide the contact information 
and further details on the use of the IRT s ystem.
Participants whose code is broken will be discontinued from treatment and the entire 
procedures equivalent to end of treatment will be performed where possible.
The parti cipant’s data willbe included in an y full anal yses.  An y broken blinds will be 
documented in the study
 report.
6.4. Study Intervention Compliance
The participant and/or a caregiver will appl y IP at home and during in -clinic visits as
specified in Schedule of Activities (SoA) . The participant and/or caregiver will be instructed 
to complete the Dosing Diary  starting with the first dose applied in the clinic on Day 1
through Week 6(each time IP is applied) for the IPdoses applied at home.   In addition, 
participants will be instructed to bring to the clinic all used, partiall y used and empty IP tubes 
in their original containers for weighing, at each visit. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 54Participant compliance with IP will be assessed on visits identified in Schedule of Activities 
(SoA) .  Compliance will be assessed b y review of the participant /caregiver completed 
Dosing Diary  and by weighing of the returned IP tubes . The difference in weight(s) of the
returned IP tubes will be used to estimate the doses applied.  Source documents will be 
placed in the participant’s study  file.  Deviation(s) from the prescribed dosage regimen 
should be recorded in the CRF.
From Day 1 (Visit 1) through and including Week 6 visit (Visit 6), non- compliance is 
defined as less than 80% or more than 120% of IP applications .  If non-compliance is 
identified, or even if a few dose applications are missed or over -applied, 
then, participants 
will be re -trained on the importance an d the process of proper IP application .  If 
non-compliance persists, t he investigator , in consultation with the Sponsor, may  withdraw 
any participant from the study  for reasons of non
-compliance with the dosing regimen.  
Investigators should indicate on th e appropriate CRF page noncompliance with study  
intervention and provide an explanation. 
Inventory  control of all IPs must be rigorousl y maintained throughout the duration of the 
study  until all medication has been accounted for and/or returned to the spo nsor.  Any  
discrepancies noted between drug dispensing records and the drug inventory must be 
reported to Pfizer.
6.5.Concomitant Therapy
Medications that are taken in the Screening period (after informed consent is obtained and 
before the first dose of IP) will be documented as prior medications.  Medications taken after 
the first dose of IPhas been administered will be documented as concomitant medications.  
All concomitant medications taken during the study must be recorded in study records with 
indication, daily  dose, and start and stop dates of a pplication .  Participants will be queried 
about concomitant medication (including topical medications and treatments, 
over-the-counter and prescription medications and treatments, and vaccinations) at each 
study  visit.  Any  new concomitant medications or dose changes to current concomitant 
medications should be evaluated for potential new or worsening adverse events.
See Appendix 10on prohibited medications and procedures.
In additi on, the following concomitant medications are allowed , unless excluded in 
Prohibited Medications list (Appendix 10
):
1.Antihistamines.
2.Acetaminophen/paracetamol and I buprofen.
3.Medications for regulation of thy roid function .
4.
Selective leukotriene receptor antagonists (e g,montelukast sodium, zafirlukast), mast 
cell stabilizers (eg, cromoly n sodium or nedocromil sodium) .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 555.Corticosteroid inhalers and intranasal spray s provided participants are on stable dose 
for at least 1 week be fore Day 1 and/or during treatment period .
6. Ophthalmic corticosteroids, provided participants are on stable dose for at least 
1week before Day 1 and/or during treatment period .
7.Hormone replacement therap y (HRT) and hormonal contraceptives that meet the 
requirements of this study are allowed to be used in participants who are women of 
childbearing potential (WOCBP) (see Appendix 4 ). 
8.Medications for chronic stable medical conditions (e g,hypertension) provided these 
are not expected to affect the study  assessments and participant is on a stable dosage .  
If prescribed, change in medication for h ypertension is allowed.
9.Topical treatments applied to areas not treated with I Punless prohibited in 
Appendix 10.
10.
Sunscreen and regular moisturizers applied to areas not treated with IP .  Site staff 
must verify that these are not emollients.
Any other concomitant medication will be considered on a case by  case basis by  the 
investigator in consultation with the Sponsor Medical Monitor.
6.5.1. Rescue Medicine
There is no rescue therapy to reverse the adverse events (AEs) observed with PF -06700841; 
standard medical supportive care must be provided to manage the AEs. 
6.6.Dose Modification 
Not applicable .
6.7.Intervention 
after the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PART ICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be n ecessary  for a participant to permanentl y discontinue IP.  Per the 
study  estimands, if IP is permanentl y discontinued, the participant will proceed to earl y 
termination and follow -upvisit per Schedule of Activities (SoA) .  The site will inform 
Sponsor Medical Monitor or Sponsor clinician if the below criteria for permanent 
discontinuation of the I P are triggered.
Note that discontinuation of investigational product does not represent withdrawal from the 
study .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 567.1.1. ECG Changes
A participant who meets either of the bulleted criteria based on the average of triplicate ECG 
readings (also see Section 8.2.2.3) will be withdrawn from the study . 
QTcF >500 msec.
Change from baseline: 
QTc >60 msec.
If a clinically  significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any c hange in participant management is 
needed.  This review of the ECG printed at the time of collection must be documented.  Any  
new clinicall y relevant finding should be reported as an AE.
7.1.2. Local Tolerability 
All participant -reported and observed application site a dverse events (AEs) should be 
recorded along with the body  region location, severity , duration and outcome as indicated on 
the CRF. 
If a participant experiences severit y Grade 3 (severe) or 4 (very  severe) on the local 
tolerability  assessment ( Section
8.2.2.9), study  treatment will be discontinued 
permanentl y and participant will proceed to earl y termination (ET) visit and 
follow -
up as described in Schedule of Activities (S oA). 
If a participant experiences application site reaction of Grade 2 (moderate) on the 
local tolerability  assessment, investigator may  temporaril y discontinue a pplication of 
IP for up to 
48 hours without consulting the Sponsor.  If in the clinical judg ment of 
the investigator IPinterruption bey ond 48 hours is advisable, the investigator must 
obtain agreement from the Pfizer medical monitor to continue withholding IP.  If 
temporary  IPinterruption for more than 5 consecutive day s is needed, then the 
participant should be permanently  withdrawn from treatment and should follow -up 
with the site until complete or near complete resolution of the AE.  This dosing gap 
may occur onl y once for the same participant.
7.1.3. A dverse Events
All treated infections occurring during the study , including, but not limited to, respiratory  
infections, cutaneous infections, urinary  tract infections and episodes of suspicious or febrile 
diarrhea, should be cultured and any identified organisms noted in the Case Report Form.  
Infections should be classified as either serious infections or treated infections, as defined 
below.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 577.1.3.1. Serious Infections
A serious infection is an y infection that requires hospitalization for treatment or requires 
parenteral antimicrobial therap y or meets other cr iteria that require it to be classified as a 
serious adverse event.  A participant who experiences a serious infection should be 
discontinued from the study  and the serious adverse event should be listed as the reason for 
discontinuation in the Case Report Form.  Appropriate laboratory  investigations, including 
but not limited to cultures should be performed to establish the etiology  of any  serious 
infection.  All adverse events, including serious adverse events, should be reported as 
described in Appendix 3 on Adverse Event Reporting.
7.1.3.2. Treated Infections
A treated infection is any infection that requires antimicrobial therap y by any route of 
administration or any surgical intervention (eg, incision and drainage).  Participants who 
experience infections that require treatment can have their blinded IPtemporaril y 
discontinued during antimicrobial therap y in consultation with the sponsor.  This information 
should be noted in the Case Report Form.
7.1.4. Potential Cases of Decreased eGFR
All participants will have serum creatinine based and serum cy statin -C based eGFR 
calculated at all time points.
Abnormal values in serum creatinine concurrent with absence of increase in blood urea
nitrogen (BUN) that meet the below criteria, in the abse nce of other causes of kidney injury ,
are considered potential cases of acute kidney injury and should be considered important 
medical events.
If an individual participant demonstrates CONCOMI TANT serum creatinine -based AND 
serum Cy statin C -based eGFR decl ine of  30% (See Section 8.2.2.6) compared to the 
participant ’s baseline eGFR (pre-dose, Day 1), then the 
participant should not be further 
dosed and adequate, immediate, supportive measures including immediate evaluation b y a 
nephrologist (preferabl y within 24 hours) with appropriate management and treatment as 
clinically  indicated. Results should be repeated as indicated by  the nephrologist or weekly  at 
a minimum until the eGFR returns to baseline 15%, or the renal parameters are deemed to 
be stable b y the nephrologist and/or Principal Investigator ( PI).
If the participant cannot be seen b y a nephrologist within 24 hours (as described above), then 
the participant should be sent to a local emergency room for e valuation and treatment as 
clinically  indicated .
Participants should return to the investigational site and be evaluated as soon as possible,
preferably within 24-48 hours from awareness of the abnormal eGFR result 
(CONCOMITANT serum creatinine based AND serum cy statin C based eGFR decline of 
30% compared to the participant’s 
baseline eGFR) for a safet y follow- up visit.  Follow -up 
evaluation sshould include laboratory  tests, detailed history , and ph ysical assessment.  I n 
addition to repeating serum creatin ine and serum cy statin C, laboratory  tests should also 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 58include: serum BUN, serum CK, serum electrol ytes (including at a minimum potassium, 
sodium, phosphate/phosphorus, calcium), in addition to urine dipstick, urine microscopic 
examination, and urinary ind ices.  All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified should be considered as potential cases of drug -induced kidney  injury  irrespective 
of ava ilability  of all the results of the investigations performed to determine etiology  of the 
abnormal serum creatinine.
All relevant test results will be forwarded to Pfizer for review immediatel y upon receipt b y 
the PI .
7.1.5. Laboratory Abnormalities
All the following laboratory  abnormalities require discontinuation if they  are confirmed.   
Confirmation through re -testing should occur within 2-5 days :
Laboratory Variable Laboratory Value
Hem atology
Absolute Neutrophil Count <1000/mm3; <1.0 x109/L
Hem oglobin <10.0 g/dL; <6.2 mmol/L; <100 g/L
Platelet count <75,000/mm3; <75.0x109/L
Lymphocytes <500/mm3; <0.5x109/L
Chemistry
ASTa>2.5x ULN
ALT >2.5x ULN
Total bilirubinb>1.5x ULN
a.Additional investigations, such as revie w of ethanol, recreation al drug and di etary supplement 
consumption should be done; testing for acute hepatitis A, B or C infec tion and biliary tract imaging 
should be promptly discussed with the Pfizer Medical Monitor or designee.
b.Participants with a history of Gilbert's syndrome may have a direct bilirubin measured and w ould be 
eligible to remain in the provided the direct bilirubin is ULN .
7.1.6. Pregnancy
Pregnancy  confirmed by  serum beta-human beta -human chorionic gonadotropin ( -hCG )
testing.  Sponsor Clinician or Medical Monitor should be notified immediately .
7.1.7. Suicidal Ideation and Behavior
Participants triggering criteria for suicidal ideation and behavior as described in 
Section 8.2.2.8.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 597.1.8. Temporary Discontinuation 
Temporary  discontinuations of IP
will occur in cases of positive urine pregnancy  test which if confirmed b y serum 
pregnancy  test will lead to permanent discontinuation ( Section 7.1.6). 
may apply  in some cases application site reaction during local tolerab ility 
assessments ( Section 8.2.
2.9). 
additional instances of temporary  discontinuation may  be appropriate (eg, surgery , 
infection, etc). 
All temporary  discontinuations should be discussed with Sponsor Clinician or Sponsor 
Medical Monitor to determine
if participant may  continue in the study .  If possible, site will 
consult sponsor prior to temporary  discontinuation. 
7.1.9. Discontinuation/End of Treatment Monitoring for Adverse Events, Laboratory, 
and Vital Signs
Any participant meeting discontinuation criteria must enter into the Follow up Period with 
their first follow up visit occurring 1 week after their last dose whenever possible (instead of 
two weeks described in Schedule of Acti vities (SoA) and continue visits per Investigator’s 
discretion until the event has returned to normal or baseline levels or is deemed clinically  
stable.  The procedures scheduled for Week 6(end of treatment) visit will be performed on 
the last day  the participant takes the investigational product or as soon as possible thereafter.
The only  exception to this is when a 
participant specificall y withdraws consent for an y 
further contact with him or her or persons previously  authorized by  the participant to provide 
this information.  Additional follow up visits may  occur as needed until any clinically  
relevant abnormalities or adverse events have resolved, returned to a baseline state, or are 
deemed clinicall y stable.
See the SoA for d ata to be collected at the time of intervention discontinuation and follow -up 
and for an y further evaluations that need to be completed.
7.2.Participant Discontinuation/Withdrawal f rom the Study 
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted.  See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 60The early discontinuation visit applies only  to participants who are rando mized and then are 
prematurel y withdrawn from the study.  Participants should be questioned regarding their 
reason for withdrawal.  The participant will be permanently  discontinued both from the study  
intervention and from the study  at that time.
If a part icipant withdraws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will continue to be available, and may 
be used to protect the integrity  of existing anal yses.  The investigator must docu ment an y 
such requests in the site study  records.
If the participant withdraws from the study  and also withdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected .  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
When a participant withdraws from the stud y because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial (CT) SAE Report.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
Withdrawal of Consent: 
Participants who request to discontinue receipt of study  treatme nt will proceed to ET visit as 
soon as possible.  The only  exception to this is when a participant specifically  withdraws 
consent for an y further contact with him or her or persons previousl y authorized by the 
participant to provide this information.  Part
icipants should notify  the investigator in writing 
of the decision to withdraw consent from future follow-up, whenever possible.  The 
withdrawal of consent should be explained in detail in the medical records by  the 
investigator, as to whether the withdraw al is only  from further receipt of IP or also from 
study  procedures and/or posttreatment study  follow -up, and entered on the appropriate CRF 
page.  In the event that vital status (whether the participant is alive or dead) is being 
measured, publicl y availa ble information should be used to determine vital status only  as 
appropriatel y directed in accordance with local law.
7.3.Lost to Follow -up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible an d counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study ;

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 61Before a participant is deemed lost to follow- up, the investigator or designe e must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods).  These contact attempts should be documen ted 
in the participant’s medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole is handled as part of Appendix 1 .
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures. 
Study  procedures and their timing are summa rized in the SoA .  Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontin ue study  
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potentia l 
participants meet all eligibility  criteria.  The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame d efined in the SoA .
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant.  When a protocol- required test cannot be performed, the 
investigator wi ll document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 62For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual part icipants during treatment period is 
approximately  195 mL.  The actual collection times of blood sampling may change.  
Additional blood samples may  be taken for safety assessments at times specified b y Pfizer, 
provided the total volume taken during the stud y does not exceed 550 mL during an y period 
of 60 consecutive day s.
8.1.Efficacy Assessments
All efficacy assessments will be based 
on areas treated with IP, but excluding scalp, 
palms and soles.
8.1.1. Rater Qualifications
For specific rating assessments, only  qualified raters will be allowed to evaluate and/or rate 
participants in this study .  The minimum qualifications a rater must meet for each stud y 
rating assessment will be outlined in the Rater Assessment Manual provided to each 
participating site.  The level of experience with the target population (or equivalent), specific 
scale experience (or equivalent), and certification required (if applicable) will be listed and 
used to determine whether a rater is approved for a given assessment.  Proposed raters who 
do not meet specific criteria but who may  be qualified based on unique circumstances may  be 
individually  reviewed by the study  clinical team to determine whether or not a waiver may  be 
issued.  The rater must become certified to perform selected stud y assessme nts before he or 
she can participate in the conduct of the stud y.  For specifically defined assessments, rater 
training and standardization exercises may  be conducted, and written and signed 
documentation will be provided by  the site for each rater’s certification.  In return, each site 
will be provided written and signed documentation outlining each rater’s certification for 
specific stud y assessments.  Recertification may be required at periodic intervals during the 
study .  The raters who administer speci fic study  assessments will be documented in a 
centralized location and all site staff who administer ratings will be verified in the site study  
documentation during the conduct of the stud y.
8.1.2. Investigator’s Global Assessment (IGA)
The Investigator’s Global 
Assessment of atopic dermatitis is scored on a 5 -point scale (0 -4), 
reflecting a global consideration of the ery thema, induration and scaling.  The clinical 
evaluator of atopic dermatitis will perform an assessment of the overall severity  of atopic 
dermati tis and assign an IGA score and category  as described below. 
The assessment will be a static evaluation without regard to the score at a previous visit. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 63Table 5. Investigator’s Global Assessment (IGA) Score
Score Category Descript ion
0 ClearAtopic dermatitis is cleared, except for any residual discoloration 
(post -inflammatory hyperpigmentation and/or hypopigmentation).
1 Almost ClearOverall, the atopic dermatitis is not entirely cleared and remaining lesions are 
light pink (no t including post inflammatory hyperpigmentation) and/or; have 
barely palpable hard thickened skin and/or papules and/or; have barely 
perceptible lichenification; excoriation and oozing/crusting are absent.
2 MildOverall, the atopic dermatitis consists of lesions that are light red; w ith slight, 
but definite hard thickened skin and/or papules; with slight, but definite linear 
or picked scratch marks or penetrating surface injury; with slight, but definite 
thickened skin, fine skin markings, and lichenoid scale; oozing/crusting is 
absent.
3 ModerateOverall, the atopic dermatitis consists of lesions that are red; w ith easily 
palpable moderate hard thickened skin and/or papules; with moderate linear or 
picked scratch marks or penetrating surface injury; with moderate thickened 
skin, coarse skin markings, and coarse lichenoid scale; with slight 
oozing/crusting.
4 SevereOverall, the atopic dermatitis consists of lesions that are deep, dark red; w ith 
severe hard thickened skin and/or papules; with severe linea r or picked scratch 
marks or penetrating surface injury; with severe thickened skin with very coarse 
skin markings and lichenoid scale; w ith moderate to severe oozing/crusting.
The IGA will exclude scalp, palms, and soles from the assessment/scoring.
8.1.3. Eczema Area and Severity Index (EASI)
The EASI quantifies the severit y of a participant’s atopic dermatitis based on both severity  of 
lesion byclinical signs and the percent of BSA affected .  EASI  is a composite scoring by  the 
atopic dermatitis clinical ev aluator of the degree of ery thema, induration/papulation, 
excoriation, and lichenification (each scored separately ) for each of four body  regions, with 
adjustment for the percent of BSA involved for each body  region and for the proportion of 
the body  regio n to the whole body .
8.1.3.1. Lesion Severity by Clinical Signs 
The basic characteristics of atopic dermatitis lesions- erythema, induration/papulation, 
excoriation, and lichenification -provide a means for assessing the severity  of lesions.  
Assessment of these four main clinical signs is performed separatel y for four body regions: 
head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including 
buttocks).  Average ery thema, induration/papulation, excoriation, and lichenification are 
score d for each body  region according to a 4 point scale: 0 =absent; 1 =mild; 2 =moderate; 
3 =severe.  Morphologic descriptors for each clinical sign severit y score are shown below.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 64Table 6. Clinical Sign Severity Scoring Criteria fo r the Eczema Area and Severity 
Index (EASI)
Score Description*
Erythema (E)
0 AbsentNone; may have residual discoloration (post -inflammatory hyperpigmentation 
and/or hypopigmentation)
1 Mild Light pink to light red
2 Moderate Red
3 Severe Deep, dark red
Induration/Papulation (I)
0 Absent None
1 Mild Barely palpable to slight, but definite hard thickened skin and/or papules
2 Moderate Easily palpable moderate hard thickened skin and/or papules
3 Severe Severe hard thickened skin and/or papules
Excoriation (Ex)
0 Absent None
1 Mild Slight, but definite linear or picked scratch marks or penetrating surface injury
2 Moderate Moderate linear or picked scratch marks or penetrating surface injury
3 Severe Severe linear or picked scratch marks or pen etrating surface injury
Lichenification (L)
0 Absent None
1 MildBarely perceptible to slight, but definite thickened skin, fine skin markings, 
and lichenoid scale
2 Moderate Moderate thickened skin, coarse skin markings, and coarse lichenoid scale
3 Severe Severe thickened skin with very coarse skin markings and lichenoid scale
The EASI will exclude scalp, palms, and soles from the assessment/scoring.
8.1.3.2. Percent BSA with Atopic Dermatitis (for efficacy)
Percent BSA affected b y AD should be calculated in each o f the four bod y regions ie head
and neck ( h), upper extremities ( u), trunk ( t),and lower extremities ( l ).  The area within each 
body  region with the key signs of the disease is estimated using handprint as a measure , 
where the full palmar hand o f the 
participant (ie, the participant ’s fully  extended palm, 
fingers and thumb together) represents approximately  1% of the total BSA .
Each region is t ypicall y assigned proportionate body  surface areas of 10 (h), 20 ( u), 3 0 (t ), 
and 40 (l)handprints resp ectivel y.  Refer to Table 7to identify  the surface area equivalent of 
1handprint in each respective body  region. 
Table 7. Determination of Body Region Surface Area
Body RegionTotal Number of 
Handprints in Body 
RegionSurface Area of Body 
Region Equivalent of 
One Handprint
Head and Neck 10 10%
Upper Limbs 20 5%
Trunk (including axillae and groin) 30 3.33%
Lower Limbs (including buttocks) 40 2.5%

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 65Area Score
The extent (%) to which each of the four bod y regions is involved with AD (by  using Table 7
above) is categorized using a non -linear scaling method to a numerical area score according 
to the following BSA scoring criteria (Table 8).
Table 8. Area Score Criteria
Percent BSA with Atopic 
Derm atitis in a Body RegionArea Score
0% 0
>0-<10% 1
10-<30% 2
30-<50% 3
50-<70% 4
70-<90% 5
90-100% 6
Body Region Weighting :Each bod y region is weighted according to its approximate 
percentage of the whole body  (Table 9). 
Table 9. Body Region Weighting
Body Region Body Region Weighting
Head and Neck 0.1
Upper Limbs 0.2
Trunk (including axillae and groin) 0.3
Lower Limbs (including buttocks) 0.4
8.1.3.3. Calculation of EASI Score 
In each bod y region, the sum of the Clinical Signs Severity  Scores for ery thema, 
induration/ papulation , excoriation, and lichenification is multiplied by  the Area Score and by  
the Bod y Region Weighting to provide a body  region value, which is then summed across all 
four bod y regions resulting in an EASI  score as described in Equation.
Equation: EASI =0.1Ah(E h+Ih+Ex h+Lh) + 0.2Au(E u+Iu+Ex u+Lu) + 0.3At(E t+It+Ex t+Lt) + 
0.4Al(E l+Il+Ex l+Ll)
A = Area Score; E = erythema; I =induration/papulation; Ex = excoriation; L =lichenification; 
h = head and neck; u =upper limbs; t = trunk; l = lower limbs .
The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores 
representing greater severity  of atopic dermatitis.   Since the scalp , palms and soles (even if 
hairless scalp , palms and soles are being treated with 
the IP) will be excluded from the EASI 
assessment in this study , the maximum possible score will be less than 72.0.
Calculation will be don e centrall yby Sponsor programmers.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 668.1.4. Body Surface Area
The BSA affected (%) is calculated by  adding the %BSA affected in each body  region area.  
The extent to which each of the four areas of the body
 is affected (% BSA) is obtained by  
multiply ing the % obta ined from Table 7with a weighting factor as shown in Table 9.  The 
% BSA is captured on the CRF (to 2 decimal places, as necessary ). 
The sum of the weighted percent involvement obtained for each of the four body  areas is the 
grand total BSA with AD, as described in the following equation:
BSA (%)=
0.1S h+ 0.2S u+ 0.3S t+ 0.4S l
where S =body region surface area with AD; h = head; u =upper limbs; t =trunk; l =lowerlimbs.
Symptoms (e g,pruritus), alo ng with secondary  signs (e g,xerosis, scaling) are excluded from 
the area assessments.
8.1.4.1. Body Surface Area for IP need 
Evaluation of BSA for IP need is the total BSA across all body  locations being treated wi th 
the IP.  BSA for IP need evaluation method wil
l be the same as the BSA Efficacy  evaluation 
(Section 8.1.4), except that theBSA for IP need w ill include AD on all IP treated body  
locations, some of which may
 be excluded from the BSA Effic acy evaluation.  If a 
participant has atopic dermatitis on palms, and/or soles, these body  locations will be included 
in the BSA for IP need estimation.
Participants with atopic dermatitis on the groin or genitals at Day 1 (Visit 1) are not eligible 
for the stud y.  If new atopic dermatitis occurs on the groin and/or genitals following Day 1 
(Visit 1), the groin and/ or genitals may  be treated with IP, but the groin and genitals will be 
excluded from the clinical evaluation of atopic dermatitis for efficacy . New atopic dermatitis 
occur ringon the groin and/or genitals following Day 1 (Visit 1)will be included in the 
clinical evaluation of atopic dermatitis BSA for IP need to ensure the participant has an 
adequate suppl y of IP.
Investigational product should be applied to the BSA determined at Day 1 (Visit 1)
throughout the treatment period regardless of clearing or improvement of atopic dermatitis.  
Any new atopic dermatitis on treatment
-eligible locations occurring following Day 1 
(Visit 1) should also be tr eated with the IP.  Therefore, the BSA for IP need at subsequent 
visits should be equal to or greater than the value at Day 1.
A checklist of bod y siteareas currentl y affected b y AD will be completed at the Day 1 visit.  
Location of skin lesions will be s
elected from a prepopulated listing of body locations.
The body site checklist will be reviewed at every  visit to the site to update for any  new, 
treatable areas, if needed.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 678.1.5. Peak Pruritus Numerical Rating Scale (PP -NRS) 
The intensity  of pruritus will be a ssessed b y a numerical rating scale ( NRS ), an 11-categor y 
numeric rating scale from 0 to 10, which is patient reported (see Appendix 12).  The PP -NRS 
will be completed by participant .  The PP -NRS will be completed once dail y at least 7 days 
prior to Day 1, and completed once daily  every  day from Day 1 to Week 6before IP morning 
dose is applied preferably at the same time of each day
 if applicable, as noted in the Schedule 
of Acti vities (SoA) . 
Pruritus will be evaluated by  asking participants to assign a numerical score representing the 
worst imaginable itch over the last 24 hours on a scale from 0 to 10, with 0 indicating no 
symptoms and 10 indicating the worst imaginable sy mpto ms.  The PP -NRS is presented in
Figure 3.  This item will be administered to all participants. 
Figure 3.Peak Pruritus Numerical Rating Scale (PP -NRS)
8.2.Safety Assessments
Planned time points for all safe ty assessments are provided in the Schedule of Activities 
(SoA) .  Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  concerns.
8.2.1. Assessments at Screening Only
8.2.1.1. Medi cal History
Investigators should make all reasonable efforts to obtain an accurate and complete medical 
history  and history  of prior medication use when evaluating whether a participant is eligible 
for the stud y.  The following will be collected at Screening: complete medical history , AD 
disease history  (including disease duration and prior treatments) and alcohol and tobacco use 
history . 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 68Complete AD disease history  includes collection of details of AD at Screening: AD 
diagnosis, the use of topical treatme nts, s ystemic treatments and other treatments for AD 
taken during the 3 months/90 days prior to Screening/Washout with dose, duration of 
treatment, and reason for discontinuation.  All other drugs (including sunscreen, over the 
counter medication, vitamins, and dietary  supplements) taken within 28 days prior to the 
Screening/Washout visit should be recorded .
Medical history  in addition to AD history  including disease duration will be collected at 
screening.  Medical history  also includes history  of alcohol 
and tobacco use.  Smoking status 
and average weekl y alcohol consumption (units/week) will be collected, where a unit 
contains 12 g of pure alcohol , an amount equivalent to that contained in 5 oz/150 mL (a 
glass) of wine, 12 oz/360 mL  of beer, or 1.5 oz/45 mL of 90 proof of spirits. 
If the status of a participant’s medical history is in doubt or information pertaining to a 
critical variable is conflicting, every  reasonable step to secure proper documentation of 
correct medical status should be attempted.  D ocumentation of the medical and medication 
histories over the protocol defined time periods should be available for sponsor review 
during the source data verification process.  Questions about prior medications or eligibility  
should be directed to the Sponsor Clinician or Sponsor Medical Monitor.
8.2.1.2. Tuberculosis Testing
At the time of screening, all participants will undergo tuberculosis (TB) testing unless 
performed within 12 weeks of Screening (with available documentation) using one of the 
tests below. 
8.2.1.2.1. Interferon Gamma Release Assay (IGRA) Tuberculin Test
Participants may  be screened for TB using an IGRA per local guidelines.  Interferon gamma 
release assay  will be tested during screening or within 12 weeks prior to Day 1.  The 
following are acceptable IGRA assay s: QuantiFERON-TB Gold test ( QFT -G), 
QuantiFERON-TB Gold I n-Tube test ( QFT -GIT) and T-SPOTTB test.  Site personnel 
should follow the processing and anal yses steps based on the assay  chosen.  Ensure 
incubation steps are followed as appropriate.
AnIGRA is preferred for participants with a prior bacille Calmette -Guerin ( BCG)
vaccination, but may  be used for an y participant.  Documentation of IGRA product used and 
the test result must be in the participants’ source documentation.
If the results of the IGRA are indeterminate, the test may  be repeated, and if a negative result 
is obtained, enrollment may  proceed.  A positive test on repeat is exclusionary . 
Participants with repeat indeterminate IGRA results may  be enrolled after consultation with 
pulmonary  or infectious disease specialist that determines low risk of infection 
(ie,participant would be acceptable for immunosuppressant (eg, anti -tumor necrosis factor 
[TNF ]) treatment without additional action).

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 69Participants who test positive for IGRA test (including borderline T- SPOT result), but in the 
opinion of the PI  areat low risk of TB infection may  be referred to pulmonary  or infectious 
disease specialist for consultation and potential I GRA test repeated once.  Participants will be 
eligible if the repeat test is negative before the randomization.
Refer to lab manual for any  additional processing information and shipping instructions.
8.2.1.2.2. Mantoux/Purified Protein Derivative (PPD) Tuberculin Skin Test
Participant s can be TB screened using the Mantoux/PPD Tuberculin Skin Test.  
Mantoux/PPD 
testing can also be performed if there are indeterminate QFT -G test results.  
Participant s must have a Mantoux/PPD tuberculin skin test administered and then evaluated 
by a health care professional 48 to 72 hours later.  A positive Mantoux/PPD tuberculin skin 
test is exclusionary .
8.2.1.3. Chest Radiograph
Participants must have chest radiograph (posterior -anterior and lateral views are 
recommended however local guidelines should be followed) or other appropriate diagnostic 
image o f the chest/thorax (ie , compute rized axial tomograph y [CAT] or magnetic resonance 
imaging [MRI ]) taken at Screening and read b y a qualified radiologist.   Documentation of 
official reading must be available in source documentation.  Chest imaging may  be 
performed to aid in TB status determination 
for all adults, and recommended for adolescents
according to local guidelines and standard of care and/or in countries with a high incidence 
rate of TB.
If chest radiograph had been taken within 12 weeks prior to Screening and read by  a qualified 
radiologist as normal, the test does not have to be repeated at screening, provided 
documentation is available. 
Participants with e vidence of currentl y active TB, general infections, heart failure or 
malignancy  will be excl uded.  Participants with changes suggestive of untreated latent or 
active TB infection may be enrolled after consultation with a pulmonary  or infectious disease 
specialist who determines low risk of infection.
8.2.1.4. Skin Type Assessment
As part of 
screening, a skin ty pe assessment will be done using the Fitzpatrick Skin Ty pe 
assessment (Refer to Appendix 11 ).  This is used to classify a person’s skin type b y their 
response to sun exposure (ie, burning or tanning).
8.2.2. Assessments d uring Study
8.2.2.1. Physical Examinations
Physical examinations, including height, andweight will be performed at times specified in 
the S chedules of A ctivities section of this protocol.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 70Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation.
Full Physical Examination: includes, but is not limited to the following organ or bod y 
systems -head, ears, ey es, nose, mouth, skin, heart and lung examinations, lymph nodes, 
gastrointestinal, musculoskeletal , abdomen, cardiovascular, and neurological sy stems.  In 
addition, an assessment will be made of the condition of all AD involved skin (skin 
assessments should be completed by  PI or Sub- I). 
A full phy sical examination will be performed at Screening ,Day 1, and at Week 6 visit . 
Disease focused Physical Examination: includes all AD involved skin (in treatable and 
non-treatable areas) and evaluation of anycurrent or reported s ymptoms for clinically  
significan
t changes. A disease -focused ph ysical examination will be performed at Week 1, 
Week 2, Week 4, follow - up and at early  termination (ET) visits.
Any clinically  significant changes from the most recent ph ysical examination should be 
recorded as adverse event s (AEs).  Lack of efficacy  is generall y not considered an AE.
Any treatment -emergent finding of other forms of dermatitides/eczematous conditions, 
(eg,contact dermatitis, seborrhoeic, discoid, gravitational, asteatotic) should be recorded as 
an AE.
Invest igators should pay  special attention to clinical signs related to previous serious 
illnesses. 
8.2.2.1.1. Weight and Height
It is recommended that weight bemeasured in kilograms (kg) to the nearest 0.1 kg and that 
height be measured in centimeters (cm) with shoes re moved. 
For measuring weight, a scale with appropriate range and resolution is used and must be 
placed on a stable, flat surface.  Participants must remove shoes, bulk y layers of clothing, and 
jackets so that only  light clothing remains.  They
 must also re move the contents of their 
pockets and remain still during measurement of weight.
8.2.2.2. Vital Signs
Vital signs will be measured with the participant in supine position after 5 minutes of rest as 
indicated in the Sche dule of Activities (SoA) and will include temperature, sy stolic and 
diastolic blood pressure, and pulse rate (PR)
.  On study  day visits when clinical laboratory  
tests are performed, assessment of vital signs should precede blood draw.
Body temperature wil l be collected using the t ympanic or oral methods and the same method 
should be used consistently  throughout the study . 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 71Blood pressure (BP) will be measured using a standard calibrated blood pressure measuring 
device.  A BP device that uses multiple cuff sizes based on the arm circumference is the 
required t ype of device.  The following method should be used to record the blood pressure:
Participants should be seated in a chair, back supported, and arms bared (free of 
restrictions such as rolled -up sleeves , etc.) and supported at heart level.
Measurements should be taken on the same arm at each visit (preferabl y 
non-dominant) and in same position (sitting or supine) as their baseline visit .
Participants should refrain from smoking or ingesting caffeine dur ing the 30 minutes 
preceding the measurements.  Measurements should begin after at least 5 minut es of 
rest without distractions
.  When the timing of BP and pulse (heart) rate measurements 
coincides with a blood collection or other study  procedure, BP and p
ulse (heart) rate 
should be obtained first.
The appropriate cuff size for the participant must be used to ensure accurate 
measurement.  The arm circumference at the midpoint of the length of the upper arm 
should be measured to determine the appropriate cu ff size in accordance with the 
specifications of the BP measuring device.  The same properly  sized and calibrated 
blood pressure cuff will be used to measure blood pressure each time .
BP should be recorded to the nearest mmHg value.
Pulse rateshould be m easured at approximately  the same time as BP for a minimum of 
30seconds. 
8.2.2.3. Electrocardiograms
A single 12-Lead ECGs should be collected at times specified in the Schedule of Activities
(SoA) section of this pro tocol using an ECG machine that automatically  calculates the heart 
rate and measures PR, QT, and QTc intervals and QRS complex.  Additional ECG may  be 
performed upon request by
 the Sponsor Clinician or the Sponsor Medical Monitor. 
All scheduled ECGs shoul d be performed after the participant has rested quietly  for at le ast 
10 minutes in supine position.  When the timing of these measurements coincides with a 
blood collection, theECG should be obtained prior to the nominal time of the blood
collection, BP, and pulse rate.
ECGs will be read and interpreted locally .  To ensure safety of the participants, aqualified 
individual (eg, sub -investigator )at the investigator site will make comparisons to baseline 
measurements taken at Day 1.  ECG parameters (PR, QT, QTc and QRS intervals) should be 
recorded on the CRF.  A copy  of the ECG should be available as source document for review.
Durin gscreening, if 
participants have initial screening value QTcF >450 milliseconds (ms) , 
ECG should be repeated two more times and the average of the three QTcF should be used to 
determine the participant eligibility .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 72If at an y subsequent time QTcF  500 msec or change from baseline QTc 60msec, ECG 
should be repeated two more times and average of these values should be used to determine 
withdrawal from I P (see Section
7.1.1).   If average is above these thresholds, participants 
should be monitored hourly  with triple ECGs. 
If a postdose QTc interval remains 30msec from the baseline andis >450 msec; or b) an 
absolute QTc value is 500msec for an y scheduled ECG for greater than 4 hours (or sooner ,
at the discretion of the investigator), or QTc intervals get progressivel y longer, the participant
should undergo continuous ECG monitoring.  A cardiolo gist should be consulted if QTc 
intervals do not return to less than the criterion listed above after 8 hours of monitoring (or 
sooner ,at the discretion of the investigator). 
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7.
8.2.2.4. Herpetiform Rash
For an y occur rence of a suspected herpetiform rash (e g,herpes zoster and herpes simplex), 
specimens for viral deoxy
ribonucleic acid ( DNA )analysis will be obtained: A swab of the 
affected area will be collected for confirmation; a blood sample for viral surveillance w ill be 
collected for the anal ysis of viral load. Details for these collections will be provided in the 
laboratory  manual.
8.2.2.5. Clinical Safety Laboratory Assessments
See Appendix 2for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CR F.  
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28days after the last dose of stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 73All protocol -required laboratory  assessments, as d efined in Appendix 2, must be conducted 
in accordance with the laboratory  manual and the SoA.
If laboratory  values from non
-protocol -specified laboratory  assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
If the screening serum chemistry  and hematology  tests are performed within 7 days prior to 
Day 1, whether the Day 1 serum chemistry  and hematology  tests are to be performed will be 
at the discretion of the i nvestigator or his/her designee.
At the discretion of the investigator or his/her designee , a lidocain e-based topical anesthetic 
(eg,lidocaine 4%cream) may  be used prior to clinical laboratory  sample collection to 
decrease potential discomfort to the participant provided the anesthetic does not contain 
propy lene gl ycol ( PG).  However, the skin must be th oroughly  cleansed prior to blood 
sample collection.
The Investigator will review all clinical laboratory  test results for safety  evaluation upon 
receipt.  After reviewing the laboratory  reports and evaluating the results for clinical 
significance, the i nvestigator or his/her designee must sign and date the laboratory  report.  
Clinically  significant laboratory  abnormalities are defined as abnormal values that have 
clinical manifestations or require medical intervention.  Clinically  significant laboratory  
abnormalities noted from the Screening Visit will be recorded in the medical history . 
A clinically  significant laboratory  abnormality  detected after the Screening Visit may  reflect 
the development of an AE.  Whenever possible, Investigators should report the clinical 
diagnosis suggested b y the laboratory  abnormality  rather than listing individual abnormal test 
results as AEs.  If no diagnosis has been found to explain the abnormal laboratory  result, the 
clinically  significant lab result should be recorded as an AE.
8.2.2.6. Creatinine, Cystatin C, and estimates of Glomerular F iltration Rate
Serum creatinine will be measured as part of serum chemistry  at times specified in the 
Schedule of Activities (SoA) sectionof the prot ocol.  Creatinine elevations above the upper 
limit of normal (UL N) will be followed until resolution or baseline.  Serum creatinine based 
eGFR will be calculated.  Serum cy statin C will be measured and cy statin C based eGFR will 
be calculated at correspond ing times per Schedule of Activities (SoA) . 
The eGFR will be calculated using the 2 sets of equations developed by  the Chronic Kidney  
Disease Epidemiology Collaboration ( CKD -EPI), which utilize se rum creatinine ( SCr) and 
serum c ystatin C (SCystatin C) respectivel y
(Appendix 14).
8.2.2.7. Samples for 
Lipid Analysis
Blood samples (3.5mL) to provide approximately 1.2 mL serum for the analy sis of lipids 
will be collected as per Schedule of Activities (SoA) .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 748.2.2.8. Suicidal Ideation and Behavior Risk Monitoring
Participants meeting exclusionary  results as described in Section 5.2 on the C -SSRS should 
be excluded from participation ; it is recommended the participant’s primary care ph ysician 
(PCP) should be informed, and the participant referred to a mental health professional, either 
by the PCP or the investigator according to their usual practice.
8.2.2.8.1. Columbia Suici de Severity Rating Scale (C -SSRS)
The Columbia Suicide Severit y Rating Scale is a validated tool for investigative staff to use 
to evaluate suicidal ideation and behavior ( Appendix 13).  At the screening visit, if there are
“yes” answers on items 4 or 5 in the past y ear or on any  question in the suicidal behavior 
section of the C -SSRS in the past 5 years, the participant will not be included in the study .  
Trained site staff is to administer the C
-SSRS to all participants at screening and assess the 
participant’s eligibility  based on the answers.
At any  of the visits in Schedule of Activities (SoA) when C -SSRS will be administered , if 
there are “y es” answers on items 4, 5 or on an y question 
in the suicidal behavior section of 
the C -SSRS, theparticipant will be discontinued from the I P and referred to a mental health 
professional for appropriate evaluation and treatment.  If the participant cannot be seen b y a 
mental health profess ional within 24 hours, then the participant should be sent to a local 
emergency  room for ps ychiatric assessment.
8.2.2.9. Local Tolerability
The investigator or designee will assess tolerability  at the site of I P application (pre-dose and 
immediately  post -dose) .  This assessment will focus on the treated non -lesional skin using 
scale inTable 10.27  See Section 7.1.2 for permanent and temporary  discontinuat ion criteria 
based on local tolerability  assessment. 
Table 10.Skin Tolerability Grading System
Grade Severity Description
0 None No evidence of local intolerance
1 Mild Minimal erythema and/or oedema, slight glazed appearance
2 ModerateDefinite erythema and/or oedema with peeling and/or cracking but 
needs no adaptation of posology
3Severe (to be 
reported as an AE)Erythema, oedema glazing with fissures, few vesicles or papules: 
consider removing topical agent (if still in pla ce)
4Very  severe (to be 
reported as an AE)Strong reaction spreading beyond the treated area, bullous 
reaction, erosions: removal of topical agent (if still in place)
8.2.2.10. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests, but must have a sensiti vity of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .  
Following a negative pregnancy test result at screening, appropriate contraception must be 
commenced and a second negative pre gnancy  test result will be required at the baseline visit 
prior the participant’s receiving the investigational product.  Pregnancy  tests will also be 
done whenever 1 menstrual cy cle is missed during the active treatment period (or when 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 75potential pregnancy is otherwise suspected) and at the end of the study .  Pregnancy  tests may  
also be repeated if requested by  institutional review boards (IRBs)/ethics committees (ECs) 
or if required b y local regulations.  If a urine test cannot be confirmed as negative (eg , an 
ambiguous result), a serum pregnancy  test is required.  In such cases, the participant must be 
excluded if the serum pregnancy  result is positive.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3.
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caus ed the participant to discontinue the 
study  intervention (see Section 7). 
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1.
Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent , 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving investigational product), through and including 
a minimum of 28 calendar day s, except as indicated below, after the last administration of the 
investigational product.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
Medical occurrences that begin before the start of study  intervention but after obtain ing 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the case report form (CRF), not the AE section.
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
Investigators are not obligated to activel y seek AEs or SAEs after conclusion of the study 
participation.  However, if the investigato r learns of any  SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 768.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form immediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3.  The investigator will submit any  updated SAE 
data to the sponsor within 24
hours of it being available.
SAEs occurring in a participant after the active collection period has ended are reported to 
Pfizer Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurr
ences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain adequate information until resolut ion, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the e vent in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for S AEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 77The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRBs)/ethics committees 
(ECs), and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local r egulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate according to local requirements.
8.3.5. Exposure d uring Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the investigational product under s tudy during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure During Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of ma le 
participants will be collected after the start of study intervention and until 28days after the 
last dose .
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During Breastfeeding
Scenarios of exposure du ring breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure du ring breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 78An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a par ticipant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
8.3.6. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength. 
Exposures to the investigational product under study  may  occur in clinical trial settings, such 
as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participa nt exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
Such medication errors occurring to a stud y participant are to be captured on the m edication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigat or, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
8.4.Treatment of Overdose
For this study , any  dose of investigational product greater than BID dosing within a 24 -hour 
time period will be considered an overdose.
Sponsor does not recommend specific treatm ent for an overdose.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 79In the event of an overdose, the investigator should:
1.Contact the medical monitor immediately .
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities until 
investigational product can no longer be detected sy stem ically (at least 7 days).
3.Obtain a blood sample for PK anal ysis within 1days from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case -by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
5.Overdose is reportable to Safety  only when associated with an SAE .
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the medical monitor based on the clin ical evaluation of the participant.
8.5.Pharmacokinetics 
Blood samples of approximately  3mL, to provide a minimum of 1.5 mL  plasma will be 
collected into appropriately  labeled tubes containing dipotassium ethy lenediaminetetraacetic 
acid (K2EDTA ) for measurem ent of plasma concentrations of PF-06700841 as specified in 
the Schedule of Activities ( SoA).  Instructions for the collection and handling of biological 
samples will be provided in the laboratory  manual or by  the sponsor.  The actual date and 
time (24
-hour clock time) of each sample will be recorded.   The actual times may  change, but 
the number of samples will remain the same. 
All efforts will be made to obtain the samples at the exact nominal time relative to dosing.  
The exact time of the collection should be noted on the source document and data collection 
tool (eg, CRF).
Samples collected for analy ses of PF -06700841 concentration may  also be used to evaluate 
safet y or efficacy aspects related to concerns arising during or after the study , for metabolite 
identification and/or evaluation of the bioanal ytical method, or for other internal exploratory  
purposes.
Genetic anal yses will not be performed on these plasma samples.  Participant confidentiality  
will be maintained.
Samples collected for measurement of plasma concentrations of PF- 06700841 will be 
analyzed using a validated anal ytical method in compliance with applicable standard 
operating procedures (SOPs).

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 0 T h e  P K  s am p l e s  m u s t  b e  p r o c e s s e d  a n d  s h i p p e d  a s  i n d i c a t e d  i n  t h e  i n s t r u c t i o n s  p r o v i d e d  t o  
t h e  i n v e s t i g a t o r  s i t e  t o  m a i n t a i n  s am p l e  i n t e g r i t y .   A n y  d e v i a t i o n s  f r om  t h e  P K  s am p l e  
h a n d l i n g  p r o c e d u r e  ( e g ,  s am p l e  c o l l e c t i o n  a n d  p r o c e s s i n g  s t e p s ,  i n t e r im  s t o r a g e  o r  s h i p p i n g  
c o n d i t i o n s ) ,  i n c l u d i n g  a n y  a c t i o n s  t a k e n ,  m u s t  b e  d o c um e n t e d  a n d  r e p o r t e d  t o  t h e  s p o n s o r .   
O n  a  c a s e -b y -c a s e  b a s i s ,  t h e  s p o n s o r  m a y  m a k e  a  d e t e rm i n a t i o n  a s  t o  w h e t h e r  s am p l e  
i n t e g r i t y  h a s  b e e n  c om p r om i s e d . 
D r u g  c o n c e n t r a t i o n  i n f o rm a t i o n  t h a t  m a y  u n -b l i n d  t h e  s t u d y  w i l l  n o t  b e  r e p o r t e d  t o  
i n v e s t i g a t o r  s i t e s  o r  b l i n d e d  p e r s o n n e l . 
A n y  c h a n g e s  i n  t h e  t im i n g  o r  a d d i t i o n  o f  t im e  p o i n t s  f o r  a n y  p l a n n e d  s t u d y  a s s e s sm e n t s  m u s t  
b e  d o c um e n t e d  a n d  a p p r o v e d  b y  t h e  r e l e v a n t  s t u d y  t e am  m em b e r  a n d  t h e n  a r c h i v e d  i n  t h e  
s p o n s o r  a n d  s i t e  s t u d y  f i l e s ,  b u t  w i l l  n o t  c o n s t i t u t e  a  p r o t o c o l  am e n dm e n t .   T h e  I R B / E C  w i l l  
b e  i n f o rm e d  o f  a n y  s a f e t y  i s s u e s  t h a t  r e q u i r e  a l t e r a t i o n  o f  t h e  s a f e t y  m o n i t o r i n g  s c h em e  o r  
am e n dm e n t  o f  t h e  I C D . 
 
 
 
  
 
 
 
 
 
 
 
 
 
 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 1  
 
 
 
 
 
 
 
 
 
 
 
.C C I 
C C I 
C C I 
C C I 
C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 2  
 
8 . 7 . G e n e t i c s 
8 . 7 . 1 . S p e c i f i e d  G e n e t i c s 
G e n e t i c s  ( s p e c i f i e d  a n a l y s i s )  a r e  n o t  e v a l u a t e d i n  t h i s  s t u d y .
 
 
 
 
 
 
 
 
 
8 . 8 . B i om a r k e r s 
B i o s p e c im e n s  c o l l e c t e d  f o r  b i om a r k e r  a s s e s sm e n t s  m a y  i n c l u d e  p e r i p h e r a l  b l o o d a n d  s k i n  
t i s s u e  a n d  m a y  b e  u s e d  t o  a n a l y z e  D N A ,  R N A ,  p r o t e i n s ,  o r  m e t a b o l i c  b i om a r k e r s ,  f o r  
a c h i e v i n g  p l a n n e d  b i om a r k e r  o b j e c t i v e s .   R e f e r  t o  t h e  S c h e d u l e  o f  A c t i v i t i e s  ( S o A ) f o r  
s am p l e  c o l l e c t i o n  t im e  p o i n t s  a n d  t h e  l a b o r a t o r y  m a n u a l  f o r  s am p l e  p r o c e s s i n g  a n d  s h i p p i n g .  
 
 
 C C I 
C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 . 9 . H e a l t h  E c o n om i c s 
H e a l t h  e c o n om i c s /m e d i c a l  r e s o u r c e  u t i l i z a t i o n  a n d  h e a l t h  e c o n om i c s  p a r am e t e r s  a r e  n o t  
e v a l u a t e d i n  t h i s  s t u d y .C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 4 8 . 1 0 .P a t i e n t  R e p o r t e d  O u t c om e s 
E v e r y  e f f o r t  s h o u l d  b e  m a d e  f o r  t h e  p a r t i c i p a n t  t o  c om p l e t e  a l l  p a t i e n t  r e p o r t e d  o u t c om e  
( P R O )  q u e s t i o n n a i r e s b e f o r e  a n y  o t h e r  e v a l u a t i o n s .   T h e  am o u n t  o f  t im e  r e q u i r e d  f o r  
p a r t i c i p a n t s  t o  c om p l e t e  t h e  P R O  q u e s t i o n n a i r e s  i s  a p p r o x im a t e l y  1 0 - 3 0 m i n u t e s ( d e p e n d i n g  
o n  t h e  v i s i t  a n d  a s s o c i a t e d  P R O s ) .   T h e  P R O s  s h o u l d  b e  c h e c k e d  f o r  c om p l e t e n e s s  b y  t h e  
s t u d y  s i t e  s t a f f a t  e v e r y  i n -c l i n i c  v i s i t .
O n c e  p a r t i c i p a n t s  h a v e  m e t  a l l  i n c l u s i o n / e x c l u s i o n  c r i t e r i a ,  t h e y  w i l l  b e  p r o v i d e d  a  h a n d h e l d  
d e v i c e  ( p r o v i d e d b y  t h e  S p o n s o r )  f o r  d o s i n g  d i a r y  a n d p a t i e n t -r e p o r t e d -o u t c om e s  ( eP R O s )o r  
p a p e r  v e r s i o n s  o f  t h e  a b o v e  t o  b e  c om p l e t e d  a t  h om e  a s  p e r  t h e  t im e  p o i n t s  d e f i n e d  i n 
S c h e d u l e  o f  A c t i v i t i e s  ( S o A ) .   T h e  c l i n i c  s i t e s  m a y  u s e  p a p e r  v e r s i o n s  o f  P R O s . 
T h e  f o l l o w i n g  P R O s  w i l l  b e  c om p l e t e d  o n l y  o n  s t u d y  v i s i t  d a y s i d e n t i f i e d  i n  S c h e d u l e  o f  
A c t i v i t i e s  ( S o A ) ,  s t a r t i n g  o n  D a y 1 :  P O EM ,  D L Q I / Ch i l d r e n s  D L Q I ( C D L Q I ) ,  a n d    
  O t h e r  p r o t o c o l -s p e c i f i e d  P R O s  
ie , P P -N R S ,   a n d   w i l l  b e  u s e d  b y  p a r t i c i p a n t s  f o r  d a i l y  c om p l e t i o n  o f  P R O s  a t  
h om e ,  s t a r t i n g  f r om  7 d a y s  p r i o r  t o  t h e  d o s i n g / r a n d om i z a t i o n  d a y  ( D a y 1 ) a n d  a s  d e f i n e d  i n  
t h e  S c h e d u l e  o f  A c t i v i t i e s  ( S o A ) . 
A l l  p a r t i c i p a n t s  w i l l  c om p l e t e P R O s  a t  f o l l o w -u p  v i s i t  i n  c l i n i c . 
De l e g a t e d  s i t e  s t a f f  w i l l  m o n i t o r  c om p l e t i o n  o f  P R O s  f o r  a d h e r e n c e a n d  w i l l  r e v i e w  
a d h e r e n c e  w i t h  p a r t i c i p a n t s a t  e a c h  v i s i t  a n d  c o u n s e l  a s  a p p r o p r i a t e .   I f  a  p a r t i c i p a n t  h a s  
r e p e a t e d  n o n  a d h e r e n c e ,  t h e  p a r t i c i p a n t  s h o u l d  b e  r e t r a i n e d  o n  u s e  o f  t h e  d e v i c e o r  f i l l i n g  o u t  
p a p e r  v e r s i o n s .   I f  a  p a r t i c i p a n t  i s  u n a b l e  t o  c om p l e t e  e P R O s  d u e  t o  d o c um e n t e d  t e c h n i c a l  
i s s u e  o r  d i s a b i l i t y  o r  o t h e r  l im i t a t i o n ,  t h e  p a r t i c i p a n t  w i l l  b e  p e rm i t t e d  t o  e n t e r  o r  r em a i n  i n  
t h e  s t u d y  p r o v i d i n g  t h a t  a  v a l i d  a l t e r n a t e  s o u r c e  o f  d a i l y  d a t a  e n t r y  i s  c om p l e t e d  a n d  
r e v i e w e d  b y  i n v e s t i g a t i o n a l  s i t e  s t a f f .   N o  p r o t o c o l  d e v i a t i o n s  w i l l  b e  r e c o r d e d  i n  r e g a r d  t o  
P R O  c om p l e t i o n  a d h e r e n c e .   I n  t h e  e v e n t  o f  e l e c t r o n i c  m a l f u n c t i o n o f  a n  e P R O  o r  
m i s p l a c em e n t  o f  p a p e r  v e r s i o n s  o f  t h e  P R O s ,  a  r e p l a c em e n t  d e v i c e  o r  p a p e r  P R O s  w i l l  b e  
s h i p p e d  t o  t h e  s i t e .   E x am p l e s  o f  t h e  v a l i d a t e d  p a p e r  v e r s i o n s  o f  P a t i e n t  R e p o r t e d  O u t c om e s  
i n s t r um e n t s  a r e  i n c l u d e d  i n  t h e  A p p e n d i c e s  o f  t h i s  p r o t o c o l .   T h e  e l e c t r o n i c  v e r s i o n  m a y  
d i f f e r  s l i g h t l y  i n  f o rm a t  o r  w o r d i n g  c om p a r e d  w i t h  t h e  p a p e r  v e r s i o n  t o  f a c i l i t a t e  e l e c t r o n i c  
im p l em e n t a t i o n . 
8 . 1 0 . 1 . P a t i e n t -O r i e n t e d  E c z em a  M e a s u r e  ( PO EM ) 
T h e  P O EM  i s  a  v a l i d a t e d  7 - i t em  P R O  m e a s u r e  u s e d  t o  a s s e s s  t h e  im p a c t  o f  A D  r e c a l l e d  o v e r  
t h e  p a s t  w e e k  ( A p p e n d i x 1 2 ) .   T h e  P O EM  s h o u l d  b e  c om p l e t e d  i n  c l i n i c  a s  p e r  S c h e d u l e  o f  
A c t i v i t i e s  ( S o A ) .
8 . 1 0 . 2 . D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x  ( D LQ I )  a n d  C h i l d r e n ’ s  D e rm a t o l o g y  L i f e  
Q u a l i t y  I n d e x  ( C D LQ I ) 
T h e  D L Q I  i s  a  v a l i d a t e d  g e n e r a l  d e rm a t o l o g y  q u e s t i o n n a i r e  t h a t  c o n s i s t s  o f  1 0 i t em s  t o  a s s e s s  
p a r t i c i p a n t -r e p o r t e d h e a l t h -r e l a t e d  q u a l i t y  o f  l i f e  ( d a i l y  a c t i v i t i e s ,  p e r s o n a l  r e l a t i o n s h i p s ,  
s y m p t om s  a n d  f e e l i n g s ,  l e i s u r e ,  w o r k  a n d  s c h o o l ,  a n d  t r e a tm e n t )  ( A p p e n d i x 1 2 ) .   I t  h a s  b e e n  C C I C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 5 e x t e n s i v e l y  u s e d  i n  c l i n i c a l  t r i a l s  f o r  A D .   T h e  D L Q I  i s  a  p s y c h om e t r i c a l l y  v a l i d  a n d  r e l i a b l e  
i n s t r um e n t  t h a t  h a s  b e e n  t r a n s l a t e d  i n t o  s e v e r a l  l a n g u a g e s ,  a n d  t h e  D L Q I  t o t a l  s c o r e s  h a v e  
b e e n  s h o w n  t o  b e  r e s p o n s i v e  t o  c h a n g e .   T h e  m i n im a l l y  im p o r t a n t  d i f f e r e n c e  f o r  t h e  D L Q I  
h a s  b e e n  e s t im a t e d  a s  a  3  t o  5p o i n t  c h a n g e  f r om  b a s e l i n e .   A  v e r s i o n  o f  t h e  i n s t r um e n t  
s p e c i f i c a l l y  d e v e l o p e d  a n d  v a l i d a t e d  f o r  u s e  b y  a d o l e s c e n t s  f r om  a g e  1 2  t o  1 7 i s  c a l l e d  t h e  
C D L Q I  ( A p p e n d i x 1 2 ) .  
T h e  D L Q I / C D L Q I  s h o u l d  b e  c om p l e t e d  i n  c l i n i c  a s  p e r  S c h e d u l e  o f  A c t i v i t i e s  ( S o A ) .
 
 
 
 
 
 
8 . 1 0 . 5 . P e a k  P r u r i t i s  N um e r i c a l  R a t i n g  S c a l e  ( P P -N R S ) 
S e e  S e c t i o n  8 . 1 . 5 f o r  d e t a i l s . 
 
  
 
 C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C C I C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 7  
 
 
  
 
 
 
 
 
 
 
9 . S T A T I S T I C A L  CO N S I D E R A T IO N S 
D e t a i l e d  m e t h o d o l o g y  f o r  s umm a r y  a n d  s t a t i s t i c a l  a n a l y s e s  o f  t h e  d a t a  c o l l e c t e d  i n  t h i s  s t u d y  
i s  o u t l i n e d  h e r e  a n d  f u r t h e r  d e t a i l e d  i n  a  s t a t i s t i c a l  a n a l y s i s  p l a n  ( S A P ) ,  w h i c h w i l l  b e  
m a i n t a i n e d b y  t h e  s p o n s o r .   T h e  S A P  m a y  m o d i f y  w h a t  i s  o u t l i n e d  i n  t h e  p r o t o c o l  w h e r e  
a p p r o p r i a t e ;  h o w e v e r ,  a n y  m a j o r  m o d i f i c a t i o n s  o f  t h e  p r im a r y  e n d p o i n t  d e f i n i t i o n s  o r  t h e i r  
a n a l y s e s  w i l l  a l s o  b e  r e f l e c t e d  i n  a  p r o t o c o l  am e n dm e n t . 
9 . 1 . E s t im a n d s  a n d S t a t i s t i c a l  H y p o t h e s e s 
T h e  p r im a r y  e s t im a n d  w i l l  b e  t h e  p o p u l a t i o n a v e r a g e  t r e a tm e n t  e f f e c t  o n  p e r c e n t  c h a n g e  f r om  
b a s e l i n e  i n  E A S I  s c o r e  r e l a t i v e  t o  v e h i c l e  ( w i t h  t h e  s am e  d o s i n g  s c h e d u l e ,  Q D  o r  B I D )  a t  
6w e e k s  i n  t h e  a b s e n c e  o f  p r o h i b i t e d  m e d i c a t i o n  w i t h o u t  r e g a r d  t o  c om p l i a n c e .  A l l  
o b s e r v a t i o n s  a f t e r  t h e  i n i t i a t i o n  o f  p r o h i b i t e d  m e d i c a t i o n  w i l l  b e  s e t  t o  m i s s i n g .   M i s s i n g  d a t a  
f r om  a l l  c a u s e s ,  i n c l u d i n g p o s t -p r o h i b i t e d  m e d i c a t i o n  u s e  w i l l  b e  im p u t e d  i n  t h e  
P F -0 6 7 0 0 8 4 1  a rm s  u s i n g  a  j um p  t o  c o n t r o l  m e t h o d  u s i n g  t h e  d i s t r i b u t i o n  o f  t h e  v e h i c l e  g r o u p  
w i t h  m a t c h i n g  B I D  o r  Q D  r e g im e n  ( i e  m i s s i n g  d a t a  i n  1%  Q D  r e g im e n  w i l l  b e  im p u t e d  f r om  
t h e  d i s t r i b u t i o n  o f  p a r t i c i p a n t s  o n  Q D  v e h i c l e ) .   P a r t i c i p a n t s  w i t h  i n a d e q u a t e  c om p l i a n c e  w i l l  
h a v e  t h e i r  r e c o r d e d  E A S I  s c o r e s  u s e d  a s -i s  i n  t h e  a n a l y s i s .   T h e  p o p u l a t i o n  b a s e d  t r e a tm e n t  
e f f e c t  w i l l  b e  t h e  d i f f e r e n c e s  i n  t h e  m e a n  c h a n g e  f r om  b a s e l i n e  i n  e a c h  t r e a tm e n t  a rm  
c om p a r e d  t o  t h e  c o r r e s p o n d i n g  v e h i c l e .  
T h e  s e c o n d a r y  e s t im a n d  w i l l  b e  t h e  e s t im a t e d  p o p u l a t i o n a v e r a g e  t r e a tm e n t  e f f e c t  o n  t h e  
r a t e s  o f  I G A  r e s p o n s e  ( p a r t i c i p a n t s  w i t h  a  s c o r e  o f  0  o r  1  a n d  a  2 p o i n t  o r  g r e a t e r  d e c r e a s e  
f r om  b a s e l i n e )  a t  W e e k 6  r e l a t i v e  t o  v e h i c l e  ( w i t h  t h e  s am e  d o s i n g  s c h e d u l e ,  Q D  o r  B I D )  
w i t h o u t  r e g a r d  t o  c om p l i a n c e  w i t h  I P i n  t h e  a b s e n c e  o f  p r o h i b i t e d  m e d i c a t i o n .   T h i s  i s  a  
c om p o s i t e  e s t im a n d  w h e r e  s u c c e s s  i s  d e f i n e d  a s  a c h i e v em e n t  o f  a n  I G A  r e s p o n s e  a s  d e f i n e d  
a b o v e  w h i l e  r em a i n i n g  o n  s t u d y ,  p r o v i d i n g  d a t a  a n d  n o t  t a k i n g  p r o h i b i t e d  m e d i c a t i o n ;  l a c k  o f  
c om p l i a n c e  o r  a d v e r s e  e v e n t s  w i l l  n o t  b e  c o u n t e d  a s  a  f a i l u r e .   T h e  p o p u l a t i o n  b a s e d  
t r e a tm e n t  e f f e c t  w i l l  b e  t h e  d i f f e r e n c e s  i n  t h e  p r o p o r t i o n s  o f  s u c c e s s  i n  e a c h  t r e a tm e n t  a rm  C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 88compared to the corresponding vehicle.  EASI - 75 and other EASI scores will be treated in a 
similar manner.
All other secondary  continuous clinical endpoints will be anal yzed using the primary  
estimand, while all other secondary  categorical clinical endpoints will be analy zed using the 
secondary  estimand described above.  Tertiary  and Exploratory  anal yses may  or may  not be 
analyzed using these estimands and may  be anal yzed in a descriptive manner without 
reference to an estimand.   Other estimands may  be used for some of the primary  and 
secondary  endpoints as a means to examine the robustness of the results and to compare to 
available literature as needed.  Details of these analy
ses will be presented in the statistical 
analysis plan (SAP).
9.2.Sample Size Determination
The sample size calculation is based on the primary endpoint (percentage change from 
baseline in EASI score at Week6) and the key  secondary  endpoint (IGA response rate of 
clear or almost clear and 2 points improvement at W eek6).  A total of 280 randomized 
participants in 6 treatments groups and two vehicle groups (35/arm) will provide 
approximately  90% power to detect a difference of 50 in percentage change from baseline 
with a common standard deviation 48
%between PF -06700841 and a vehicle arm, controlling 
the one -sided family  wise error rate a 0.05 with a Bonferroni correction (alpha=0.008 after 
Bonferroni adj ustment for 6 comparisons).  These calculations allow for a 20% dropout rate 
leaving 224 evaluable participants (28/arm).
For the key  secondary  endpoint, I GA response rate of clear or almost clear and 2points 
improvement at W eek6, assuming 20% rate for vehicle and 60% rate for the treatment, this 
sample size also ensures the 80% power.
9.3.Populations for Analysis
For purposes of analy sis, the following populations are defined:
Population Description
Safety  Anal ysis Set All participants randomly  assigned to IP and who apply  at 
least 1 dose of IP.  Participants will be analy zed according to 
the product they  actually  received.
Defined Population for 
AnalysisDescription
Modified Intention to 
Treat (mITT)All participants randomly  assigned to IP and who apply at 
least 1 dose of IP.  
PK concentration set All enrolled participants who applied at least one dose of 
PF-06700481 and in whom a t least once concentration value 
is reported.

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  8 9 9 . 4 .S t a t i s t i c a l  A n a l y s e s 
T h e  S A P  w i l l  b e  d e v e l o p e d  a n d  f i n a l i z e d  b e f o r e  d a t a b a s e l o c k  a n d  w i l l  d e s c r i b e  t h e  
p a r t i c i p a n t  p o p u l a t i o n s  t o  b e  i n c l u d e d  i n  t h e  a n a l y s e s ,  a n d  p r o c e d u r e s  f o r  a c c o u n t i n g  f o r  
m i s s i n g ,  u n u s e d ,  a n d  s p u r i o u s  d a t a .   T h i s  s e c t i o n  i s  a  s umm a r y  o f  t h e  p l a n n e d  s t a t i s t i c a l  
a n a l y s e s  o f  t h e  p r im a r y  a n d  s e c o n d a r y  e n d p o i n t s . 
9 . 4 . 1 . E f f i c a c y  A n a l y s e s 
E n d p o i n t S t a t i s t i c a l  A n a l y s i s  M e t h o d s 
P r im a r y A  l a n dm a r k  a n a l y s i s  u s i n g  a n a l y s i s  o f  c o v a r i a n c e  o f  p e r c e n t  c h a n g e  f r om  
b a s e l i n e  i n  E A S I ,  a d j u s t i n g  f o r  t h e b a s e l i n e  E A S I  s c o r e ,  t o  e s t im a t e  t h e  
e f f e c t  o f  t h e  i n i t i a l l y  r a n d om i z e d  t r e a tm e n t  i n  t h e  a b s e n c e  o f  p r o h i b i t e d  
m e d i c a t i o n  r e g a r d l e s s  o f  t r e a tm e n t  c om p l i a n c e .   T h e  a n a l y s i s  w i l l  u s e  t h e  
m I T T  a n a l y s i s  s e t .   M i s s i n g  d a t a  d u e  t o  a n y  c a u s e  i n c l u d i n g  c e n s o r i n g  d u e  
t o  i n i t i a t i o n  o f  p r o h i b i t e d  m e d i c a t i o n  w i l l  b e  im p u t e d  u s i n g  t h e  
c o r r e s p o n d i n g  v e h i c l e  a rm ,  m i s s i n g  d a t a  i n  a  v e h i c l e  a rm  w i l l  b e  im p u t e d  
u s i n g  d a t a  f r om  t h e  v e h i c l e  a rm  a s s um i n g  d a t a  a r e  m i s s i n g  a t  r a n d om  
(M A R ) .   T h e  a n a l y s i s  w i l l  c om b i n e  t h e  r e s u l t s  f r om  t h e  m u l t i p l e  
im p u t a t i o n s  u s i n g  R u b i n ’ s  r u l e ’ s  a s  im p l em e n t e d  i n  S A S  P R O C  
M I A N A L Y Z E .   T h e  o v e r a l l  f am i l y  w i s e  T y p e  I  e r r o r  r a t e  w i l l  b e  c o n t r o l l e d  
a t  t h e  o n e -s i d e d  0 . 0 5  l e v e l  u s i n g  t h e  H o c h b e r g  s t e p  u p  p r o c e d u r e . 
S e c o n d a r y A  l a n dm a r k  a n a l y s i s  o f  t h e  c om p o s i t e  e n d p o i n t ;  a c h i e v i n g  I G A  w i t h o u t  
p r o h i b i t e d  m e d i c a t i o n , w h i l e  r em a i n i n g  o n  s t u d y  a n d  p r o v i d i n g  d a t a .   T h e  
a n a l y s i s  w i l l  u s e  t h e  m I T T  a n a l y s i s  s e t .   B a s e d  o n  t h e  d e f i n i t i o n  o f  t h e  
c om p o s i t e  e n d p o i n t  a l l  p a r t i c i p a n t s  i n  t h e  m I T T  s e t  w i l l  h a v e  a  r e s p o n s e  f o r  
a l l  v i s i t s  ( i e ,  t h e r e  i s  n o  m i s s i n g  d a t a ) .   T h e  p r o p o r t i o n s  r e s p o n d i n g  a n d  t h e  
c o r r e s p o n d i n g  r i s k  d i f f e r e n c e  c om p a r i n g  a c t i v e  t r e a tm e n t  a rm t o  v e h i c l e  
g r o u p  w i l l  b e  a n a l y z e d  u s i n g  t h e  u n c o n d i t i o n a l  e x a c t  m e t h o d ;  t h e  r i s k  
d i f f e r e n c e s  a n d  t h e  c o r r e s p o n d i n g  2 -s i d e d  u n c o n d i t i o n a l  e x a c t  9 0%  
c o n f i d e n c e  i n t e r v a l s  w i l l  b e  c om p u t e d  u s i n g  C h a n  a n d  Z h a n g 2 8 ( 1 9 9 9 )  
m e t h o d .   N o  a d j u s tm e n t s  f o r  m u l t i p l i c i t y  w i l l  b e  m a d e . 
 
O t h e r  c o n t i n u o u s  s e c o n d a r y  e n d p o i n t s  a t  t im e  p o i n t s  s p e c i f i e d  i n  t h e  S c h e d u l e  o f  A c t i v i t i e s  
( S o A ) i n c l u d i n g  c h a n g e  f r om  b a s e l i n e  E A S I ,  w i l l  b e  a n a l y z e d  a s  d e s c r i b e d  f o r  t h e  p r im a r y  
e s t im a n d  a l o n g  w i t h  d e s c r i p t i v e  s t a t i s t i c s  a n d  p o s s i b l y  g r a p h i c a l  d i s p l a y s .   N o  a d j u s tm e n t s  
f o r  m u l t i p l i c i t y  w i l l  b e  m a d e  f o r  t h e s e  e n d p o i n t s . C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  9 0  E A S I -9 0 , ,  I G A  o f  c l e a r  o r  a lm o s t  c l e a r w i l l  b e  
a n a l y z e d  a s  d e s c r i b e d  f o r  t h e  s e c o n d a r y  e s t im a n d  a l o n g  w i t h  d e s c r i p t i v e  s t a t i s t i c s  a n d  
p o s s i b l y  g r a p h i c a l  d i s p l a y s .   N o  a d j u s tm e n t s  f o r  m u l t i p l i c i t y  w i l l  b e  m a d e  f o r  t h e s e  
e n d p o i n t s . 
 
9 . 4 . 2 . S a f e t y  A n a l y s e s 
A l l  s a f e t y  a n a l y s e s  w i l l  b e  p e r f o rm e d o n  t h e  s a f e t y  p o p u l a t i o n . 
E n d p o i n t S t a t i s t i c a l  A n a l y s i s  M e t h o d s 
P r im a r y T h e  s a f e t y  d a t a  w i l l  b e  s um m a r i z e d  i n  a c c o r d a n c e  w i t h  P f i z e r  D a t a  
S t a n d a r d s .   A l l  p a r t i c i p a n t s  w h o  r e c e i v e  I P  ( s a f e t y  p o p u l a t i o n )  w i l l  b e  
i n c l u d e d  i n  t h e  s a f e t ya n a l y s e s .   A l l  s a f e t y  d a t a  w i l l  b e  s umm a r i z e d  
d e s c r i p t i v e l y  t h r o u g h  a p p r o p r i a t e  d a t a t a b u l a t i o n s ,  de s c r i p t i v e  s t a t i s t i c s ,  
c a t e g o r i c a l  s umm a r i e s ,  a n d  g r a p h i c a l  p r e s e n t a t i o n s .   S a f e t y e n d p o i n t s  f o r  t h e  
s t u d y  i n c l u d e : 
T r e a tm e n t -em e r g e n t  A E s  a n d  S A E s ; 
W i t h d r a w a l s f r om a c t i v e t r e a tm e n td u e t oA E s ; 
S e r i o u s i n f e c t i o n s , d e f i n e d a s a n y i n f e c t i o n ( v i r a l , b a c t e r i a l , a n d f u n g a l ) 
r e q u i r i n g h o s p i t a l i z a t i o n  o r  p a r e n t e r a l  a n t im i c r o b i a l s ; 
S a f e t y l a b o r a t o r y t e s t s ( e g , h em a t o l o g y  [ i n c l u d i n g  c o a g u l a t i o n  p a n e l ] ,  
c h em i s t r y  a n d l i p i d  p r o f i l e s ) ; 
V i t a l s i g n s . 
C h a n g e  f r om  b a s e l i n e  o n  l a b o r a t o r y  d a t a  a n d  v i t a l  s i g n s  w i l l  b e  a d d i t i o n a l l y  
s umm a r i z e d .   P a r t i c i p a n t l i s t i n g s  w i l l  a l s o  b e  p r o d u c e d  f o r  t h e s e  s a f e t y  
e n d p o i n t s . 
9 . 4 . 2 . 1 . E l e c t r o c a r d i o g r am  A n a l y s e s 
C h a n g e s  f r om  b a s e l i n e  f o r  t h e  E C G  p a r am e t e r s  Q T  i n t e r v a l ,  h e a r t  r a t e ,  Q T c  i n t e r v a l ,  P R  
i n t e r v a l ,  a n d  Q R S  c om p l e x  w i l l  b e  s umm a r i z e d  b y  t r e a tm e n t  a n d  t im e . C C I 
C C I C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  9 1 T h e  n um b e r  (% )  o f  p a r t i c i p a n t s  w i t h  m a x im um  p o s t d o s e  Q T c  v a l u e s  a n d  m a x im um  i n c r e a s e s  
f r om  b a s e l i n e  i n  t h e  f o l l o w i n g  c a t e g o r i e s  w i l l  b e  t a b u l a t e d  b y  t r e a tm e n t :  
S a f e t y  Q T c  A s s e s sm e n t 
D e g r e e  o f  P r o l o n g a t i o n M i l d  (m s e c ) M o d e r a t e  (m s e c ) S e v e r e  (m s e c ) 
A b s o l u t e  v a l u e > 4 5 0 -4 8 0 > 4 8 0 -5 0 0 > 5 0 0 
I n c r e a s e  f r om  b a s e l i n e 3 0 -6 0 > 6 0 
I n  a d d i t i o n ,  t h e  n um b e r  o f  p a r t i c i p a n t s  w i t h  u n c o r r e c t e d  Q T  v a l u e s  > 5 0 0 m s e c w i l l  b e  
s umm a r i z e d . 
 
 
 
 
 
 
 
 
 
9 . 5 . I n t e r im  A n a l y s e s 
A n  i n t e r im  a n a l y s i s  w i l l  b e  p e r f o rm e d  o n c e  a p p r o x im a t e l y  2 0%  o f  e n r o l l e d p a r t i c i p a n t s 
(1 8 y e a r s  o f  a g e )  c om p l e t e  a t  l e a s t  W e e k 2  ( D a y 1 5 )  v i s i t .   T h e  o b j e c t i v e  o f  t h i s  a n a l y s i s  i s  
t o  e v a l u a t e  t h e  s a f e t y  a n d  t o l e r a b i l i t y  o f  P F -0 6 7 0 0 8 4 1  c r e am ,  a s  c om p a r e d  t o  v e h i c l e  c r e am .   
I f  a v a i l a b l e ,  s y s t em i c  e x p o s u r e  ( P K )  d a t a  w i l l  a l s o  b e  r e v i e w e d  d u r i n g  t h i s  i n t e r im  a n a l y s i s .
T h e  i n t e r im  a n a l y s i s  w i l l  p r o v i d e  s a f e t y / t o l e r a b i l i t y  d a t a  t o  c omm e n c e  e n r o l lm e n t  o f  m a l e 
p o p u l a t i o n  o f  1 2 - 1 8 y e a r s  o f  a g e  i n  t h e  s t u d y .  
I n t e r im  a n a l y s i s  r e s u l t s  m a y  a l s o  b e  u s e d  f o r  i n t e r n a l  b u s i n e s s  d e c i s i o n s  r e g a r d i n g  f u t u r e  
s t u d y  p l a n n i n g .   I n  t h a t  c a s e ,  b e f o r e  a n y  i n t e r im  a n a l y s i s  i s  i n s t i g a t e d ,  t h e  d e t a i l s  o f  t h e  
o b j e c t i v e s ,  d e c i s i o n  c r i t e r i a ,  d i s s em i n a t i o n  p l a n ,  a n d  m e t h o d  o f  m a i n t a i n i n g  t h e  s t u d y  b l i n d  
a s  p e r  P f i z e r ’ s  S O P s  w i l l  b e  d o c um e n t e d  a n d  a p p r o v e d  i n  a n  i n t e r n a l  r e v i e w  c omm i t t e e  
( I R C )  c h a r t e r .   T h e  r e s u l t s w i l l  o n l y  b e  d i s t r i b u t e d  t o  a  s e l e c t  l i s t  o f  i n d i v i d u a l s  i n v o l v e d  i n  
t h e  i n t e r n a l  d e c i s i o n -m a k i n g p r o c e s s  i n  o r d e r  t o  p r o t e c t  t h e  i n t e g r i t y  o f  t h e  s t u d y .   T h i s  l i s t  o f  
i n d i v i d u a l s  w i l l  b e  p r o v i d e d i n  t h e  i n t e r im  a n a l y s i s  p l a n .   T h e  r e s u l t s  o f  t h e  i n t e r im  a n a l y s i s  
w i l l  n o t  e n a b l e  i n d i v i d u a l s d i r e c t l y  i n v o l v e d  i n  r u n n i n g  t h e  s t u d y  ( s u c h  a s  i n v e s t i g a t o r s )  t o  
i d e n t i f y  t r e a tm e n t a s s i g nm e n t s  f o r  i n d i v i d u a l  p a r t i c i p a n t s  s t i l l  i n  t h e  s t u d y .  T h e r e  a r e  n o 
p r o s p e c t i v e  p l a n s  t o  s t o p t h e  s t u d y  e a r l y  f o r  s u c c e s s  a s  a  r e s u l t  o f  t h e  i n t e r im  a n a l y s e s . C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  9 2 S i n c e  t h e  a n a l y s i s  a p p r o a c h  w i l l  b e  i d e n t i c a l  b e t w e e n  t h e  p r im a r y  a n a l y s i s  c o n d u c t e d  o n  t h e  
d a t a  b a s e d  o n  t h e  s n a p  s h o t  o f  t h e  d a t a b a s e  a n d  s p e c i f i e d  f i n a l  a n a l y s i s  a p p r o a c h e s ,  t h e r e  w i l l  
b e  n o  s e p a r a t e  s t a t i s t i c a l  a n a l y s i s  p l a n  ( S A P ) . 
9 . 5 . 1 . D a t a  M o n i t o r i n g  C omm i t t e e  
T h i s  s t u d y  w i l l  u s e  a n  i n t e r n a l  r e v i e w  c omm i t t e e  ( I R C ) .   T h e  I R C  w i l l  b e  r e s p o n s i b l e  f o r  
o n g o i n g  m o n i t o r i n g  o f  s a f e t y  o f  p a r t i c i p a n t s  i n  t h e  s t u d y  a c c o r d i n g  t o  t h e  c h a r t e r .   M em b e r s  
o f  t h e  I R C  w i l l  b e  q u a l i f i e d  a n d  e x p e r i e n c e d  i n  r e v i e w i n g  a n d  i n t e r p r e t i n g  c l i n i c a l  s t u d y  d a t a .   
T h e y  w i l l  b e  e x t e r n a l  t o  a n d  i n d e p e n d e n t  o f  t h e  s t u d y  t e am ,  a n d  u n b l i n d e d  t o  t r e a tm e n t .   T h e  
r e c omm e n d a t i o n s  m a d e  b y  t h e  I R C  t o  a l t e r  t h e  c o n d u c t  o f  t h e  s t u d y  w i l l  b e  f o r w a r d e d  t o  
P f i z e r  f o r  f i n a l  d e c i s i o n .   T h i s  w i l l  n o t  i n c l u d e  t h e  m em b e r s  o f  t h e  s t u d y  t e am .   P f i z e r  w i l l  
f o r w a r d  s u c h  d e c i s i o n s ,  w h i c h  m a y  i n c l u d e  s umm a r i e s  o f  a g g r e g a t e  a n a l y s e s  o f  e n d p o i n t  
e v e n t s  a n d  o f  s a f e t y  d a t a  t h a t  a r e  n o t  e n d p o i n t s ,  t o  r e g u l a t o r y  a u t h o r i t i e s ,  a s  a p p r o p r i a t e .   
P f i z e r  m a y  p e r f o rm  a n  i n t e r im  a n a l y s i s  w h i c h  m a y  i n c l u d e  s a f e t y  a n d  e f f i c a c y .   I f  a n  i n t e r im  
a n a l y s i s  i s  p e r f o rm e d ,  t h e  s am e  I R C  w i l l  b e  u s e d .   D e t a i l s  o f  t h e  I R C  a r e  d e s c r i b e d  i n  t h e  
I R C  c h a r t e r . 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 9310. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Et hical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations o f Medical 
Sciences (CIOMS) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, investigator’s brochure (IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by  the sponsor and 
submitted to an I RB/EC by  the investigator and reviewed and approved b y the IRB/EC 
before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by  
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), I CH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable) , and all other 
applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the wor ld, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 94In addition, the investigator will inform Pfizer immediately  ofany urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities.  
Invest igators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study t o the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary .  Participants or their 
legally  authorized representative defined as parent or legal guardian will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability  and Accountability  Act (HI PAA) requirements, 
where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her le gally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associate d with participation, including the risks 
associated with the processing of the participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law .  The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriat e IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or 
her pers onal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 95A cop y of the ICD(s) must be provided to the particip ant or the participant’s legall y 
authorized representative.
Participants who are rescreened are required to sign a new ICD.
The I CD will contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research.  Th e investigator or authorized designee will 
explain to each participant the objectives of the exploratory  research.  Participants will be 
told that they  are free to refuse to participate and may  withdraw their consent at any  time and 
for an y reason during t he storage period.  A separate signature will be required to document a 
participant's agreement to allow an y remaining specimens to be used for exploratory 
research.  Participants who decline to participate in this optional research will not provide 
this separate signature.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored a t the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff ha s access.  The stud y site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breac h notifications as required by  law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any participant records or data sets tha t are transferred to the sponsor will contain the 
numerical code; participant names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by  this single, participant -specific code.  The 
study  site will maintain a confidential list of participants who participated in the study , 
linking each participant’s numerical code to his or her actual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study  agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, Pfizer reports study  results outside of the 
requirements of local laws/regulations pursuant to its standard operating procedures (SOPs).
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 96www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographic al location in which the study  is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the primary  completion date 
(PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD i s defined as the date that the final participant was examined or received an intervention 
for the purposes of final collection of data for the primary  outcome, whether the clinical 
study  concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy 0070, the proactive publication of clinical 
data to the European Medicines Agency (EMA) website.  Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statisti cal methods.  Clinical data, 
under Phase 2 of this policy , includes the publishing of individual participant data.  
Policy 0070 applies to new marketing authorization applications submitted via the 
centralized procedure since 01 January 2015 and applicatio ns for line extensions and for new 
indications submitted via the centralized procedure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class.  Pfizer will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and r egulations.  CSRs will have personall y identifiable information 
redacted.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 97Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.  Research teams must include a biostatistician.  Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investigator mus t maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in en crypted 
electronic and/or paper form and are password protec ted or secur ed in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details d escribing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies and anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the 
monitoring plan .
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Study  monitors will perform ongoing sou rce data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investiga tor for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period.  No records may  be destroy ed during 
the retention period without the written approval of the sponsor.  No records may  be 
transferr ed to another location or part y without written notification to the sponsor.  The 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 98When participant data are to be deleted, the investigator will en sure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resol ve an y discrepancies that are identified 
between the stud y data and the participant's medical records.  The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent.  Before response 
submission to the regulatory  auth orities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integ rity of the data collected.  Source documents are filed at the investigator site.
Data reported on the CRF or entered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may need to request previous medical records or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in study  completion gui delines.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion.  A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y
-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organization (CRO) if requested to do so by  the responsible IRB/EC or if such 
termination is required to protect the health of study participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development.
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 9910.1.9. Publication Policy
The results of this study  may  be published or present ed at scientific meetings b y the 
investigator after publication of the overall study  results or 1 year after end of the study  (or 
study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any subsequent publ ications 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission.  This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an ypreviously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for pu blication of the overall study  results 
covering all investigator sites.  I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating investigator will be designated b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requi rements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in the study  team on demand (SToD) 
system.  To facilitate access to appropriatel y qualified medical personnel on study -related 
medical questions or problems, participants are provided with a con tact card.  The contact 
card contains, at a minimum, protocol and investigational product identifiers, participant 
numbers, contact information for the investigator site, and contact details for a contact center 
in the event that the investigator site staf f cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
participant’s participation in the study .  The contact number can also be used by  investigator 
staff if they are see king advice on medical questions or problems; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace , the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
number is not intended for use b y the participant directly, and if a partici pant calls that 
number, he or she will be directed back to the investigator site.

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 0 0 1 0 . 2 . A p p e n d i x 2 :  C l i n i c a l  L a b o r a t o r y  T e s t s 
T h e  f o l l o w i n g  s a f e t y  l a b o r a t o r y  t e s t s  w i l l  b e  p e r f o rm e d  a t  t im e s  d e f i n e d  i n  t h e  S c h e d u l e  o f 
A c t i v i t i e s  ( S o A ) s e c t i o n  o f  t h i s  p r o t o c o l .   A d d i t i o n a l  l a b o r a t o r y  r e s u l t s  m a y  b e  r e p o r t e d  o n  
t h e s e  s am p l e s  a s  a  r e s u l t  o f  t h e  m e t h o d  o f  a n a l y s i s  o r  t h e  t y p e  o f  a n a l y z e r  u s e d  b y  t h e  c l i n i c a l  
l a b o r a t o r y ;  o r  a s  d e r i v e d f r om  c a l c u l a t e d  v a l u e s .   T h e s e  a d d i t i o n a l  t e s t s  w o u l d  n o t  r e q u i r e  
a d d i t i o n a l  c o l l e c t i o n  o f  b l o o d .   U n s c h e d u l e d  c l i n i c a l  l a b o r a t o r y  m e a s u r em e n t s  m a y  b e  
o b t a i n e d  a t  a n y  t im e  d u r i n g  t h e  s t u d y  t o  a s s e s s  a n y  p e r c e i v e d  s a f e t y  c o n c e r n s . 
T a b l e 1 1 .P r o t o c o l -R e q u i r e d  L a b o r a t o r y  A s s e s sm e n t s 
H em a t o l o g y aC h e m i s t r y aU r i n a l y s i s aO t h e r 
H em o g l o b i n 
H em a t o c r i t 
R B C  c o u n t  a n d  i n d i c e s  
(M C H ,  M C H C ,  M C V ,  R B C  
M o r p h o l o g y ) 
R e t i c u l o c y t e  c o u n t 
P l a t e l e t  c o u n t 
W B C  c o u n t  w i t h  d i f f e r e n t i a l 
T o t a l  n e u t r o p h i l s  (% ,  A b s ) 
E o s i n o p h i l s  (% ,  A b s ) 
M o n o c y t e s  (% ,  A b s ) 
B a s o p h i l s  (% ,  A b s ) 
L ym p h o c y t e s  (% ,  A b s ) B U N / u r e a  &  C r e a t i n i n e 
Cy s t a t i n  C 
G l u c o s e  ( f a s t i n g ) 
C a l c i um 
S o d i um 
P o t a s s i um 
C h l o r i d e 
T o t a l  C O 2 ( b i c a r b o n a t e ) 
A S T ,  A L T 
G G T 
T o t a l ,  I n d i r e c t  &  D i r e c t  
B i l i r u b i n 
A l k a l i n e  p h o s p h a t a s e 
L a c t a t e  D e h y d r o g e n a s e 
U r i c  a c i d 
A l b um i n 
T o t a l  p r o t e i n 
C r e a t i n i n e  K i n a s e fp H 
G l u c o s e  ( q u a l ) 
P r o t e i n  ( q u a l ) 
Bl o o d  ( q u a l ) 
K e t o n e s 
N i t r i t e s 
L e u k o c y t e  e s t e r a s e 
U r o b i l i n o g e n 
U r i n e  b i l i r u b i n 
M i c r o s c o p y dA t  s c r e e n i n g  o n l y : 
F S H b
H I V 
H B s A g 
H B c A b 
H b s A b c
H B V  D N A  t e s t ( r e f l e x  te s t e d  i n  
c o u n t r i e s  w h e r e  r e q u i r e d  b y  
l o c a l  r e g u l a t i o n s )
H C V  A b 
H C V  R N A e
I G R A  o r  P P D  ( i f  p p l i c a b l e ) 
V Z V  I g G  A b 
C o a g u l a t i o n  P a n e l  ( a s  p a r t  o f  
H em a t o l o g y ) 
-a P T T 
-P T / I N R 
A t  v i s i t s  i n  S o A :
P r e g n a n c y  t e s t  ( -h C G ) g
S k i n  s w a b s  f o r  h e r p e t i f o rm  r a s h h
L i p i d  P a n e l i
-T o t a l  C h o l e s t e r o l 
-L D L 
-H D L 
-T r i g l y c e r i d e s 
A b b r e v i a t i o n s :  A b  =  a n t i b o d y ;  A b s  =  a b s o l u t e ;  A L T  =  a l a n i n e  am i n o t r a n s f e r a s e ;  A S T  =  a s p a r t a t e  am i n o t r a n s f e r a s e ; 
a P T T  =  a c t i v a t e d  p a r t i a l  t h r om b o p l a s t i n  t im e ;  -h C G  =  b e t a -h um a n  c h o r i o n i c  g o n a d o t r o p i n ;  B U N  =  b l o o d  u r e a  
n i t r o g e n ;  C h em o k i n e  ( C -C  m o t i f )  l i g a n d  1 7 ;  C O 2  =  c a r b o n  d i o x i d e ;  I g G  =  imm u n o g l o b u l i n  
G ;  F S H =  f o l l i c l e -s t im u l a t i n g  h o rm o n e ;  G G T  =  G amm a  G l u t am y l  T r a n s f e r a s e ;  H B c A b  =  H e p a t i t i s  B  C o r e  A n t i b o d y ;  
H B s A b  =  H e p a t i t i s  B  S u r f a c e  A n t i b o d y ;  H B s A g  =  H e p a t i t i s  B  S u r f a c e  A n t i g e n ;  H C VA b  =  H e p a t i t i s  C  V i r u s  
A n t i b o d y ;  H C V  R N A  =  H e p a t i t i s  C  V i r u s  R i b o n u c l e i c  A c i d ;  H D L  =  h i g h  d e n s i t y  l i p o p r o t e i n ;  H I V  =  H um a n  
Imm u n o d e f i c i e n c y  V i r u s ; ;  I G R A  =  I n t e r f e r o n  G amm a  R e l e a s e  A s s a y ;  
I N R =  I n t e r n a t i o n a l  N o rm a l i z e d  R a t i o ;   L D L  =  l o w  d e n s i t y  l i p o p r o t e i n ;  
M C H  =  m e a n  c o r p u s c u l a r  h em o g l o b i n ;  M C H C  =  m e a n  c o r p u s c u l a r  h em o g l o b i n  c o n c e n t r a t i o n ;  M C V  =  m e a n  
c o r p u s c u l a r  v o l um e ;  P P D  =  p u r i f i e d p r o t e i n  d e r i v a t i v e ;  q u a l  =  q u a l i t a t i v e ;  R B C= r e d  b l o o d  c e l l ;  
;  V Z V  =  V a r c i l l a  Z o s t e r  V i r u s ;  W B C  =  w h i t e  b l o o d  c e l l .C C I 
C C I C C I C C I 
C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 101a. Safety labs include hematology, chemistry a nd urinalysis.
b. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT).
c. Hepatitis B Surface Antibody (HBsAb) wi ll be reflex tested if participants are positive for HBsAb.   HBsAB will 
also be tested for all participants when required by country -specific local regulations.   See country - specific details in 
Appendix 8.
d. Only if urine dips tick is positive for blood, protein, nitrites, or leukocyte esterase.
e. Hepatitis C Viral RNA (HCV RNA) will be reflex tested if participants are positive for HCVAb.
f. Fractionation only if CK is elevated >3 x ULN.
g. Serum pregnancy testing at screening is requi red for women of childbearing potential (WOCBP). Serum will also 
be collected at Day 1 to test pregnancy, the results of which may be received after Day 1.Pregnancy tests may also 
be repeated more frequently as per request of IRBs/ECs or if required by local regulations women of child -bearing 
potential. Urine pregnancy tests will be used at Day 1 and at other visits. 
h. In cases of suspected herpetiform rash (eg, suspected herpes zoster and herpes simplex) .
i. Lipid Profile Panel requires at least an 8 hour fast.
Investigators must document their review of each laboratory  safet y report.
Laboratory results that could un- blind the study  will not be reported to investigator sites or 
other blinded personnel until the study  has been unblinded.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 10210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study interve ntion, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen fro m baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.  Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/ self-harming intent.  Such overdoses should be reported regardless of 
sequelae.
“Lack of efficacy ” or “failure of expected pharmacological action” per se will not 
be reported as an AE or SAE.  Such instances will be captured in the efficacy  
assessments.  H owever, the signs, s ymptoms, and/or clinical sequelae resulting 
from lack of efficacy  will be reported as an AE or SAE if they  fulfill the definition 
of an AE or SAE.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 103Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, sig ns, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which a n untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medic al occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event.  It does not refer to an event tha t 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an ove rnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting.  Complications that occur during hospitalization are AEs.  If a 
complication prolongs hosp italization or fulfills any other serious criteria, the event is 
serious.  When in doubt as to whether “hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen from 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 104baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experie nces of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the participant or may  require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition.  These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse .
10.3.3. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to Pfizer Safety .  These requirements are delineated for 3 types of 
events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the 
investigational product under study  during pregnancy  or breastfeeding, and occupational 
exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using co ncise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 105Safety Event Recorded on 
the CRFReported on the CT SAE 
Report Form to Pfizer Safety 
Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the investigational 
product under stud y during 
pregnancy  or breastfeeding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP] supplemental 
form for EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form/AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfiz er Safety.  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the eve nt based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes suffi cient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 106described in the definition of an SAE, NOT when it is rated as severe.   
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the investigator’s brochure (IB) and/or product 
information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor .  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the investigational p roduct caused 
the event, then the event will be handled as “related to investigational product” for 
reporting purposes, as defined by  the sponsor.  In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such 
an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 107Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  the 
sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible.  This may  include additio nal laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfiz er Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the infor mation.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety  will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the sit e will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, t he electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electr onic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 108SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier servi ce.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 10910.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study  intervention, which 
corresponds to the time needed to eliminate study  intervention(s): 
Refrain from donating sperm.
PLUS either:
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persi stent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person.
Inaddition to male condom use, a highl y effective method of contraception may be 
consider ed in WOCBP partners of male participants (refer to the list of highly  effective 
methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate
if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3 ).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per year), with low user dependency , as described below during the 
intervention period and for at least 28daysafter the last dose of study  intervention,
which corresponds to the time needed to e liminate any  study  intervention(s) .  The 
investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study  intervention. 
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a fa ilure 
rate of <1% per year), with high user dependency , as described below during the 
intervention period and for at least 28daysafter the last dose of study  intervention,
which corresponds to the time needed to eliminate any  study  intervention(s) .  In 
addition, a second 
effective method of contraception, as described below, must be 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 110used.   The investigator should evaluate the effectiveness of the contraceptive method 
in relationship to the first dose of study  intervention. 
OR 
Is a WOCBP 
and i s abstinent from heterosexual intercourse during the entire period 
of risk associated with the study  intervention.  The reliability  of sexual abstinence 
needs to be evaluated in relation to the duration of the study  and be the preferred and 
usual lifesty le of the par ticipant.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  interv ention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any of the abov e categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview.  The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausa l female:
A postmenopausal state is defined as age 60 yearsor older or no menses for 
12months without an alternative medical cause . 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 111A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormon ereplacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the nonestrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y.  Otherwise, they  must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
10.4.4.
Contraception Methods
Highly Effective Methods That Have Low User Dependency 
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device (IUD).
3.Intrauterine hormone -releasing s ystem (IUS).
4.Bilateral tubal occlusion.
5.Vasectomized partner.
Vasectomized partner is a highl y effective contraceptive method provided that the partner is 
the sole sexual partner of the WOCBP and the absence of sperm has been confirmed.  If not, 
an additional highl y effective method of contraception should be used.  The spermatogenesis 
cycle is approximately  90days.
Highly Effective Methods That Are User Dependent (must be used in combination with 
another effective method; see below)
1.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
oral;
intravaginal;
transdermal;
injectable.
2. Progestog en-only hormone contraception associated with inhibition of ovulation:
oral;
injectable.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 112Effective Methods
1. Male or female condom with or without spermicide.
2. Cervical cap, diaphragm, or sponge with spermicide.
3. A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Collection of Pregnancy Information
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational pr oduct;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a participant or participant’s partner becomes or is found to be pregnant during the 
participant’s treatment with the investigational product, the investigator must report this 
information to Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, 
regardless of whether an SAE has occurred.  In addition, the investigator must sub mit 
information regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a 
participant reports that she is pregnant and has been exposed to a cytotoxic product b y 
inhalation or spillage) to Pfizer Safety using the EDP supplemental form .  This must be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery  (see 
below for information related to termination of pregnancy ).
Follow-up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, i f clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 113If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 1 4 1 0 . 5 . A p p e n d i x  5 :  G e n e t i c s 
U s e / A n a l y s i s  o f  D N A 
G e n e t i c  v a r i a t i o n  m a y  im p a c t  a  p a r t i c i p a n t ’ s  r e s p o n s e  t o  s t u d y  i n t e r v e n t i o n ,  
s u s c e p t i b i l i t y  t o ,  a n d  s e v e r i t y  a n d  p r o g r e s s i o n  o f  d i s e a s e .   T h e r e f o r e ,  w h e r e  l o c a l  
r e g u l a t i o n s  a n d  I R B s / E C s  a l l o w ,  a  b l o o d  s am p l e  w i l l  b e  c o l l e c t e d  f o r  D N A  a n a l y s i s . 
G e n e t i c  r e s e a r c h  m a y  c o n s i s t  o f  t h e  a n a l y s i s  o f  1  o r  m o r e  c a n d i d a t e  g e n e s  o r  t h e  
a n a l y s i s  o f  g e n e t i c  m a r k e r s  t h r o u g h o u t  t h e  g e n om e  o r  a n a l y s i s  o f  t h e  e n t i r e  g e n om e  
( a s  a p p r o p r i a t e ) . 
T h e  s am p l e s m a y  b e  a n a l y z e d  a s  p a r t  o f  a  m u l t i s t u d y  a s s e s sm e n t  o f  g e n e t i c  f a c t o r s  
i n v o l v e d  i n  t h e  r e s p o n s e  t o  P F - 0 6 7 0 0 8 4 1 o r  s t u d y  i n t e r v e n t i o n s  o f  t h i s  c l a s s  t o  
u n d e r s t a n d  t r e a tm e n t s  f o r  t h e  d i s e a s e ( s )  u n d e r  s t u d y  o r  t h e  d i s e a s e ( s )  t h em s e l v e s . 
T h e  r e s u l t s  o f  g e n e t i c a n a l y s e s  m a y  b e  r e p o r t e d  i n  t h e  c l i n i c a l  s t u d y  r e p o r t  ( C S R )  o r  
i n  a  s e p a r a t e  s t u d y  s umm a r y ,  o r  m a y  b e  u s e d  f o r  i n t e r n a l  d e c i s i o n  m a k i n g  w i t h o u t  
b e i n g  i n c l u d e d  i n  a  s t u d y  r e p o r t . 
T h e  s p o n s o r  w i l l  s t o r e  t h e  D N A  s am p l e s  i n  a  s e c u r e  s t o r a g e  s p a c e  w i t h  a d e q u a t e  
m e a s u r e s  t o  p r o t e c t  c o n f i d e n t i a l i t y .  
 
 
 
 
 C
C
I
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 11510.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments and 
Study Intervention Re -challenge Guidelines
Potential Cases of Drug-I nduced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participants, trans aminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who e xperience a transaminase elevation above 3 times the 
upper limit of normal ( ×ULN) should be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same laboratory  
sample).  In rare instances, by  the time TBili elevations are detected, AST/AL T values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The thr eshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions.  Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential D ILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2×ULN w ith no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
dependi ng on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal r ange: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 116Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgme nt; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawi ng a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel histor y, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liv er imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above sh ould be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test (LFT) abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of t he investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 11710.7. Appendi x 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brad ycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or b y 60 msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.
New -onset t ype I second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent premature ventricular complexes (PVCs), t riplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST- T changes suggestive of my ocardial ischemia.
New -onset left bundle branch b lock (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole 3.0 seconds or any  escape rate <40 bpm, or with an escape r hythm 
that is below the AV node; 
In awake, s ymptom -free patients with atrial fibrillation and brad ycardia with 
1 or more pauses of at least 5 seconds or longer; 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant s ymptoms or lasting >1 minute).
Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (rate 
<40 bpm), accelerated idioventricular rh ythm (40< x <100), and 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 118monomorphic/poly morphic ventricular tachy cardia >100 bpm (such as torsades de 
pointes).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pat tern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recom mended as 
“alerts” or notifications from the core ECG laboratory  to the investigator and Pfizer study  
team, and not to be considered as all inclusive of what to be reported as AEs/SAEs.

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 11910.8. Appendix 8 : Country- Specific Requirements
Exclusion Criteria # 20
In countries where required, all participants may undergo testing for Hepatitis B Virus 
(HBV )surface antigen (HBsAg), HBV core antibody  (HBcAb), and HBV surface antibody  
(HBsAb).   The testing will be performed in Clinical Laborato ry Improvement Amendments 
(CLIA)certified Laboratory  or similar. 
Participants who are negative for all three serology  tests may  be eligible. 
Participants who are HBsAg positive will be excluded. 
Participants who have negative HBsAg, positive HBcAb, and negative HBsAb will be 
excluded. 
Participants who have negative HBsAg, negative HBcAb and positive HBsAb and provide a 
documentation of prior HBV vaccination, may  be eligible for the study  and will not require 
HBV DNA monitoring during the stud y. 
Partic ipants who have negative HBsAg, negative HBcAb and positive HBsAb without 
documentation of prior HBV vaccination, and participants who have negative HBsAg, 
positive HBcAb and positive HBsAb are required to undergo HBV DNA testing
If detectable HBV DNA , participants will be excluded; and 
If not detectable HBV DNA, participants may be eligible.   If enrolled, HBV DNA 
will be assessed at Week 6 also. 

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 12010.9. Appendix 9: Diagnosis Criteria for Atopic Dermatitis
Per Inclusion Criterion #
2, a participant is to have a c linical diagnosis of atopic dermatitis 
according to the criteria of Hanifin and Rajka .26
Hanifin and Rajka’s Diagnostic Criteria for Atopic Dermatitis
Must have three or m ore basic features described below:
Pruritus
Typical morphology and distribution:
Flexural lichenification in adults
Facial and extensor eruptions in infants and children
Chronic or chronically -relapsing dermatitis
Personal or family history of atopy (asthma, allergic rhinitis, atopic der matitis)
Must have three or m ore following m inor features:
Xerosis
Ichthyosis/palmar hyperlinearity, keratosis pilaris
Immediate (type 1) skin test reaction
Elevated serum IgE
Early age of onset
Tendency tow ard cutaneous infections (esp. staph. aure us and herpes simplex), impaired cell -mediated 
immunity
Tendency tow ard non -specific hand or foot dermatitis
Nipple eczema
Cheilitis
Recurrent conjunctivitis
Dennie -Morgan infraorbital fold
Keratoconus
Anterior subcapsular cataracts
Orbital darkeni ng
Facial pallor, facial erythema
Pityriasis alba
Anterior neck folds
Itch when sweating
Intolerance to w ool and lipid solvents
Periofollicular accentuation
Food intolerance
Course influenced by environmental and emotional factors
White dermograph ism, delayed blanch

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 12110.10. Appendix 1 0: Prohibited Concomitant Medications
The following medications & procedures are prohibited until the last Follow -up visit, unless 
stated otherwise.   If a participant receives prohibited medication or procedure, the 
investig
ator should either 1) ask the participant to stop I P immediatel y and schedule ET visit 
as soon as possible with follow- up visits per Schedule of Activities or 2) contact Sponsor 
Clinician or Sponsor Medical monitor to determine if participant may  stay in the study .  This 
will be based on the T
able below.  Medications listed below are prohibited even if used for a 
different indication than noted below.
Drug Classes and/or Drugs and/or Procedures Timeframe of Restriction 
Prior to Screening VisitIf taken, then
Stop IP, 
Proceed to 
ET and 
F/UPContact 
Sponsor 
Light therapy
Narrow -band Ultraviolet B light (UVB) 
Broadband phototherapy 
Ultraviolet A light (UVA) 
Excimer laser (308 nm)  1 monthX
Any cell -depleting agents, includi ng but not 
limited to
Rituximab
Alemtuzumab [CamPath]
Alkylating agents [eg, cyclophosphamide or 
chlorambucil]
Total lymphoid irradiation, etc6months or 5 half-lives, 
whichever is longer OR 
until lymphocyte count 
returns to normal, 
whichever is longerX
Anti-AD or p soriasis biologics 
Efalizumab (Raptiva)
Certolizumab pegol (Cimzia)
Alefacept (Amevive®)
Duplimab
Infliximab (Remicade) and biosimilar
Adalimumab (Humira) and biosimilar2 months X
Ustekinumab (Stelara)
Secukinumab (Cosentyx) 
Ixekizumab (Taltz)
Brodalumab (Siliq)
Guselkumab (Tremfya)
Tildrakizumab
Risankizumab3 monthsX
Etanercept (Enbrel) and biosimilar 1 month X
Systemic treatments other than biologics that 
could affect AD, including but not limited to:
oral or injectable (eg, intraarticular, 
intramuscular, or intravenous) corticosteroids
retinoids
methotrexate
cyclosporine
fumaric acid derivatives
sulfasalazine
hydroxycarbamide (hydroxyurea)2 weeksX

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 122Drug Classes and/or Drugs and/or Procedures Timeframe of Restriction 
Prior to Screening VisitIf taken, then
Stop IP, 
Proceed to 
ET and 
F/UPContact 
Sponsor 
azathioprine
intramuscular gold
Otezla (Apremilast)
Any herbal medicine
Other sy stemic treatments known to possibly 
worsen ADunless on a stable dose for 
>12weeks (eg lithium, -blockers, 
angiotensin -converting enzyme inhibitors, 
synthetic anti -malarials, anticonvulsants, 
antidepressants, cyclosporine, 
testosterone/estrogens, imiquim od, calcium 
channel blockers, etc)
Tofacitinib
Any other oral JAK inhibitors1 month or 5 half –live 
whichever is longerX
Topical treatments applied on AD areas treated 
with IP and which could affect AD.  If applied 
to other areas not treated with IP, this is 
allow ed.
Including but not limited to:
Corticosteroids
Tars
Keratolytics
Anthralin
vitamin D analogues
retinoids2 weeksX
sunscreens, moisturizers or non -medicated 
emollients2 weeksX
Topical AD medication (eg Eucrisa)1 month or 5 half–live 
whichever is longerX
Any topical JAK inhibitors1 month or 5 half –live 
whichever is longerX
CYP3A4, 5, 7 Inhibitors
HIV antivirals:
delavirdine (Rescriptor)
indinavir (Crixivan)
nelfinavir (Viracept)
ritonavir (Kaletra, Norvir)
saquin avir (Fortovase)
cimetidine (Tagamet)
ciprofloxacin (Cipro)
clarithromycin (Biaxin, Prevpac)
diethyl -dithiocarbamate
diltiazem (Cardizem, Tiazac)
fluconazole (Diflucan)
fluvoxamine (Luvox)
gestodene (Femodene, Melodene, Minulette,1 month or 5 half -lives, 
whichever is longerX

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 123Drug Classes and/or Drugs and/or Procedures Timeframe of Restriction 
Prior to Screening VisitIf taken, then
Stop IP, 
Proceed to 
ET and 
F/UPContact 
Sponsor 
Mirelle, Triodene ED)
grapefruit juice and marmalade
itraconazole (Sporanox)
ketoconazole (Nizoral)
Itraconazole
Erythromycin
protease inhibitors
verapamil 
diltiazem
Amiodarone 10 monthsX
CYP3A Inducers
barbiturates
efavirenz (Sustiva)
nevirapine (Viramune)
barbiturates
carbamazepine (Carbatrol, Tegretol)
modafinil (Provigil)
phenobarbital
Phenytoin (Dilantin, Phenytek)
rifampin (Rifadin, Rifamate, Rifater)
St. John’s w ort
troglitazone (Rezulin)
pioglit azone (Actos)
rifabutin (Mycobutin)1 month or 5 half -lives, 
whichever is longerX
Strong P -gp inhibitors
Quinidine1 month or 5 half -lives, 
whichever is longerX
Substrates of MDR1
Digoxin1 month or 5 half -lives, 
whichever is longerX
Substrates of OCT2/MATE
Dofetilide1 month or 5 half -lives, 
whichever is longerX
Vaccination with live or attenuated live vaccine
(See Section 5.3.4 )6 weeksX

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 12410.11. Appendix 1 1: Fitzpatrick Skin Type

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 12510.12. Appendix 1 2: Patient Reported Outcomes
10.12.1. Peak Pruritis Numerical Severity Scale (PP -NRS)
On a scale of 0 to 10, with 0 being “no itch” and 10 being “worst itch imaginable”, how 
would y ou rate y our itch at the worst moment during the previous 24 hours?
1
9 8 7 6 5 4 3 2 1 0 1 9 8 7 6 5 4 3 2 1 0
N
itchWorst 
itch 
imaginable

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 2 6 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 2 7 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 2 8 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 2 9 C C I 
C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 13010.12.3. Patient -Oriented Eczema Measure (POEM)

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 13110.12.4. Dermatology Life Quality Index (DLQI)/Children’s DLQI
DERMATOLOGY LIFE QUALITY INDEX
The aim of this questionnaire is to measu re how much your skin problem has affected 
your life OVER THE LAST WEEK.  Please tick one box for each question .
1.Over the last week, how itchy, sore, painful or stinging has your 
skin been?Very much 
A lot
A little 
Not at all 
 
 
 
2.Over the last week, how embarrassed or self conscious have you been 
because of your skin?Very much 
A lot
A little 
Not at all 
 
 
 
3.Over the last week, how much has your skin interfered with you going
shopping or looking after your home or garden ?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  
4.Over the last week, how much has your skin influenced the clothes
you wear?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  
5.Over the last week, how much has your skin affected any social or
leisure activities?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  
6.Over the last week, how much has your skin made it difficult for you to 
do any sport ?Very much 
A lot
A little 
Not at all 
 
 
 Not relevan t  
7.Over the last week, has your skin prevented you from workingor
studying ?yes 
no 
 Not relevant  
If "No", over the last week how much has your skin been a problem at
workor studying ?A lot 
A 
little
Not at all 
 
 
8.Over the last week, h ow much has your skin created problems with your
partner or any of your close friends or relatives ?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  
9.Over the last week, how much has your skin caused any 
sexual difficulties ?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  
10.Over the last week, how much of a problem has the treatment for your 
skin been, for example by making your home messy, or by taking up 
time?Very much 
A lot
A little 
Not at all 
 
 
 Not relevant  

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 132

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 3 3 C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 3 4 C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 13510.13. Appendix 1 3: C-SSRS – Columbia Suicide Severity Rating Scale
C-SSRS for Screening and Baseline Visits:

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 136

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 137C-SSRS for post -baseline visits

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 138

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 13910.14. Appendix 1 4: eGFR Calculations
The estimated GFR (eGFR) will be calculated using the 2 sets of equations developed by  the 
Chronic Kidney  Disease Epidemiology Collaboration (CKD -EPI), which utilize serum 
creatinine (SCr) and serum Cy statin C (S Cy statin C) respectivel y
.
CKD -EPI 2009Scr
If female and SCr is  0.7mg/dL :
GFR (mL/ min/1.73 m2) = 144 x (Scr/0.7)–0.329x 0.993age (x 1.159, if black).
If female and SCr is >0.7 mg/dL :
GFR (mL/min/1.73 m2) = 144 x (Scr/0.7) –1.209x 0.993age(x 1.159, if black) .
If male and SCr is  0.9mg/dL :
GFR (mL/min/1.73 m2) = 141 x (Scr/0.9) –0.411x 0.993age(x 1.159, if black) .
If male and SCr is >0.9 mg/dL :
GFR (mL/min/1.73 m2) = 141 x (Scr/0.9) –1.209x 0.993age(x 1.159, if black) .
CKD -EPI 2012cys
If female and Scy s is 0.8mg/L :
GFR (mL/min/1.73 m2) = 1 33x (Scys /0.8) –0.499x 0.996agex 0.932 .
If female and Scysis >0.8
mg/L :
GFR (mL/min/1.73 m2) = 133 x ( Scys /0.8) –1.328x 0.996agex 0.932 .
If male and Scy sis 0.8mg/L :
GFR (mL/min/1.73 m2) =133 x ( Scys /0.8) –0.499x 0.996age.
If male and Scy sis >0.8 mg/L :
GFR (mL/min/1.73 m2) = 133 x ( Scys /0.8) –1.328x 0.996age.

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 4 0 1 0 . 1 5 . A p p e n d i x  1 5:  A b b r e v i a t i o n s 
T h e  f o l l o w i n g  i s  a  l i s t  o f  a b b r e v i a t i o n s  t h a t  m a y  b e  u s e d  i n  t h e  p r o t o c o l . 
A b b r e v i a t i o n T e rm 
A A a l o p e c i a  a r e a t a 
A b a n t i b o d y 
A b s ab s o l u t e 
A D a t o p i c  d e rm a t i t i s 
A E a d v e r s e  e v e n t 
A L T a l a n i n e  am i n o t r a n s f e r a s e 
A S T a s p a r t a t e  am i n o t r a n s f e r a s e 
A U C a r e a  u n d e r  t h e  c u r v e 
A U C 2 4 a r e a  u n d e r  t h e  c o n c e n t r a t i o n - t im e  c u r v e  f r om  t im e  0  t o  2 4  h o u r s  
a f t e r  d o s e 
A U C i n f a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  f r om  t im e  0  t o  i n f i n i t y  
A U C t a u a r e a  u n d e r  t h e  c o n c e n t r a t i o n -t im e  c u r v e  d u r i n g  a n y  d o s i n g  i n t e r v a l  
a t  s t e a d y  s t a t e 
A Z A a z a t h i o p r i n e 
B C G b a c i l l e  C a lm e t t e -G u e r i n 
-h C G b e t a -h um a n c h o r i o n i c  g o n a d o t r o p i n 
B I D t w i c e  d a i l y
BM I b o d y  m a s s  i n d e x 
B P b l o o d  p r e s s u r e 
B S A b o d y  s u r f a c e  a r e a 
B U N b l o o d  u r e a  n i t r o g e n 
C A T c om p u t e r i z e d  a x i a l  t om o g r a p h y
Ca v a v e r a g e  c o n c e n t r a t i o n s 
C D C r o h n ’ s  d i s e a s e 
C F R C o d e  o f  F e d e r a l  R e g u l a t i o n s 
C I OM S C o u n c i l  f o r  I n t e r n a t i o n a l  O r g a n i z a t i o n s  o f  M e d i c a l  S c i e n c e s 
C K c r e a t i n e  k i n a s e 
C K D -E P I C h r o n i c  K i d n e y  D i s e a s e  E p i d em i o l o g y  C o l l a b o r a t i o n 
C L c l e a r a n c e 
C L I A C l i n i c a l  L a b o r a t o r y  I m p r o v em e n t  Am e n dm e n t s 
Cm a x m a x im um  o b s e r v e d  c o n c e n t r a t i o n 
CM V C y t om e g a l o v i r u s 
C O 2 c a r b o n  d i o x i d e  ( b i c a r b o n a t e ) 
C O N S O R T C o n s o l i d a t e d  S t a n d a r d s  o f  R e p o r t i n g  T r i a l s 
C R F c a s e  r e p o r t  f o rm 
C R O c o n t r a c t  r e s e a r c h  o r g a n i z a t i o n 
C S R c l i n i c a l  s t u d y  r e p o r t 
C - S S R S C o l um b i a  s u i c i d e  s e v e r i t y  r a t i n g  s c a l e 
C T c l i n i c a l  t r i a l C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 4 1 A b b r e v i a t i o n T e rm 
D I L I d r u g -i n d u c e d  l i v e r  i n j u r y 
D L Q I D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x 
D N A d e o x y r i b o n u c l e i c  a c i d 
D U d i s p e n s a b l e  u n i t 
E A S I E c z em a  A r e a  a n d  S e v e r i t y  I n d e x 
E B V E p s t e i n  B a r r  v i r u s 
E C 5 0 H a l f -m a x im a l  e f f e c t i v e  c o n c e n t r a t i o n 
E C e t h i c s  c omm i t t e e 
E C G E l e c t r o c a r d i o g r am 
e C R F e l e c t r o n i c  c a s e  r e p o r t  f o rm 
E - DM C e x t e r n a l  d a t a  m o n i t o r i n g  c omm i t t e e  
E D P e x p o s u r e  d u r i n g  p r e g n a n c y 
e G F R e s t im a t e d  g l om e r u l a r  f i l t r a t i o n  r a t e 
EM A E u r o p e a n  M e d i c i n e s  A g e n c y 
E O S e n d  o f  s t u d y 
E O T e n d  o f  t r e a tm e n t 
e P R O e l e c t r o n i c  p a t i e n t  r e p o r t e d  o u t c om e 
E T e a r l y  t e rm i n a t i o n 
E U E u r o p e a n  U n i o n 
E u d r a C T E u r o p e a n  C l i n i c a l  T r i a l s  D a t a b a s e 
F b i o a v a i l i b i l i t y 
F D A F e d e r a l  D r u g  A dm i n i s t r a t i o n 
F S H f o l l i c l e -s t im u l a t i n g  h o rm o n e 
F u f r a c t i o n  u n b o u n d 
G C P G o o d  C l i n i c a l  P r a c t i c e 
G G T g amm a -g l u t am y l  t r a n s f e r a s e 
H B c A b h e p a t i t i s  B  c o r e  a n t i b o d y
H B s A b  h e p a t i t i s  B  s u r f a c e  a n t i b o d y 
H B s A g  h e p a t i t i s  B  s u r f a c e  a n t i g e n 
H B V h e p a t i t i s  B  v i s r u s 
H C V A b h e p a t i t i s  C  v i r u s  a n t i b o d y 
H I P A A H e a l t h  I n s u r a n c e  P o r t a b i l i t y  a n d  A c c o u n t a b i l i t y  A c t 
H I V h um a n  imm u n o d e f i c i e n c y  v i r u s 
H R T ho rm o n e  r e p l a c em e n t  t h e r a p y
 
I B i n v e s t i g a t o r ’ s  b r o c h u r e 
I C 5 0 h a l f -m a x im a l  i n h i b i t o r y  c o n c e n t r a t i o n  
I C D i n f o rm e d  c o n s e n t  d o c um e n t 
I C H I n t e r n a t i o n a l  C o u n c i l  f o r  H a rm o n i s a t i o n 
I D i d e n t i f i c a t i o n 
I F N - α I n t e r f e r o n  a l p h a 
I G A I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t  C C I 
C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 4 2 A b b r e v i a t i o n T e rm 
I g G imm u n o g l o b u l i n  G 
I G R A I n t e r f e r o n  G amm a  R e l e a s e  A s s a y 
I L - i n t e r l e u k i n 
I N D i n v e s t i g a t i o n a l  n e w  d r u g  a p p l i c a t i o n 
I N R i n t e r n a t i o n a l  n o rm a l i z e d  r a t i o 
I P i n v e s t i g a t i o n a l  p r o d u c t 
I P  m a n u a l i n v e s t i g a t i o n a l  p r o d u c t  m a n u a l 
I R B i n s t i t u t i o n a l  r e v i e w  b o a r d 
I R C i n t e r n a l  r e v i e w  c omm i t t e e 
I R T i n t e r a c t i v e  r e s p o n s e  t e c h n o l o g y 
I U D i n t r a u t e r i n e  d e v i c e 
I U S i n t r a u t e r i n e  h o rm o n e -r e l e a s i n g  s y s t em 
I V i n t r a v e n o u s  
IW R i n t e r a c t i v e  W e b -b a s e d  r e s p o n s e 
L F T l i v e r  f u n c t i o n  t e s t 
L L O Q l o w e r  l im i t  o f  q u a n t i f i c a t i o n 
J A K J a n u s  K i n a s e 
L D L l o w  d e n s i t y  l i p o p r o t e i n  
M A D m u l t i p l e  a s c e n d i n g  d o s e 
M C H m e a n  c o r p u s c u l a r  h em o g l o b i n 
M C H C m e a n  c o r p u s c u l a r  h em o g l o b i n  c o n c e n t r a t i o n 
M C V m e a n  c o r p u s c u l a r  v o l um e 
M g m i l l i g r am 
MM P 1 2 M a t r i x  m e t a l l o p r o t e i n a s e  1 2 
m R N A m e s s e n g e r  r i b o n u c l e i c  a c i d 
M R I m a g n e t i c  r e s o n a n c e  im a g i n g 
M s e c m i l l i s e c o n d 
M T X m e t h o t r e x a t e 
N / A n o t  a p p l i c a b l e 
N O A E L n o -o b s e r v e d - a d v e r s e - e f f e c t  l e v e l 
N R S N um e r i c a l  R a t i n g  S c a l e 
P A S I P s o r i a s i s  a r e a  a n d  s e v e r i t y  i n d e x 
P C D p r im a r y  c om p l e t i o n  d a t e 
P C P p r im a r y  c a r e  p h y s i c i a n 
P C R p o l y m e r a s e  c h a i n  r e a c t i o n  
P D p h a rm a c o d y n am i c ( s ) 
P G p o l y p r o p y l e  g l y c o l 
P I p r i n c i p a l  i n v e s t i g a t o r 
P K p h a rm a c o k i n e t i c ( s ) C C I 
C C I 
C C I C C I 
P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 4 3 A b b r e v i a t i o n T e rm 
P O EM P a t i e n t  O r i e n t e d  E c z em a  M e a s u r e 
P P D P u r i f i e d  P r o t e i n  D e r i v a t i v e 
P P -N R S P e a k  P r u r i t u s  N um e r i c a l  R a t i n g  S c a l e 
P R p u l s e  r a t e 
P R O P a t i e n t  r e p o r t e d  o u t c om e s 
P T p r o t h r om b i n  t im e 
P V C p r em a t u r e  v e n t r i c u l a r  c o n t r a c t i o n / c om p l e x 
Q D o n c e  d a i l y
Q F T - G Q u a n t i F E R O N -T B  G o l d  T e s t 
Q F T -G I T Q u a n t i F E R O N -T B  G o l d  I n -t u b e  T e s t 
Q T Q  w a v e  i n t e r v a l 
Q T c c o r r e c t e d  Q T 
Q T c F c o r r e c t e d  Q T  ( F r i d e r i c i a  m e t h o d ) 
Q u a l q u a l i t a t i v e 
QW o n c e  a  w e e k 
R B C r e d  b l o o d  c e l l 
R N A r i b o n u c l e i c  a c i d 
S A D s i n g l e  a s c e n d i n g  d o s e 
S A E s e r i o u s  a d v e r s e  e v e n t 
S A P s t a t i s t i c a l  a n a l y s i s  p l a n 
S C r s e r um  c r e a t i n i n e 
S  C y s t a t i n  C s e r um  C y s t a t i n  C 
S o A s c h e d u l e  o f  a c t i v i t i e s 
S O P s t a n d a r d  o p e r a t i n g  p r o c e d u r e 
S R S D s i n g l e  r e f e r e n c e  s a f e t y  d o c um e n t 
S S I D s u b j e c t  s t u d y  i d e n t i f i c a t i o n  n 
S T o D s t u d y  t e am  o n  d em a n d 
S U S A R s u s p e c t e d  u n e x p e c t e d  s e r i o u s  a d v e r s e  r e a c t i o n 
t 1 / 2 h a l f -l i f e 
T B t u b e r c u l o s i s 
T B i l i t o t a l  b i l i r u b i n 
T d P T o r s a d e  d e  P o i n t e s 
T E A E t r e a tm e n t  em e r g e n t  a d v e r s e  e v e n t s 
Tm a x t im e  t a k e n  t o  r e a c h  t h e  m a x im um  c o n c e n t r a t i o n 
T N F t um o r  n e c r o s i s  f a c t o r 
T Y K 2 T y r o s i n e  K i n a s e  2 
U C u l c e r a t i v e  c o l i t i s 
U L N u p p e r  l im i t  o f  n o rm a l 
U S U n i t e d  S t a t e s 
U V A u l t r a v i o l e t  A  l i g h t  
V s s v o l um e  o f  d i s t r i b u t i o n C C I C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 144Abbreviation Term
UVB ultraviolet B light
VZV varicella zoster virus
WBC white blood cell
WOCBP woman of childbearing potential

PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 14511.REFERENCES
1. Weidinger & Novak . Atopic Dermatitis. Lancet 2016; 387(10023): 1109 -1122.
2. Slater NA, Morrell DS. Sy stemic therapy  of childhood atopic dermatitis. Clin Dermatol 
2015;33(3): 289 -299.
3. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361(9352):151-160.
4. Ring J, Alomar A, Bieb er T, et al. Guidelines for treatment of atopic eczema (atopic 
dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26(8):1045 -60.
5. Furue, M., K. Yamamura , M. Kido- Nakahara, T. Nakahara, and Y. Fukui. "Emerging 
Role of Interleukin -31 and I nterleukin -31 Rec eptor in Pruritus in Atopic Dermatitis." 
Allergy  73, no. 1 (Jan 2018): 29 -36.
6. Guttman- Yassk y, E., J. G. Krueger, and M. G. Lebwohl. "S ystemic Immune 
Mechanisms in Atopic Dermatitis and Psoriasis with I
mplications for Treatment." Exp 
Dermatol 27, no. 4 (Apr 2018): 409-17.
7. Weidinger, S., L. A. Beck, T. Bieber, K. Kabashima, and A. D. Irvine. "Atopic 
Dermatitis." Nat Rev Dis Primers 4, no. 1 (Jun 21 2018): 1.
8. Bao, Y., J. Zheng, C. Han, J. Jin, H. Han, Y. L iu, Y. -L. Lau, W. Tu and X. Cao (2012). 
"Tyrosine Kinas e Btk Is Required for NK Cell Activation." The Journal of Biological 
Chemistry 287(28): 23769-23778. 
9. Amano, W. et al. The Janus kinase inhibitor JTE -052 improves skin barrier function 
through suppressing signal transducer and activator of transcription 3 signaling. The 
Journal of allergy and clinical immunology 136, 667- 677.e667, 
doi:10.1016/j.jaci.2015.03.051 (2015).
10. Fenwick, P. S., Macedo, P., Kilty , I. C., Barnes, P. J. & Donnelly , L. E. Effect of JAK 
Inhibitors on Release of CXCL 9, CXCL 10 and CXCL 11 fr om Human Airway  
Epithelial Cells. PloS one 10, e0128757, doi:10.1371/journal.pone.0128757 (2015).
11. Xu, M. et al. JAK inhibition alleviates the cellular senescence -associated secretory  
phenoty pe and frailty  in old age. Proceedings of the National Academy of Sciences of 
the United States of America 112, E6301- 6310, doi:10.1073/pnas.1515386112 (2015).
12. Suomela, S., Kariniemi, A. L
., Snellman, E. & Saarialho -Kere, U. Metalloelastase 
(MMP -12) and 92- kDa gelatinase (MMP -9) as well as their inhibitors, TI MP-1 and -3, 
are expressed in psoriatic lesions. Experimental dermatology 10, 175- 183 (2001).
13. Owczarek, W. et al. Analy sis of eotaxin 1/CCL 11, eotaxin 2/CCL 24 and eotaxin 
3/CCL 26 expression in lesional and non -lesional skin of patients with atopic dermatitis. 
Cytokin
e50, 181- 185, doi:10.1016/j.cy to.2010.02.016 (2010).

P F -0 6 7 0 0 8 4 1 
P r o t o c o l  B 7 9 3 1 0 2 2 
F i n a l  P r o t o c o l ,  3 1  O c t o b e r  2 0 1 8 
P a g e  1 4 6 1 4 . K am s t e e g ,  M . e t  a l . M o l e c u l a r  d i a g n o s t i c s  o f  p s o r i a s i s ,  a t o p i c  d e rm a t i t i s ,  a l l e r g i c  
c o n t a c t  d e rm a t i t i s  a n d  i r r i t a n t  c o n t a c t  d e rm a t i t i s .  T h e  B r i t i s h  j o u r n a l  o f  d e r m a t o l o g y 
1 6 2 ,  5 6 8 -5 7 8 ,  d o i : 1 0 . 1 1 1 1 / j . 1 3 6 5 - 2 1 3 3 . 2 0 0 9 . 0 9 5 4 7 . x  ( 2 0 1 0 ) . 
1 5 . F u j i t a ,  H . e t  a l . L e s i o n a l  d e n d r i t i c  c e l l s  i n  p a t i e n t s  w i t h  c h r o n i c  a t o p i c  d e rm a t i t i s  a n d  
p s o r i a s i s  e x h i b i t  p a r a l l e l  a b i l i t y  t o  a c t i v a t e  T -c e l l  s u b s e t s .  T h e  J o u r n a l  o f  a l l e r g y  a n d  
c l i n i c a l  i m m u n o l o g y 1 2 8 ,  5 7 4 - 5 8 2 . e 5 7 1 -5 1 2 ,  d o i : 1 0 . 1 0 1 6 / j . j a c i . 2 0 1 1 . 0 5 . 0 1 6  ( 2 0 1 1 ) . 
1 6 . F e r r a r i ,  S .  M . e t  a l . C X C L 1 0  i n  p s o r i a s i s .  A d v a n c e s  i n  m e d i c a l  s c i e n c e s 6 0 ,  3 4 9 - 3 5 4 ,  
d o i : 1 0 . 1 0 1 6 / j . a d vm s . 2 0 1 5 . 0 7 . 0 1 1  ( 2 0 1 5 ) . 
1 7 . M a r t e l ,  B .  C . e t  a l . D i s t i n c t  m o l e c u l a r  s i g n a t u r e s  o f  m i l d  e x t r i n s i c  a n d  i n t r i n s i c  a t o p i c  
d e rm a t i t i s .  E x p e r i m e n t a l  d e r m a t o l o g y 2 5 ,  4 5 3 - 4 5 9 ,  d o i : 1 0 . 1 1 1 1 / e x d . 1 2 9 6 7  ( 2 0 1 6 ) . 
1 8 . M c L e a n ,  W .  H .  F i l a g g r i n  f a i l u r e  -f r om  i c h t h y o s i s  v u l g a r i s  t o  a t o p i c  e c z em a  a n d  
b e y o n d .  T h e  B r i t i s h  j o u r n a l  o f  d e r m a t o l o g y 1 7 5  S u p p l  2 ,  4 - 7 ,  d o i : 1 0 . 1 1 1 1 / b j d . 1 4 9 9 7  
( 2 0 1 6 ) . 
1 9 . B r u n n e r ,  P .  M . ,  A .  I s r a e l ,  N .  Z h a n g ,  A .  L e o n a r d ,  H .  C .  W e n ,  T .  H u y n h ,  G .  T r a n ,  S .  
L y o n ,  G .  R o d r i g u e z ,  S .  Imm a n e n i ,  A .  W a g n e r ,  X .  Z h e n g ,  Y .  D .  E s t r a d a ,  H .  X u ,  J .  G .  
K r u e g e r ,  A .  S .  P a l l e r ,  a n d  E .  G u t tm a n - Y a s s k y .  " E a r l y -O n s e t  P e d i a t r i c  A t o p i c  
D e rm a t i t i s  I s  C h a r a c t e r i z e d  b y  T h 2 / T h 1 7 / T h 2 2 -C e n t e r e d  I n f l amm a t i o n  a n d  L i p i d  
A l t e r a t i o n s . "  J  A l l e r g y  C l i n  I mm u n o l  1 4 1 ,  n o .  6  ( J u n  2 0 1 8 ) :  2 0 9 4 - 1 0 6 .  
2 0 . C h a n ,  T .  C . ,  R .  D .  S a n y a l ,  A .  B .  P a v e l ,  J .  G l i c km a n ,  X .  Z h e n g ,  H .  X u ,  Y .  T .  C h o ,  T .  F .  
T s a i ,  H .  C .  W e n ,  X .  P e n g ,  I .  C u e t o ,  J .  G .  K r u e g e r ,  a n d  E .  G u t tm a n -Y a s s k y .  " A t o p i c  
D e rm a t i t i s  i n  C h i n e s e  P a t i e n t s  S h o w s  T h 2 / T h 1 7  S k e w i n g  w i t h  P s o r i a s i f o rm  F e a t u r e s . "  J  
A l l e r g y  C l i n  Imm u n o l  1 4 2 ,  n o .  3  ( S e p  2 0 1 8 ) :  1 0 1 3 - 1 7 .  
2 1 . G u t tm a n - Y a s s k y ,  E .  a n d  J .  G .  K r u e g e r .  " A t o p i c  D e rm a t i t i s  a n d  P s o r i a s i s :  T w o  D i f f e r e n t  
Imm u n e  D i s e a s e s  o r  O n e  S p e c t r um ? "  C u r r  O p i n  Imm u n o l .
2 2 . S a n y a l ,  R i a n a  D . ,  A n a  B .  P a v e l ,  J a c o b  G l i c km a n ,  T om  C .  C h a n ,  X i u z h o n g  Z h e n g ,  N i n g  
Z h a n g ,  I n n a  C u e t o ,  X i a n g y u  P e n g ,  Y e r i e l  E s t r a d a ,  J u d i l y n  F u e n t e s -D u c u l a n ,  A n d r e w  F .  
A l e x i s ,  J am e s  G .  K r u e g e r ,  a n d  Emm a  G u t tm a n -Y a s s k y .  " A t o p i c  D e rm a t i t i s  i n  A f r i c a n  
Am e r i c a n  P a t i e n t s  I s  T h 2 / T h 2 2 - S k e w e d  w i t h  T h 1 / T h 1 7  A t t e n u a t i o n . "  A n n a l s  o f  
A l l e r g y ,  A s t hm a  &  Im m u n o l o g y  ( 2 0 1 8 ) . 
 
 
 
 C C I 
PF-06700841
Protocol B7931022
Final Protocol, 31 October 2018
Page 14726. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 
1980;92(suppl):44-7.
27. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area
and 
severit yindex (EASI ): assessment of reliability in atopic dermatitis. EASI
Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11 -8.
28. Chan I S,Zhang Z . Test-based exa ct confidence intervals for the difference of two 
binomial proportions. Biometrics. 1999 Dec;55(4):1202-9.
